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1 INTRODUCTION 
1.1 Mesenchymal stromal cells 
 General overview 
Mesenchymal stromal cells (MSC) were described for the first time in 1970 by 
Friedenstein and colleagues [1]. These cells, addressed as fibroblast colony-forming 
cells were isolated from the bone marrow and displayed an osteogenic differentiation 
potential. At that time, they were already defined by Friedenstein as an important 
component in bone-marrow transplantation, suggesting their fundamental role in the 
support of the hematopoietic stem cells niche [1]. Indeed, these “bone-marrow 
adherent cells” were later demonstrated to support hematopoiesis in vitro for weeks 
[2]. Moreover, evidence of their differentiation potential to osteoblasts as well as 
chondrocytes was rapidly provided [3]. From these first findings, the research on MSC 
and on their potential application in medicine has widely expanded [4]. As a result of 
these broad investigations MSC were found also to be isolated from several tissue 
sources such as adipose tissue (adipose tissue-derived stromal cells – ASC) [5, 6], 
umbilical cord/cord blood (CB-MSC) [7], dental pulp [8], Wharton´s jelly (WJ-MSC) [9] 
and many others [10]. However, the use of different protocols for MSC isolation and 
culture generated a huge amount of conflicting data dealing with MSC characterization 
and especially with their therapeutic potential [11]. In their review Phinney and 
Sensebe summarized misconceptions about MSC and listed the following points as 
general reminder: (1) MSC from different tissue sources are different in terms of 
phenotype and function, (2) lack of complete correspondence of MSC function in vitro 
and in vivo, (3) heterogeneity of MSC among different species and (4) the need for 
clinical data to assess their effective mode of action [11]. 
To create uniform and at least minimal criteria for the characterization and definition of 
MSC, the International Society of Cellular Therapy (ISCT) proposed some guidelines 
[12] where MSC are defined as a fibroblast-like multipotent progenitor cells with a solid 
proliferation capacity. They should retain a trilineage mesenchymal differentiation 
capacity to adipocytes, chondroblasts and osteoblasts as well as some characteristic 
cell surface markers. For instance, MSC have to be negative for hematopoietic and 
leukocyte markers (CD34, CD45) and at least positive for CD73, CD90 and CD105 
[12, 13]. However, as studies on MSC characterization are still on going, these criteria 
Introduction 
5 
are continuously expanding, becoming more and more specific in the attempt to give 
a better understanding of MSC potential [14-16]. 
MSC multipotency, together with an increased understanding of their capacities, 
brought these cells on the spot, causing a tremendous increase of studies addressing 
their therapeutic potential on several contexts of disease. MSC have been investigated 
in tumors [17-19], wound healing [20, 21], graft vs host diseases [22-24], autoimmune 
diseases [25-27] and diabetes [28-30]. The great interest in using MSC as tool for cell-
based therapy relies on multiple findings, which characterized the potential mode of 
action of MSC when interacting with other cell types in physiological/diseased 
microenvironments. Indeed, the “modes of action” of MSC can be allocated to three 
different main mechanisms: (1) the trophic potential, (2) the immunomodulatory 
function and (3) the differentiation potential (Figure1). 
 
 
 
Figure 1 Concept of MSC application in cell-based therapy. MSC can be isolated from different sources, expanded 
and in line with the type of application, possibly modified (e.g. genetically). They can be applied in several disease 
contexts acting in accordance to their modes of action: trophic potential, immunomodulatory potential and 
differentiation potential. VEGF: vascular endothelial growth factor; HGF: hepatocyte growth factor; FGF: fibroblast 
growth factor, IL-6: interleukin 6, TGF-β: transforming growth factor beta, MCP-1: monocyte chemotactic protein-1, 
EV: extracellular vesicles.       
(1) The trophic potential of MSC resides in their ability to secrete a wide range of 
paracrine factors such as cytokines and growth factors, which have been shown to 
modulate their surrounding microenvironment and mediate the interaction with other 
cell types [31, 32]. Recently MSC have been reported to produce extracellular vesicles 
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(EV) and exosomes, denoting a new possible paracrine mechanisms. This option has 
raised the new intriguingly paradigm of MSC-cell free based therapeutic potential 
aiming to replace MSC in favor of their secretome-derived products [33].  
(2) The immunomodulatory function of MSC concerns not only their low 
immunogenicity, but it is also related to their interaction with cells of the immune 
system, generating an overall modulation of the immune response. Indeed, MSC were 
characterized for a low expression of human leucocyte antigen (HLA) class I molecules 
and the lack of costimulatory ones such as CD80 and CD86 [34]. This was interpreted 
as MSC being immune-privileged. In addition, the MSC-mediated inhibition of T cell 
proliferation, together with their ability of inducing regulatory T cells (Treg) are some of 
the most studied topics regarding MSC-mediated immunomodulation [34-36].  
(3) The differentiation potential comes from their natural multipotency. Because of their 
differentiation ability to osteogenic and chondrogenic lineages, MSC have been 
thoroughly investigated in the context of bone and cartilage repair [37, 38] and even 
potential neuron-like differentiation has been proposed [39]. They have been also 
reported to differentiate into β-pancreatic cells to restore β-cell failure in diabetes [40]. 
Despite the great interest in this last topic, the underlying mechanisms related to MSC-
migration, homing to injured site, effective differentiation and functional engraftment 
still require further elucidations. 
All these aspects contribute to make MSC still a hot topic in terms of therapeutic cell-
based approaches.  
 
 The proangiogenic potential 
As already described previously, MSC are well-known for their trophic support, which 
is dependent on their ability of secreting a large number of cytokines and growth 
factors. In particular, studies in the cardiovascular field have largely demonstrated that 
MSC retain important proangiogenic features [41]. Media obtained from cultured MSC 
have been reported to be rich in proangiogenic factors such as vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF) 
and monocyte chemotactic protein-1 (MCP-1) [42, 43]. MSC conditioned media (CM) 
supported angiogenesis of human umbilical vein endothelial cells (HUVEC) in vitro and 
this effect was abrogated after pretreatment with neutralizing antibody against VEGF, 
MCP-1 and interleukin-6 (IL-6). In the same study, identical results were obtained when 
the CM was locally injected in a mice model of hind limb ischemia and promoted 
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angiogenesis as well as reduction of inflammation [44]. In another approach, the 
analysis of the secreted proteome in CM from MSC, revealed a notable 
overrepresentation of proteins related to the development and function of the 
cardiovascular system clustering in processes like angiogenesis, neovascularization 
and development of blood vessels [45]. Notably, intravenous injection of MSC-CM 
preserved cardiac function in a pig model of myocardial infarction increasing capillary 
density and reducing the infarct size [45]. These promising evidences introduced MSC 
into the cardiovascular research and many clinical trials investigating their safety and 
efficacy were initiated [46-48]. Besides these obvious implications in the cardiovascular 
field, many studies are still going on to characterize the crosstalk between MSC and 
endothelial cells (EC) [49]. In fact, other angiogenesis-related pathways are emerging 
as being regulated by MSC. For instance, the angiopoietin-1 (Ang-1)/angiopietin-1 
receptor (Tie2) pathway and the VEGF/VEGF receptor-2 (VEGFR2) pathway resulted 
to be upregulated promoting angiogenesis and vascular stabilization in vitro and in vivo 
in a mouse model of cerebral artery occlusion [50]. In addition to that, proangiogenic 
growth factors and cytokines might act via exosomes or EV. Beneficial effects of MSC-
derived exosomes have been provided in several studies of ischemic heart disease 
[51, 52] and wound healing [53]. However, the proangiogenic ability of MSC may have 
some side effects, especially in tumor diseases. Indeed, tumor angiogenesis is a 
critical aspect in cancer diseases, mediating tumor progression and metastasis [54]. 
Some evidences suggested that MSC could promote in vitro and in vivo tumor neo-
angiogenesis via paracrine secretion of proangiogenic factors and inducing remodeling 
in endothelial cell organization [55-57]. Although mechanisms are still under 
investigation, these effects seemed to be mediated by a sort of “malignant 
transformation” of MSC or from the so called cancer-derived fibroblast (CAF), which 
might originate from recruited MSC. Once in the tumor stroma these cells might sense 
the altered microenvironment and, in the crosstalk with tumor cells, starting to co-
evolve with the disease, contributing to the progression through physical and chemical 
remodeling of the tumor microenvironment [58, 59]. 
Overall, these data indicate that MSC retain strong proangiogenic capacities. 
Moreover, as demonstrated in the case of CAF, MSC are susceptible to their 
surrounding microenvironment, which may induce changes in their phenotype as well 
as functions and drive their beneficial potential to a dangerous one. Therefore, in the 
development of MSC-mediated or MSC-free therapeutic approaches, it is important to 
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define risks and benefits of a potential induction of angiogenesis. While this may be 
the goal of ischemia and non-perfusion-related diseases, the same should be avoided 
in diseases where pathological angiogenesis is the cause of the disease such as 
angiogenic tumors, chronic inflammation or retinopathies [60]. A comprehensive 
knowledge of the disease and MSC potential in that context represents a fundamental 
step in the elaboration of cell/cell-free therapy. 
 
 The immunomodulatory potential: focus on MSC and T cell interaction 
As introduced previously, MSC can act also as potent immunomodulators regulating 
the immune response and generally skewing it towards a pro-regenerative/anti-
inflammatory milieu rather than to a pro-inflammatory one [61, 62]. 
It is long established that MSC exert a strong inhibition on activated T cells. Indeed 
when T cells are triggered by mitogenic stimuli such as phytohaemagglutinin (PHA) or 
anti-CD3/CD28 monoclonal antibodies, MSC can firmly restrict their proliferation [63-
65]. However, contrasting observations suggested that MSC could also induce the 
survival of quiescent/not-stimulated T cells [66]. Although this appeared to be related 
to culture condition i.e. MSC/mononuclear cell ratio [67], this aspect should be taken 
into account in the context of clinical application. Molecular mechanisms regulating 
MSC/T cell interplay rely on both cell-to-cell contact and secretion of soluble factors 
[34]. It has been demonstrated that CM from MSC containing IL-10 and indoleamine 
2,3-dioxygenase (IDO) induced apoptosis in splenocytes, while the direct contact with 
MSC promoted splenocytes cell arrest in the G0/G1 phase [68]. Similarly, in direct and 
indirect cocultures of MSC and peripheral blood mononuclear cells (PBMC), it was 
observed that both IL-10 and transforming growth factor beta (TGF-β) were important 
mediators in the induction of programmed cell death 1 receptor (PD-1) on T cells. The 
latter was partially involved in MSC-mediated T cell apoptosis via the PD-1/B7-H1 axis 
[65]. In addition to that, MSC priming via interferon gamma (IFN-γ), resulted in IDO up-
regulation which potentiated the suppressive potential of MSC on stimulated PBMC, 
suggesting that MSC activity can be modulated by surrounding stimuli [69, 70].    
Another important immunoregulatory function of MSC concerns their ability to affect 
the balance of the CD4 T helper (Th) subsets both in vitro and in vivo [71]. CD4 Th 
cells are normally classified into:  
(1) Th1, involved in the activation and recruitment of macrophages as well as in the 
IgG production by B cells, which secrete IFN-γ and tumor necrosis factor (TNF);  
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(2) Th2, which produce IL-4, IL-5, IL-9, IL-13 and IL-10 and mediated the switch of 
antibody secretion in B cells;  
(3) Th17, which role in inflammation concerns the recruitment of neutrophils and the 
secretion of  IL17a-f, IL-21 and IL-22 and  
(4) Treg, a subset of CD4 cells commonly described as CD4+CD25+ forkhead box P3 
positive (Foxp3+), which are essential in the regulation of the inflammatory process 
and to prevent autoimmunity [72].  
In vitro cocultures of MSC and CD4 cells showed that MSC could exert a potent 
inhibition of undifferentiated CD4 T cells, however, once the differentiation to Th1 and 
Th17 was already initiated, MSC were able to suppress only Th1 cells, while the pro-
inflammatory Th17 were promoted [73]. In another study, MSC decreased IFN-γ 
secretion from Th1 while increasing IL-4 produced by Th2, suggesting a shift from pro-
inflammatory to an anti-inflammatory background [74]. These effects were detected 
also in different disease model in vivo. For instance, an improvement of the Th1/Th2 
balance, consistent with a reduction in Th17 and increase in Treg, has been 
documented in several models of type 1 diabetes (T1D) [75-77]. In a rat model of 
inflammatory bowel disease, treatment with ASC promoted an overall amelioration of 
the disease through impairment of Th1 expansion and Th1 cytokine secretion in 
association with Treg induction, which were highly immunosuppressive in vivo and in 
vitro [62]. Many of these studies, together with the inhibition of Th1/Th17 subsets, often 
reported a concomitant induction of Treg cells. As introduced before, Treg exert a 
fundamental role in the regulation of the immune response modulating the activation 
of Th subsets. They are usually distinguished into natural or naïve Treg (nTreg) 
originating in the thymus and induced Treg (iTreg), which come from the differentiation 
of peripheral CD4 T cells [78]. Treg characterization has a long story started more than 
20 years ago when CD4+CD25+ cells were found to be fundamental in mediating self-
tolerance [79]. To date, many markers have been tested and introduced in their 
characterization. The positivity for transcription factor FoxP3 as well as the lack of 
CD127 expression are commonly accepted as Treg markers [80]. Importantly, 
CD4+CD25+CD127- were found to better reproduce the inhibitory activity of 
CD4+CD25+FoxP3+ cells suggesting that the combination of these four markers was 
highly representative of functional Treg [81]. Cocultures of MSC and CD4 cells reported 
an induction of CD4+CD25+FoxP3+ Treg cells mediated by the production of 
prostaglandin E2 (PGE2) and transforming growth factor β (TGF-β) [82]. The induction 
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of IL-10 producing Treg by ASC in coculture with PBMC corroborated these findings 
[61]. In another study Melief and colleagues demonstrated that TGF-β, produced by 
MSC, was a key factor in mediating Treg induction, which was also supported by 
monocytes. Notably, MSC and their CM supported monocyte survival while promoting 
their switch to a M2 (anti-inflammatory) phenotype enabling them to secrete chemokine 
ligand 18 (CCL-18), which was found to be essential in inducing Treg [83]. Also IL-2 
has been demonstrated to be instrumental for Treg induction [84]. Many of these 
findings were recapitulated in vivo in several settings, highlighting the protective effect 
of MSC via Treg induction [85-87]. 
 
The evaluation of MSC-mediated effects on the immune response following their 
transplantation/application in diabetic settings has a long history with promising 
outcomes [88]. For instance, MSC injections in STZ rats lowered blood glucose levels, 
ameliorated insulin secretion and promoted pancreatic islets renewal [89, 90]. 
Likewise, in pre-diabetic non obese diabetic (NOD) mice, intravenous injection of 
human MSC delayed the onset of  diabetes and reduced high levels of pro-
inflammatory cytokines [91]. These evidences, in addition to the growing interest in 
developing MSC-mediated therapies, promoted many clinical studies, which gave 
successful and promising results [92-94]. However, investigations on specific MSC 
immuno-mediated effects on diabetic complication are still under evaluation. Especially 
in diabetic retinopathy (DR), where the MSC therapeutic potential is mainly 
investigated in terms of provision of trophic factors and structural support (pericyte-like 
function), the role of MSC as immunomodulators is almost not considered. 
 
Taken together these studies constitute a solid base for further pre-clinical and clinical 
studies in many disease settings from autoimmune diseases to transplantation. A 
continued investigation on the complex interactions between MSC and cells of the 
immune system will be required to gain further insights on the MSC-mediated 
immunomodulation. 
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1.2 Mesenchymal stromal cells in diabetic retinopathy 
 Diabetic retinopathy 
Diabetes mellitus is a pathological condition, which comprehends a large group of 
metabolic disorders characterized by two distinctive traits: high levels of glucose in the 
blood stream and impaired glycemic control. Diabetic patients may often develop eye-
related complications and the most common is known as DR [95]. While its onset is 
asymptomatic, the appearance of first clinical signs described as “at least one 
microaneurysm” denotes already the stage of a mild non-proliferative DR (NPDR). The 
disease can then progress to moderate NPDR where microaneurysms appear together 
with hemorrhages. The severe NDPR is internationally classified as followed [96, 97]:  
(1) more than 20 intraretinal hemorrhages in each of four quadrants and (2) venous 
beading and prominent intraretinal microvascular abnormalities in two/one or more 
quadrants. The last stage of the disease is the proliferative DR (PDR) characterized 
by retinal neovascularization, vitreous/preretinal hemorrhages and even traction retinal 
detachments [96, 97]. Another important classification in DR is that of the diabetic 
macular edema (DME), which can occur across all stages of DR. This represents the 
main cause of vision loss through fluids accumulation in the neural retina as well as 
cystoid edema of the macula [98]. 
 
DR is a progressive neurovascular disease, which involves the microvascular and 
neuronal compartments of the eye [99]. Following the hypothesis of the neurovascular 
unit, microvascular and neuronal changes might be interconnected, contributing 
together to the progression of the disease [99]. Although the temporal connection 
between vascular and neuronal changes is unclear and physio-pathological 
mechanisms still need elucidation, many papers reported early degeneration in the 
neuronal district. For instance, apoptosis of retinal ganglion cells (RGC), reduction in 
photoreceptors and alteration in the inner neuronal retina were documented prior to 
vascular changes [100-102]. The glial fibrillary acidic protein (GFAP) has also been 
proposed as marker to target activation/alteration in Müller glial cells in early phases 
of diabetes [103]. Starting from these findings, the concept of inflammation as one of 
the leading processes in the early pathogenesis of the disease arose [104]. Indeed, 
many “classical” inflammatory markers such as tumor necrosis factor α (TNF-α), IL-1β, 
IL-6 and intercellular adhesion molecule 1 (ICAM-1) were identified at high 
concentration in eyes of diabetic patients [105-107]. In addition, “traditional 
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inflammatory processes” such as increased vascular permeability, tissue edema, 
microglia activation and macrophage infiltration have been described in many animal 
models [108-110]. 
The retinal microvascular compartment can be simultaneously considered as the 
source and the consequence of retinal inflammation. Pro-inflammatory cytokines were 
found to be produced directly by endothelial cells as well as by infiltrating leukocytes. 
Several studies demonstrated that increased leakage in retinal vessels and 
consequent infiltration of immune cells (monocytes) were related to a rising expression 
of adhesion molecules such as ICAM-1 and vascular cell adhesion molecule 1 (VCAM-
1) [111]. Similarly, in a streptozotocin (STZ) mouse model, it was observed that 
inhibition of ICAM-1 prevented the adhesion of leukocytes to the retinal capillaries, 
which started to take place immediately after induction of diabetes [112]. Damaged 
endothelial cells can also act as principal mediators of the inflammation supporting the 
angiogenic response typical of the PDR. Indeed, it has been demonstrated that the 
expression of VEGF can be sustained and promoted by pro-inflammatory cytokines 
such as TNF-α and IL-6 [113]. Similarly, VEGF could act as pro-inflammatory cytokine 
itself favoring other pro-inflammatory mediators [114, 115]. Overall this self-
propagating mechanism contributes to retinal degeneration, supporting vascular 
alterations not only at early stages of DR but also in later ones guiding and promoting 
the angiogenic response. 
 
Focusing only on the microvascular retina, is it possible to define two cell type, which 
are mainly involved in the vascular degeneration, pericytes and endothelial cells. 
Pericytes are cells of mesodermal origin with a perivascular location, wrapping around 
micro and macro-vessels, establishing a very tight contact with endothelial cells [116]. 
Studies on these cells revealed a large heterogeneity of this cell population, mainly 
related to their location and function [117]. Regarding their function, pericytes are 
generally involved in the regulation and preservation of vascular homeostasis 
participating in processes like angiogenesis and vascular permeability [118]. PDGF-
β/PDGFR-β, Ang1-2/Tie2 and Notch signaling are the signals which mediate the 
interaction with endothelial cells in the developing and resting retina, promoting 
homeostasis or angiogenesis [119]. Moreover, the 1:1 ratio between pericytes and 
endothelial cells is fundamental to maintain the tightness of the blood retinal barrier 
(BRB) [120]. In DR, because of the hyperglycemia-mediated insults, the normal 
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communication and interaction between EC and pericytes is interrupted. Indeed, 
pericyte loss is one of the earliest changes in the diabetic retina [121]. Even if the 
temporal relation between loss of pericytes and duration of diabetes in humans is still 
unclear, the loss of pericytes contributes to the vascular remodeling, which leads first 
to acellular capillaries, microaneurysms and non-perfused area, ending up with vessel 
hyper proliferation to counteract the retinal ischemia [121]. 
 
These changes in pericyte-endothelial cell interactions, together with hyperglycemia-
mediated cell damage in the retinal endothelium and the spreading inflammation, 
contribute to the pathogenesis of DR (Figure 2). 
 
 
Figure 2 Progression of DR and factors involved in the pathogenesis. ROS: reactive oxygen species, AGEs: 
advanced glycation end products, VEGF: vascular endothelial growth factor. 
 
To date, the majority of therapeutic strategies in the cure of DR, target mainly late stage 
of the disease. Together with tight glycemic control, laser photocoagulation, injection 
of anti-VEGF antibodies, corticosteroids, non-steroidal anti-inflammatories as well as 
inhibitors of the renin-angiotensin system are some of the most used therapeutic 
approaches [122]. However, it is now clear that specifically targeting the early phases 
of DR would lead to a notable improvement in preventing or delaying the progression 
of the disease. In this sense, cell-based therapy may represent a good option because 
of their potential ability to replace/promote tissue repair in the damaged retina [123]. 
 
 MSC-based therapeutic approach in DR 
The role of MSC as cell-therapy approach to DR has been intensively studied in several 
animal models, producing interesting and promising results. For instance, beneficial 
effects of ASC were demonstrated in vitro and in vivo in a study from Rajashekhar and 
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colleagues [124]. Cocultures of ASC and retinal endothelial cells (REC) revealed that 
ASC supported REC angiogenic network formation and intravitreal injection of ASC in 
a STZ mice reduced vascular leakage and inflammation in the retina. Notably, ASC 
were localized in proximity of retinal vessel, suggesting a potential pericyte-like 
function [124]. Similarly, ASC were found to induce a cytoprotective microenvironment 
in the retina of STZ mice, preventing pathological neovascularization through reduction 
of oxidative stress and prevention of retinal ganglion cell loss [75]. An important 
evaluation on timing of MSC injection has been provided by Mendel and colleagues in 
a mice model of oxygen-induced retinopathy (OIR) [125]. They found that injection of 
ASC before OIR vessel destabilization prevented capillary dropout in addition to a 
perivascular/pericyte-like localization around retinal vessels. The ASC even expressed 
pericyte markers such as neural/glia antigen 2 (NG-2) and α smooth muscle actin (α-
SMA). Similar findings were recapitulated also in a DR Akimba mouse model [125]. 
The pericyte-like behavior of ASC was also confirmed in a mouse model of retinopathy 
of prematurity (ROP) [126]. Here, changes in inflammatory and angiogenesis-related 
cytokines were found in comparing ASC-treated/non-treated mice, suggesting an 
active modulation of retinal microenvironment by ASC. Similarly, beneficial effects of 
ASC were demonstrated also in vitro, where ASC CM abrogated HG-induced oxidative 
stress and NF-κB activation in endothelial cells exposed to hyperglycemia [126]. 
Finally, the interaction between ASC and REC has been shown to be dependent on 
NOTCH signaling [127]. In summary, all these studies characterized at least two main 
roles of MSC in DR. The first one is related to the ability of MSC to tightly interact with 
endothelial cells in the retinal microvasculature, acquiring a pericytes-like phenotype 
suggesting a potential role as modulator of vascular homeostasis. Secondly, thanks to 
their trophic potential, MSC can secrete numbers of cytokines and growth factors, 
which can modulate the local microenvironment resulting in a modulation of retinal 
inflammation. 
 
As mentioned before, among MSC capacities, the immunomodulatory potential is one 
of the most studied in several disease contexts. These capacities are until now almost 
not considered in DR and beside findings confirming the reduction of pro-inflammatory 
cytokines upon MSC application, no real evidences about an interaction with microglia 
or T cells were reported. Although, these cells could play a relevant role in DR, as 
suggested by a recent paper [128]. Indeed, Deliyanti and colleagues investigated 
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whether Treg were detectable in the retina at different time points after the generation 
of OIR in mice. They found that while in controls Treg were residing within the 
vasculature, the acute phase (switch from hyperoxia to hypoxia) caused an 
extravasation of Treg cells in the retinal tissue. At the same time point, Treg were also 
expanding in spleen and lymph nodes. Besides this, they also showed that these cells 
were of therapeutic relevance: increasing the Treg numbers via IL-2/anti-IL-2 mouse 
antibody or via adoptive transfer, not only reduced retinal neovascularization but also 
favored an anti-inflammatory switch of the microglia, both in vivo and in vitro [128]. 
These data demonstrated that acute retinal ischemia represented a stimulus to induce 
transient Treg expansion, which migrated to retina. Once there, however, quantities 
were not enough to modulate the microenvironment and restrict pathological 
neovascularization. Notably, increasing the number of circulating Treg, caused a delay 
in the progression of the disease and prevented neovascularization. These promising 
evidences introduced the hypothesis of Treg manipulation as potential treatment of 
retinopathies. Because of this, the potential use of MSC in cell-based therapeutic 
approach of DR, might start to consider MSC-mediated Treg induction as a possible 
therapeutic mechanism beside pericytes-like function and trophic support. 
 
Despite the promising results obtained in animal models, further studies are still 
required to clarify safety and efficacy of MSC-mediated cell therapy. Moreover, 
important aspects such as timing and route of administration, allogenic versus 
autologous MSC and the fine characterization of the MSC potential in retinal 
microenvironment have to be taken in consideration [123].    
 
 
1.3 Molecular mechanisms of hyperglycemia-mediated cell damage 
Hyperglycemia and poor glycemic control are two main features of diabetes mellitus. 
People affected by this disease are prone in developing serious secondary 
complications, which actually affect their life resulting in impaired life quality and even 
increased mortality [129]. Some of those secondary complications are microvascular 
pathologies, which can affect the retina (DR), kidney (diabetic nephropathy) and 
peripheral nerves (diabetic neuropathy) [130]. The pathophysiological features of these 
complications are very similar in the three different districts and concern a progressive 
microvascular degeneration, which impairs the normal microvascular functions and 
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vascular permeability. With time, these alterations lead to cell loss, overproduction of 
extracellular matrix and capillary occlusion, which are the preamble for ischemia, 
hypoxia-induced neovascularization, edema and matrix deposition [131, 132]. 
 
Hyperglycemia is considered one of the leading factors driving diabetic complications, 
especially because of glucose-mediated cell damage, which is particularly evident in 
endothelial cells. Four mechanisms have been proposed to explain how 
hyperglycemia-induced damage takes place and were gathered together by Brownlee 
in the “unifying hypothesis” [133, 134]. The mechanisms are the following: (1) 
increased flux in the polyol pathway as well as (2) through the hexosamine pathway; 
(3) abnormal activation of protein kinase C (PKC) and (4) increased formation of 
advanced glycation-end products (AGE) [134]. The upstream factor initiating this 
cascade of events is indeed glucose, which uptake in endothelial cells is insulin-
independent. Therefore, too high glucose concentrations in the blood stream 
corresponds with high glucose concentrations in the cells [135]. Increased glucose 
influx in the cells may be directed to the (1) polyol pathway and metabolized by aldose 
reductase through NADPH consumption. Similarly, exceeding fructose-6-phosphate 
(F-6-P) obtained by metabolized glucose in the first step of glycolysis, may be directed 
to (2) the hexosamine pathway. Here, F-6-P may act as substrate for enzymes driving 
protein glycosylation by addiction of N-acetylglucosamine (GlcNAc), which has been 
demonstrated to modulate the activity of transcription factors. Also (3) PKC activation 
is mediated by high intracellular glucose levels, since this may cause increased 
production of diacylglycerol (DAG). DAG mediates PKC activation, which may act as 
second messenger to the modulation/activation of several enzymes/pathways such as 
endothelial nitric oxide synthase (eNOS), VEGF production, NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) and NADP(H) oxidase activation. 
Lastly, glucose may contribute to (4) AGE formation through the generation of glucose-
derived precursors (like glyoxal or methylglyoxal). Increased production of AGE may: 
(1) affect normal cell function via AGE-modification of proteins, (2) impair cell adhesion, 
via generation of AGE-modified extracellular matrix and (3) activate the NF-κB pathway 
through AGE-receptor of AGE (RAGE) stimulation [134].  
The “unifying hypothesis” proposed by Bronwlee, suggested that all these pathogenic 
mechanisms, induced by hyperglycemia, may contribute to a single, unique process: 
superoxide production by the mitochondrial electron transport chain. Superoxide 
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production by mitochondria has been demonstrated to be strictly related to the cell 
metabolic status and glucose consumption. Moreover, superoxide can reduce 
glyceraldehyde-3-phospathe dehydrogenase (GAPDH) activity resulting in 
accumulation of glucose metabolites, which will be directed to the polyol and 
hexosamine pathways. Similarly, GAPDH inhibition may promote PKC activation and 
formation of AGE caused by triose phosphate accumulation [134]. 
As microvascular complications arise mainly from endothelial dysfunction, the reported 
molecular pathways were largely investigated in endothelial cells [135]. However, 
many cell type resulted impaired by hyperglycemia. For instance, retinal pericytes 
[121], neuronal cells [136] and even cells of the immune system [137].  
 
 Are MSC affected by hyperglycemia/diabetes? 
The large interest in the therapeutic use of MSC comes not only from their multipotency 
but also from their relatively easy isolation and expansion in vitro. For instance, large 
quantities of ASC can be isolated with non-invasive procedures, rendering them a very 
promising candidate for autologous treatment [138, 139]. 
However, as introduced previously, diabetes is a particular metabolic condition where 
normal cell metabolism and functions are altered. Moreover, dysfunction in the 
homeostasis of adipose tissue has been strongly related to obesity and related 
disorders [140]. Considering these aspects, we asked: whether, how and how much 
hyperglycemia/diabetes can impair MSC? 
To date, despite several studies investigated the effect of diabetes (both T1D and type 
2), conflicting results did not help in finding a clear answer. While some papers reported 
similarities in potency and functions of MSC/ASC isolated from healthy or diabetic 
patients [141, 142], others denoted important differences [143, 144]. This, of course 
may impair their therapeutic function, opening questions on whether the use of 
autologous or rather allogeneic MSC is favored in potential cell-based interventions. 
Comparing ASC isolated from fat pads of diabetic and healthy mice, Cianfarani and 
colleagues observed a differential expression of surface markers, suggesting a 
depletion of certain cell subpopulations, which might affect their therapeutic potential. 
Indeed, the efficacy of wound healing support of ASC isolated from diabetic mice was 
reduced compared to the one from healthy ones [145]. In similar studies, the 
angiogenic potential of ASC isolated from diabetic mice was impaired in vivo and in 
vitro and this was related to a depletion in certain ASC subpopulations. Rennert and 
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colleagues identified a depletion in CD45-CD31-CD34+ ASC from stromal vascular 
fractions (SVF) of diabetic patients, while Inoue et al. observed that reduced CD271+ 
subpopulation in CD34+CD31−CD271+ ASC  was critical for the impairment of diabetic 
ASC.  [146, 147]. In a model of DR, diabetic ASC did not improve retinal 
vascularization, despite no metabolic differences in terms of ATP-dependent, 
uncoupled and non-mitochondrial respiration [148].  
Taking into account these studies, autologous MSC from diabetic patients should not 
be then considered totally safe. Indeed, it has been demonstrated that genetically 
modified diabetic ASC, expressing the enzyme glyoxalase-1 (GLO-1), had improved 
viability, migration and proangiogenic capacity and were equal to healthy ASC in 
restoring blood perfusion [149]. Similarly, pretreatment of diabetic MSC with 
deferoxamine resulted to be significant in increasing VEGF, hypoxia inducible factor-1 
(HIF-1) and FGF-2 restoring their angiogenic potential [150]. 
 
Asking on whether, how and how much hyperglycemia affects MSC functions, 
Hajmousa and colleagues recently reported a specific hyperglycemia-mediated effect 
on ASC [151]. ASC cultured in media with high glucose concentration (HG; 30 mM) 
were characterized by changes in the bioenergetics of metabolism, denoting increased 
reactive oxygen species (ROS) production and mitochondrial reorganization. Despite 
this, ASC in presence of HG, reduced glucose uptake, denoting their great plasticity in 
adapting to the surrounding microenvironment [151]. Another study demonstrated the 
involvement of ROS as consequence of hyperglycemia in MSC [152]. Indeed, HG 
exposure altered mRNA expression of adipokines and transcriptional factors in 
adipocytes differentiated from BM-MSC. These changes did not interfere with the 
differentiation process, but were all associated to increased intra- and extracellular 
ROS production [152]. In contrast to previous studies, hyperglycemia was found to 
induce BM-MSC apoptosis in a time dependent manner, while increased production of 
ROS was also confirmed [153].   
 
These discrepancies highlight that more studies are still needed to fully elucidate 
whether MSC transplantation can be considered as a therapeutic alternative in diabetic 
disorders. At the same time, investigations on diabetic/hyperglycemia-mediated effects 
that may occur once healthy MSC are in a diabetic/hyperglycemic environment can 
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give important insights on how MSC-mediated cell therapy can be improved in this 
particular pathological setting.         
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2 AIM OF THE STUDY 
The study of MSC as tools for cell-based therapy in several diseased contexts 
represents one of the most investigated fields of the last twenty years. However, in 
some situations, the lack of homogenous results still limits the translation to the clinical 
research. This is the case in the field of diabetes. Indeed, while 
transplantation/application/infusion of allogenic MSC is widely investigated as 
previously reported, the research on the application of autologous MSC is still lagging 
behind. It has been proven that in diabetes and hyperglycemia-related syndromes, 
high glucose concentrations in the blood flow, together with poor glycemic control, 
represent one of the first causes of cell damage. Hyperglycemia-mediated cell damage 
has been largely documented especially in endothelial cells uncovering mechanisms 
of the pathogenesis of some diabetes-related microvascular diseases, such as DR and 
diabetic nephropathy. However, effects of hyperglycemia on MSC are poorly studied 
and to date some contrasting evidences have proposed that MSC isolated from 
diabetic patients may be impaired in their therapeutic potential. 
 
Hypothesizing that ASC may serve as future cell-based therapy to prevent or 
ameliorate pathological consequences of DR by exerting pericyte-like/proangiogenic  
functions, we asked whether ASC are affected by hyperglycemia and if so, which of 
the proposed therapeutic mechanisms is changed: the angiogenic function, the 
pericyte-like, and/or the immunomodulatory capacity. Therefore, we developed our 
research strategy around four main aims here presented (Figure 3). 
  
 
Figure 3 Aims of the study. 
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(1) Aim 1: Evaluating effects of hyperglycemia on cellular phenotypes. 
Postulating that hyperglycemia-mediated effects on ASC would have been 
detectable on their phenotype, ASC were isolated from lipoaspirate of multiple 
donors and directly after isolation, cells from the same donor were cultured in 
normal glucose (ASCNG; 1g/L) and high glucose (ASCHG; 4.5 g/L) cell culture 
medium. These two counterparts were compared in terms of phenotype, cell 
growth, differentiation potential and cell surface markers. Oxidative stress (total 
intracellular ROS content) and glucose uptake were also measured.  
Similarly, hyperglycemia-mediated effects were also assessed on 
microvascular retinal endothelial cells (HRMVEC). Growth rate of NG and HG 
cultured HRMVEC was monitored as well as oxidative stress and glucose 
uptake. Angiogenic potential of NG/HG HRMVEC was tested trough basement 
matrix angiogenesis (BMA) assays on gel membranes. 
 
(2) Aim 2: Evaluation of ASC proangiogenic potential under hyperglycemia. 
Hypothesizing that the proangiogenic potential of ASC would not be affected by 
HG, we established cocultures with EC, analyzing their supernatants for 
angiogenic growth factors. 
First, ASCNG-HG were cocultured with GFP-transfected human umbilical vein 
endothelial cells (HUVECGFP). Coculture supernatants were assessed 
comparing ASCNG cocultures in NG and HG culture media. 
Second, cocultures between ASCNG-HG and GFP-transfected HRMVEC 
(HRMVECGFP) were set and coculture supernatants were analyzed comparing 
ASCNG-HG monoculture with cocultures (in NG culture media). 
Third, supernatants of cocultures and ASC monocultures were used as 
conditioned media (CM) for culturing HG HRMVEC in BMA assays. 
 
(3) Aim 3: Evaluation of pericyte-like function of ASC. 
We hypothesized that ASC could serve as functional pericytes interacting and 
stabilizing endothelial cells independently of HG. Immunofluorescence was 
used to investigate ASC for pericyte-like markers when cocultured with dTomato 
transfected HRMVEC. Anti-α-SMA and anti-NG-2 antibodies were tested. 
Moreover, the proangiogenic capacity of retinal pericytes as well as pericyte 
markers were tested in coculture angiogenesis assays of pericytes and 
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HUVECGFP/HRMVECGFP in NG/HG culture media hypothesizing that pericyte 
functions might be impaired by HG. 
   
(4) Aim 4: Evaluation of ASC immunomodulatory potential under hyperglycemia. 
To verify whether ASC immunomodulatory potential is affected by HG, 
interactions between ASCNG-HG and CD4 T cells were characterized through 
ASCNG-HG:PBMC direct and indirect (transwell) cocultures. Two distinct 
conditions were evaluated: (a) stimulated coculture, where PBMC were 
stimulated with CD3/CD28 beads and (b) not-stimulated cocultures. For both 
(a) and (b) CD4 T cell proliferation, quantification of CD4+CD25+ and Treg 
fractions and analysis of coculture supernatants were performed.    
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3 MATERIAL AND METHODS 
3.1 Material 
 Cells 
Product Company Catalog No. 
Adipose derived 
mesenchymal stromal cells 
(ASC) 
Self-isolated; 
Mannheim Ethics Commission II (vote numbers 2006-192 
N-MA). 
Human umbilical vein 
endothelial cells (HUVEC) 
Self-isolated; 
Mannheim Ethics Commission II (vote numbers 2010-262 
N-MA) 
Human retinal microvascular 
endothelial cells (HRMVEC) PeloBiotech PBCH-1608511 
Human retinal microvascular 
pericytes (HRMVPC)  PeloBiotech PBCH-0612211  
293FT cells 
Kindly provided by Prof. Patrick Maier, Department of 
Radiation Oncology, University Medical Centre Mannheim, 
Germany. 
Peripheral blood 
mononuclear cell (PBMC) 
Self-isolated from Buffy coat 
provided by the German Red Cross Blood Donor Service 
in Mannheim. 
 Cell culture/cell isolation products 
Product Company Catalog No. 
NB6 GMP grade collagenase SERVA Electrophoresis 17458 
Collagenase Gibco 17100017 
EDTA Applichem A3145,0500 
DMEM (normal glucose 1g/L) PAN Biotech P04-01500 
DMEM (no glucose) PAN Biotech P04-01549 
Pooled human allogeneic serum from 
AB donors (AB serum) 
German Red Cross Blood Donor Service, 
Institute Mannheim 
Penicillin/Streptomycin PAN Biotech P06-07100 
L-glutamine PAN Biotech P04-80100 
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D-glucose Sigma-Aldrich G7021 
Endothelial cell basal medium (EBM) PromoCell C-22011 
Supplement Mix endothelial cell growth 
medium 2 PromoCell C-39216 
Pericytes Growth Medium  PeloBiotech PB-MH-0314000 
Speed Coating Solution PeloBiotech PB-LU-000-0002-00 
Trypsin/EDTA PAN Biotech P10-024100 
Fetal Bovine Serum Sigma F7524 
Dymethylsulphoxide (DMSO) Wak-chemie Medical GmbH WAK-DMSO-10 
Ficoll-Paque™ Premium GE Healthcare Bio-science AB 17-5442-03 
DPBS (1X) Gibco 14190-094 
Albumin fraction V (bovine serum 
albumin) Carl Roth 8076.2 
RPMI 1640 Lonza 12-918F 
RPMI 1640 (no glucose) Gibco 11879020 
IL-2 human recombinant PromoCell C-61240 
Casy-Ton OMNI Life Science 5651808 
Mesenchymal Stem Cell Adipogenic 
Differentiation Medium Promocell C-28016 
Supplement mix Adipogenic 
Differentiation Medium Promocell C-39816 
Mesenchymal Stem Cell Osteogenic 
Differentiation Medium Promocell C-28013 
Supplement mix Osteogenic 
Differentiation Medium Promocell C-39813 
Hoechst 33342 Invitrogen H3570 917368 
Geltrex™ LDEV-Free Reduced Growth 
Factor Basement Membrane Matrix  Gibco A14132-01 
N-Acetylcysteine (NAC) Sigma A9165 
WZB-117 (3-hydroxy-benzoic acid, 3-
fluoro-1,2-phenylene)ester Cayman Chemicals 19900 
Speed Coating Solution PeloBiotech PB-LU-000-0002-00 
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 Cell culture media 
Name Composition 
DMEM AB or DMEM AB NG (normal glucose 1 g/L) 
500 ml DMEM normal glucose 
10% AB serum 
1% Penicillin/Streptomycin 
2% L-glutamine 
DMEM AB HG (high glucose 4.5 g/L) 
500 ml DMEM normal glucose 
10% AB serum 
1% Penicillin/Streptomycin 
2% L-glutamine 
4.5 g/L D-glucose 
Complete ECGM-2 NG (normal glucose 1 g/L) 
500 ml EBM (Endothelial basal 
medium) 
12.5 ml ECGM-2 supplement mix 
endothelial cell growth medium 2 
Complete ECGM-2 HG (high glucose 4.5 g/L) 
500 ml EBM 
12.5 ml ECGM-2 supplement mix 
endothelial cell growth medium 2 
4.5 g/L D-glucose 
¼ ECGM-2 NG (normal glucose 1 g/L) 
7.5 ml EBM 
2.5 ml ECGM-2 supplement mix 
endothelial cell growth medium 2 
¼ ECGM-2 HG (high glucose 4.5 g/L) 
7.5 ml EBM 
2.5 ml ECGM-2 supplement mix 
endothelial cell growth medium 2 
4.5 g/L D-glucose 
Reduced RPMI 1640  
500 ml RPMI 1640 
2.5% FBS 
1% Penicillin/Streptomycin 
2% L-glutamine 
Glucose starvation medium 
500 ml RPMI1640 (no glucose) 
1% Penicillin/Streptomycin 
2% L-glutamine 
Full RPMI 1640 
500 ml RPMI 1640 
10% FBS 
1% Penicillin/Streptomycin 
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 Solutions 
Name Composition 
Erythrocyte lysis buffer 
1 mM EDTA 
1.55 mM NH4Cl 
0.1 M NH4HCO3 
Stopping Medium 
50 ml DPBS 
10% FBS 
PBS/EDTA 
500 ml DPBS 
2mM EDTA 
Freezing Medium 
FBS 
10% DMSO 
 Cell transfection 
3.1.5.1 Plasmids 
 
Name Reference 
dTomato pHR′SIN-cPPT-SEW 
Kindly provided by Prof. Patrick Maier, Department of 
Radiation Oncology, University Medical Centre 
Mannheim, Germany. 
See Appendix 8.1, Figure 40 for maps. 
GFP pHR′SIN-cPPT-SEW 
pCMVDR8.91 
pMD.G 
3.1.5.2 Reagents 
 
Product Company Catalog No. 
LB Broth Sigma L3022 
LB Broth with Agar Sigma L2897 
E. Coli DH5alpha  Bioline BIO-85025 
SOC medium Sigma Aldrich S1797 
Ampicillin Calbiochem 2776677 
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EndoFree Palsmid Maxi Kit Quiagen 12362 
Metafectene Biontex T020-2.0 
Na-butyrat Sigma B5887 
PolyDLysine Hydrobromide Sigma 27964-99-4 
Polybrene Sigma 107689 
EcoRI Thermo Science ERO271 
XBal Thermo Science ERO685 
Tango Buffer Fermentas BY5 
EcoRI Buffer  Thermo Science B12 
Agarose Bioron HS-LF45140050 
Loading Dye Invitrogen R0611 
Tris Base Serva 37180 
Acetic acid J.T. Baker 6052 
EDTA Applichem A3145,0500 
TAE Buffer  40 mM Tris Base, 20 mM Acetic acid, 1mM EDTA 
Broth Culture medium 20g LB Broth in 1L of distilled water 
Culture plate Agar 35g LB Broth with Agar in 1L of distilled water 
 
 
 Flow Cytometry 
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3.1.6.1 Flow cytometry solutions 
 
Name Composition 
FACS Buffer 
1L DPBS 
0.4% BSA 
0.02% NaN3 
MACS Buffer 
1L DPBS 
2mM EDTA 
0.5% BSA 
Cell wash BD Catalog No. 349524 
 
3.1.6.2 Fixation/Permeabilization Buffers 
Product Company Catalog No. 
Transcription Factor Buffer Set BD Pharmingen 562574 
IC Fixation Buffer eBioscience 00-8222-49 
Permeabilization Buffer 10x Invitrogen 00-8333-56 
 
3.1.6.3 Conjugated Antibodies 
Antibody Fluorochrome Clone Catalog No. Brand 
Anti-IDO PE eyedio 12-9477-42 eBioscience 
Treg characterization 
Anti-CD4 FITC RPAT4 555346 BD 
AntiI-CD25 APC M-A251 555434 BD 
Anti-CD127 PE-Cy7 REA614 130-099-719 Miltenyi Biotec 
Anti-FoxP3 PE 259D/C7 560046 BD 
ASC characterization 
Anti-CD29 Alexa Fluor 488 TS2/16 303016 BioLegend 
Anti-CD73 PE AD2 550257 BD 
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Anti-CD90 APC 5E10 559869 BD 
Anti-CD44 APC IM7 103012 BioLegend 
Anti-CD106 FITC 51-10C9 551146 BD 
Anti-CD146 PE TEA1/34 A07483 Beckman Coulter 
Anti-CD3 FITC UCHT1 300406 BioLegend 
Anti-CD14 FITC M5E2 555397 BD 
Anti-235a FITC GA-R2 559943 BD 
Anti-CD19 FITC HIB19 555412 BD 
Anti-CD45 FITC HI30 555482 BD 
Anti-CD34 PE 8G12 345802 BD 
CD105 APC SN6 17-1057-42 eBioscioence 
Anti-CD15 FITC HI98 555401 BD 
Anti-CD31 APC WM59 17-0319-73 EBioscience 
Anti-CD133_1  APC AC133 Miltenyi BD 
Anti-CD144 PE TEA1/31 A07481 Beckman Coulter 
Anti-HLA-DR FITC L234 307618 BioLegend 
Anti-HLA-ABC APC G46-2.6 555555 BD 
HUVEC characterization 
Anti-CD34 FITC 581 555821 BD 
Anti-VEGF-R2 PE 89106 FAB357P RnD 
Anti-CD31 FITC WM59 555445 BD 
Anti-CD133/1 APC AC133 130-090-826 Miltenyi 
Anti-CD144 PE TEA1/31 A07481 Beckman Coulter 
Anti-CD105 APC SN6-4 17-1057-42 eBioscience 
Material and Methods 
30 
Anti-CD45 FITC HI30 555482 BD 
Anti-CD146 PE TEA1/34 A07483 Beckman Coulter 
Anti-CD62P APC AK-4 550888 BD 
Anti-CD14 FITC M5E2 555397 BD 
Anti-CD117 PE 104D2 332785 BD 
Anti-CD62E APC 68-5H11 551144 BD 
 
3.1.6.4 Viability dyes and other reagents 
 
Product Company Catalog No. 
FcR blocking reagent (human) Miltenyi Biotec 130-059-901 
Fixable Viability dye eFluor780 
(eF780) 
eBioscience 65-0865-14 
BD Horizon™ Violet Proliferation Dye 
450 (VPD450) 
BD  
562158 
Sytox Blue Invitrogen S34857 
Sytox Red Invitrogen S34859 
Carboxy-H2DFFDA Thermo Fisher Fisher C13293 
2-NBD Glucose (2-NBDG) Cayman Chemicals 11046 
Precision Count beads BioLegend 424902 
 
 Immunofluorescence 
3.1.7.1 Reagents 
 
Product Company Catalog No. 
DPBS (1X) Gibco 14190-094 
Paraformaldehyde (PFA) Roth 0335.3 
Triton x100 Sigma Aldrich 23,472-9 
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Albumin fraction V (bovine serum 
albumin) Carl Roth 8076.2 
DAPI Sigma 1.24653 
Mounting medium ibidi 50001 
3.1.7.2 Solutions 
 
Name Composition 
2% PFA 
50 ml DPBS 
1 ml PFA 
0.1% Triton 
50 ml DPBS 
50 μl Triton x100 
2% BSA 
50 ml DPBS 
1 ml Bovin serum albumin 
0.1% BSA 
50 ml DPBS 
50 μl Bovin serum albumin 
3.1.7.3 Primary Antibodies 
 
Product Clone Species Type Company Catalog No. 
Anti human-alpha 
smooth muscle 
actin 
ASM-1 Mouse Monoclonal IgG2a PROGEN 65001 
Anti-human NG-2 9.2.27 Mouse Monoclonal IgG2a Santa Cruz sc-80003 
3.1.7.4 Secondary Antibody 
 
Product Clone Species Type Company Catalog No. 
Anti mouse-alexa 
Fluor 488 F(ab´)2 Polyclonal Goat 
IgG, IgM 
(H+L) Invitrogen A10684 
 
 Protein/Cytokine detection 
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3.1.8.1 Reagents 
 
Product Company Catalog No. 
L-Kynurenine Santa Cruz Sc-202688 
Trichloroacetic acid Roth 8789.2 
para-Dimethylaminobenzaldehyde Santa Cruz Sc202888 
Acetic acid J.T.Baker 6052 
DPBS Gibco 14190-094 
Tween-20 Serva 37470.01 
Albumin Fraction V (bovine serum 
albumin) Roth 8076.2 
Color Reagent A (H2O2) R&D Systems DY999 
Color Reagent B 
(Tetramethylbenzidine) R&D Systems DY999 
2N H2SO4 (ELISA Stop soultion) Sigma 1.60313 
ELISA Wash Buffer 0.05% Tween-20 in DPBS 
ELISA Dilution Reagent 1% BSA in DPBS, 0.22 μm filtered 
3.1.8.2 Kits 
 
Product Company Catalog No. 
BD Cytometric Bead Array (CBA) Human 
Th1/Th2/Th17 Cytokine kit BD 560484 
LEGENDplex Human Angiogenesis Panel 1 
(10-plex) 
BioLegend 740698 
LEGENDplex Human Th Cytokine Panel (13-
plex) 
BioLegend 740722 
Human TGF-β1 DuoSet ELISA R&D Systems DY240-05 
Human TNF-α DuoSet ELISA R&D Systems DY210-05 
 Human CCL-18/PARC DuoSet ELISA R&D Systems DY394-05 
Human Angiogenesis Array C1000 RayBiotech AAH-ANG-1000-4 
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 Consumables 
Product Company Catalog No. 
96-well cell culture plate Eppendorf 0030 790.119 
24-well cell culture plate Thermo Fisher 142475 
12-well cell culture plate Thermo Fisher 150628 
6-well cell culture plate Thermo Fisher 140675 
Transwell inserts (pore size 0.4 μm 
transparent ThinCerts-TC inserts) Greiner bio-one 657641 
175 cm2 cell culture flasks Thermo Fisher 159910 
25 cm2 cell culture flasks Thermo Fisher 156367 
96-well black cell culture plate Perkin Elmer 6005550 
8-well μ-slide ibidi 80826 
Petri dish Corning 353803 
50 ml Cell star tubes Greiner bio-one 188271 
15 ml Cell star tubes Greiner bio-one 227261 
1000 μl sterile filter tips SurPhob VT0263X 
200 μl sterile filter tips SurPhob VT0243X 
10/20 μl sterile filter tips Star Lab S1120-3710 
10 ml PD sterile tips brand 631060 
5 ml PD sterile tips brand 702390 
2.5 ml PD sterile tips brand 702388 
1.25 ml PD sterile tips brand 702386 
25 ml serological sterile pipettes Star Lab 190105-071 
10 ml serological sterile pipettes Star Lab 180720-070 
5 ml serological sterile pipettes Star Lab 180806-069 
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100 μm EASY strainer  Greiner 542000 
Rotilabo syringe filters 0.22 μm Roth SE2M035I07 
0.2 ml Thin tubes with flat caps Thermo Fisher AB0622 
5 ml Polystyrene round FACS bottom 
tubes Corning 352052 
CASY cup OMNI Life Science 5651794 
CASY Ton OMNI Life Science 5651808 
50 ml syringes Dispomed 21050 
Vivaspin 20, 100.000 MWCO PES Sartorius VS2041 
 
 Laboratory equipment 
Device  Name Provider 
Centrifuge ROTINA 450 Hettich Zentrifugen 
Centrifuge ROTINA 450R Hettich Zentrifugen 
Cell counter CASY OMNI Life Science 
Cell counter Nucleo Counter Chemometec 
Plate washer Well wash 4MK2 Thermo Fisher 
Small Centrifuge Minispin Eppendorf 
Microscope Axiovert 100 ZEISS 
Microscope Camera AxioCam M Rc ZEISS 
Live imaging microscope  IncuCyte Zoom live imaging device 
Essen BioScience, 
Ltd. 
Laminar flow hood Hera safe Thermo Fisher  
Chemical flow hood Airflow-Control EN14175  Caspar and Co. Labora 
Cell culture incubator  Binder 
Microplate reader TECAN infinite M200PRO Tecan 
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Flow cytometer BD FACS Canto II BD 
Flow cytometer FACS Aria IIu BD 
Confocal microscope SP5 MP Leica 
Thermal cycler DNA Engine Peltier thermal cycler BIO-RAD 
Chemiluminescent detector UVP Epi Chemi II Darkroom UVP Inc. 
 Software for data analysis 
Software Version Company 
FlowJo 10 FlowJo, LLC, Ashland, OR, USA 
FlowJo 7 FlowJo, LLC, Ashland, OR, USA 
GraphPad Prism 7 
GraphPad Software Inc. San 
Diego, USA 
ImageJ 1.51j8 NIH 
i-Control 1.10 TECAN 
LEGENDplex™ Data Analysis 
Software 8.0 BioLegend 
FCAP Array Software 3.0 BD 
IncuCyte S3 software  S3 Essen BioScience, Ltd. 
DoubleDigest Calculator Free 
Software   Thermo scientific 
 
3.2 Methods 
Methods are here gathered following the four different aims presented in section 2: 
(1) Aim 1: Evaluating effects of hyperglycemia on cellular phenotype; 
(2) Aim 2: Evaluation of ASC proangiogenic potential under hyperglycemia; 
(3) Aim 3: Evaluation of pericyte-like function of ASC; 
(4) Aim 4: Evaluation of ASC immunomodulatory potential under hyperglycemia. 
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 Methods Aim 1: Evaluating effects of hyperglycemia on cellular 
phenotype 
To investigate the impact of glucose on ASC 
and HRMVEC, cultures and experiments in 
NG/HG culture media were established.  ASC 
were, immediately after their isolation, 
continuously cultured in either NG or HG 
media; they were fully characterized following 
ISCT guidelines and compared in regard of 
their cell growth, differentiation potential and cell surface marker expression.  
Hyperglycemia-mediated effects were also evaluated on HRMVEC cell growth and 
angiogenic potential. For both ASC and HRMVEC intracellular oxidative state and 
glucose uptake were assessed upon HG exposure.   
 
3.2.1.1 Adipose derived mesenchymal stromal cells 
Adipose derived mesenchymal stromal cells were isolated from multiple donors after 
having obtained informed consent (Mannheim Ethics Commission II; vote numbers 
2006-192 N-MA). 
Briefly, raw lipoaspirate was washed with DPBS to remove cellular debris and red 
blood cells and centrifuged at 420g for 10 minutes. Washed lipoaspirate was treated 
with NB6 collagenase (final concentration 0.15 PZU/ml) in 1:1 dilution with pure DMEM 
and left for 50 minutes at 37°C under gentle agitation. After incubation, collagenase 
was inactivated with an equal volume of DMEM 10% FBS and the solution was 
centrifuged at 1200g for 10 minutes, to obtain the high-density stromal vascular fraction 
(SVF). Supernatant was aspirated and incubated for 10 minutes at room temperature 
(RT) with erythrocytes lysis buffer, to eliminate the excess of red blood cells. Another 
centrifugation step followed and afterwards, the SVF-pellet was resuspended in pure 
DMEM. The SVF-pellet was filtered through a 100 μm nylon mesh filter and again 
centrifuged. The remaining SVF was resuspended in DMEM AB NG or HG and plated 
in a T25 or T175 (in accordance to pellet size), incubated at 37°C with 5% CO2. The 
day after, flasks were extensively washed with DPBS prior to media change.  
After isolation, ASC were routinely cultured in T175 flasks at 200 cells/cm2 in DMEM 
AB NG and HG and therefore named as ASCNG and ASCHG, respectively. 
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Upon 70-80% confluence, ASC were passaged with Trypsin/EDTA, counted using a 
CASY cell counter and seeded according to the experimental conditions. Cell 
morphology was constantly monitored by microscope observation. 
ASC growth rate was monitored recording cell number at every passage. Cell 
Doublings (CD) and Doubling Time (DT) were calculated as follow:  
 
 
 
Where: Fcn is final cell number and Icn initial cell number. 
All cells were cryopreserved in FBS with 10% DMSO in liquid nitrogen, thawed and 
cultivated for at least one passage before use. 
Before use, each newly generated batch of ASCNG-HG was thoroughly characterized 
based on growth potential, differentiation potential and expression/non-expression of 
MSC-specific surface markers, mycoplasma testing, microbial and viral sterility testing 
(the latter at German Red Cross Blood Donor Services Baden-Württemberg – Hessen, 
Institute Mannheim). 
 
3.2.1.1.1 ASC characterization 
3.2.1.1.1.1 Adipogenic differentiation 
To assure ASC differentiation capacity, ASC were cultured in adipogenic differentiation 
medium (Mesenchymal Stem Cell Adipogenic Differentiation Medium) and in DMEM 
AB NG or HG media as control. On day 14th, ASCNG-HG were fixed in 10% PFA for 30 
minutes, washed and incubated with Hoechst-33342 (1:100 final concentration, 10 
mg/ml stock) for other 30 minutes. Hoechst fluorescence (excitation/emission (nm): 
354/442) was measured on a plate reader and considered as baseline for 
normalization. Adipogenic differentiation was measured with AdipoRed Assay 
following the manufacturer’s instructions. Briefly, after washing with DPBS, Adipored 
(5 μl/well in a 96 well plate) diluted in 200 μl of DPBS was added and incubated in the 
dark for 15 minutes. After incubation, AdipoRed fluorescence was measured on a plate 
reader at 485/572 nm. AdipoRed OD (optical density) were normalized on Hoechst OD 
and presented as Normalized Ratio. 
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3.2.1.1.1.2 Osteogenic differentiation 
ASC were cultured in osteogenic differentiation medium (Mesenchymal Stem Cell 
Osteogenic Differentiation Medium) and in DMEM AB NG or HG media as control. On 
day 14th, ASCNG-HG were fixed in 10% PFA for 30 minutes, washed and incubated with 
Hoechst-33342 (1:100 final concentration, 10 mg/ml stock) for other 30 minutes. 
Hoechst fluorescence (excitation/emission (nm): 354/442) was measured on a plate 
reader and considered as baseline for normalization. Osteogenic differentiation was 
measured with Osteoimage Mineralization Assay following the manufacturer’s 
instructions. Briefly, after washing with Wash Buffer, Osteoimage staining reagent 
(1:100 final dilution in Staining Reagent Dilution Buffer) was added to the cells and left 
in incubation for 30 minutes at RT. After incubation, staining reagent was removed and 
Wash Buffer was used to perform three washing steps. Fluorescence was measured 
on a plate reader at 492/520 nm. Osteoimage OD were normalized on Hoechst OD 
and presented as Normalized Ratio. 
3.2.1.1.1.3 Immunophenotype 
ASC from multiple donors were analyzed at passage 2 for their immunophenotype. 
1x105 ASC were collected in FACS tubes and resuspended in FACS buffer. 10 μl of 
FcR blocking reagent were added to each tube and incubated at 4°C for 5 minutes. 
Next, staining with the following anti-human antibodies was performed: Anti-CD29 
Alexa Fluor 488, Anti-CD73-PE, Anti-CD90-APC, Anti-CD44-APC, Anti-CD106-FITC, 
Anti-CD146-PE, Anti-CD3-FITC, Anti-CD14-FITC, Anti-235a-FITC, Anti-CD19-FITC, 
Anti-CD45-FITC, Anti-CD34-PE, Anti-CD105-APC, Anti-CD15-FITC, Anti-CD31-APC, 
Anti-CD133_1-PE, Anti-CD144-PE, Anti-HLA-DR-FITC and Anti-HLA-ABC-APC. All 
antibodies were used in optimal concentrations after proper titration. After staining, 
cells were incubated 20 minutes in the dark at 4°C. Prior to be analyzed, cells were 
washed in Cell wash twice and finally resuspended in SYTOX blue dead cell stain (final 
dilution 1:2000 in FACS buffer). 10,000 viable cells were acquired with BD FACS Canto 
and .fcs files analyzed with FlowJo 10 software. 
 
3.2.1.2 Human retinal microvascular endothelial cells (HRMVEC) 
Human retinal microvascular endothelial cells (HRMVEC) were purchased from 
PeloBiotech. Cells were cultured following the provider’s instructions. Briefly, a frozen 
vial of HRMVEC was thawed in a 37°C water bath. The cell suspension was transferred 
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in a 15 ml tube containing 9 ml of complete ECGM-2 and centrifuged at 200g for 5 
minutes. Supernatant was discarded, cell were resuspended in complete ECGM-2 and 
placed into one T25 previously coated with Speed Coating Solution. Cells were 
maintained at 37°C, 5% CO2. Cell morphology was constantly monitored by 
microscope observation. Upon confluence, HRMVEC were first washed with DPBS 
and then treated with trypsin/EDTA for 5 minutes. Trypsin was stopped with stopping 
medium, cells collected and counted with the CASY cell counter. Cells were cultured 
in complete ECGM-2 at 4x104 cells/cm2 for normal maintenance or seeded according 
to the experiment. 
All cells were cryopreserved in FBS with 10% DMSO thawed and cultivated for at least 
one passage before use. 
To test hyperglycemia-mediated effects on cell growth, HRMVEC were cultured in HG 
ECGM-2 medium. Hypothesizing that the high content of growth factors in the complete 
medium might hide HG detrimental effects, cells were also cultured in growth factor-
reduced medium (¼ ECGM-2) and cell growth was assessed.  
 
3.2.1.2.1 HRMVEC angiogenic potential: basement matrix angiogenesis assay 
(BMA assay) 
17,000 HRMVEC/well were seeded in a 96 well plate on top of 50 μl/well layer of 
Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane Matrix, in ¼ 
ECGM-2 NG and HG. Phase contrast pictures were taken every 30 minutes with the 
IncuCyte Zoom live cell imaging system. Tube length and number of junctions were 
measured after 4 hours, analyzing pictures with the Angiogenesis tool plug-in on 
ImageJ software (Figure 4). 
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Figure 4 Representative picture of analysis of BMA assay. Pictures collected at 4 hours from IncuCyte are analyzed 
with the Angiogenesis tool plug-in on ImageJ software. The tool processes the image and quantifies tube formation 
giving multiple parameters. For our analysis “total length” and “number of junctions” were used. 
 
3.2.1.3 Measurement of intracellular oxidative stress (total reactive oxygen 
species measurements) 
20,000 ASCNG and ASCHG per well or 1x105 HRMVEC/well were seeded in 12-well 
plate in reduced RPMI 1640 with/without HG. After overnight incubation, cells were 
treated/untreated for 1 hour with the antioxidant N-Acetylcysteine (NAC, 1mM final 
concentration). Carboxy-H2DFFDA (10µM final concentration) was then added for 45 
minutes. Afterwards, cells were harvested with trypsin/EDTA, collected in FACS tubes 
and resuspended in FACS Buffer supplemented with SytoxRed (1:2000 final dilution). 
Cell suspensions were immediately analyzed at BD FACS Canto II. Fluorescence of 
Carboxy-H2DFFDA was measured in linear scale and .fcs files analyzed with FlowJo 
10 software. Carboxy-H2DFFDA MFI on viable cells was analyzed and reported as 
ratio normalized on ASCNG and NG HRMVEC. 
In regard of ROS measurement with carboxy-H2DFFDA or DCF, DCFDA-derived 
products it is important to give some specifications. Indeed, as carboxy-H2DFFDA 
penetrates in cells, it is subjected to oxidation by several cytoplasmic ROS species 
such as hydrogen peroxide, organic hydroperoxides, nitric oxide and peroxynitrite, 
which turn it into being fluorescent. Moreover, its oxidation has been found to be 
influenced by glutathione (GSH) [154]. Thus, carboxy-H2DFFDA oxidation results to be 
dependent on several intracellular oxidative stressors as well as anti-oxidant 
mechanisms. Therefore, as suggested by Jakubowski and Bartosz “…increased 
H2DCF oxidation should be referred to as an index of oxidative stress rather than of 
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increased ROS formation unless a more precise statement can be fully justified.” [154]. 
In line with this, in our work, decreases/increases in total ROS measurement are 
interpreted as decreases/increases in the overall intracellular oxidative stress level.     
 
3.2.1.4 Measurement of glucose uptake 
To monitor glucose uptake in NG and HG cultivated cells, 2-NBD glucose (2-NBDG) 
was applied following the manufacturer´s instructions. Briefly, 10,000 ASCNG-HG/well 
and 20,000 HRMVEC/well were seeded in a 96 black well plate and left overnight in 
NG or HG culture conditions. The next day, ASC and HRMVEC were put 2 hours in 
glucose starvation medium and incubated at 37°C. To inhibit glucose uptake, samples 
were treated during starvation with the GLUT-1 inhibitor WZB-117 at 100 μM and 10 
μM final concentration for ASC and HRMVEC, respectively. After 2 hours, 2-NBDG 
was added for 10 minutes at a final concentration of 150 μg/ml for ASC and 25 μg/ml 
for HRMVEC. 2-NBDG fluorescence was detected with a plate reader using 485 nm 
excitation and 535 nm emission wavelengths. At last, Hoechst staining (1:2000 final 
concentration in DPBS) was performed and used to normalize 2-NBDG signals. Data 
are reported as ratio calculated on ASCNG and NG HRMVEC. 
 
 Methods Aim 2: Evaluation of ASC proangiogenic potential under 
hyperglycemia 
The proangiogenic potential of ASCNG-HG was 
evaluated establishing cocultures with 
HUVEC and HRMVEC in NG/HG culture 
media. To monitor tube formation, both 
HUVEC and HRMVEC were transfected with 
lentivirus expressing either green fluorescent 
protein (GFP) or dTomato fluorescent 
protein. Supernatants collected from ASC:HUVEC and ASC:HRMVEC were screened 
for proangiogenic factors comparing them in respect of the culture medium (NG vs HG) 
and ASC (ASCNG vs ASCHG). 
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3.2.2.1 Human Umbilical Vein Endothelial Cells (HUVEC) 
Human umbilical vein endothelial cells (HUVEC) were isolated from multiple donors 
after having obtained informed consent (Mannheim Ethics Commission II; vote 
numbers 2010-262 N-MA). 
Cord blood was first washed out using DPBS and the cord placed in a glass petri dish. 
Then 1 cm from each end was cut. A buttoned cannula was inserted in the vein, fixed 
with a clip and the whole cord blood fixed to a vertical support. The cannula was used 
to flush solutions inside the vein. A 50 ml syringe filled with DPBS was used to flush 
the vein and 100 U/ml of collagenase (final concentration) diluted in EBM were 
prepared in a 10 ml syringe. As this solution was pushed through the cord vein, the 
opposite end of the cord was clipped, and the whole collagenase solution pushed 
through. The buttoned cannula was then closed and the whole cord put into a glass 
backer with warm DPBS. This was incubated at 37°C for 1 hour. After incubation, the 
cord was cut at the lower end and the fluid poured into a 50 ml tube. The vein was 
flushed with 10 ml of EBM and the solution collected. The tube was then centrifuged 
10 minutes at 420g and the supernatant aspirated. The pellet was resuspended in 
complete ECGM-2 and seeded in a T25 cell culture flask. Cells were incubated at 37°C 
with 5% CO2. 
After isolation, HUVEC were routinely cultured in T75 flaks at 8x103 cells/cm2 in 
complete ECGM-2. Cell characterization including morphological and growth 
assessment as well as immunophenotypic characterization were performed as 
previously reported [155].   
Upon confluence, HUVEC were passaged with Trypsin/EDTA, counted and seeded 
according to the experimental conditions. Cell morphology was constantly monitored 
by microscope observation. 
All cells were cryopreserved in FBS with 10% DMSO in liquid nitrogen, thawed and 
cultivated for at least one passage before use. 
HUVEC were also transfected with GFP and dTomato lentiviruses (used for 
immunofluorescence) to obtain green/red fluorescent cells (see section 3.2.2.2).  
 
3.2.2.1.1 HUVEC characterization 
HUVEC from multiple donors were analyzed for their surface cell markers. 1x105 
HUVEC were collected in FACS tubes and resuspended in FACS buffer. 10 μl of FcR 
blocking reagent were added to each tube and incubated at 4°C for 5 minutes. Next, 
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staining with the following anti-human antibodies was performed: Anti-CD34-FITC, 
Anti-VEGF-R2-PE, Anti-CD133/1-APC, Anti-CD31-FITC, Anti-CD144-PE, Anti-
CD105-APC, Anti-CD45-FITC, Anti-CD146-PE, Anti-CD62P-APC, Anti-CD14-FITC, 
Anti-CD117-PE and Anti-CD62E-APC. All antibodies were used in optimal 
concentrations after proper titration. After staining, cells were incubated 20 minutes in 
the dark at 4°C. Prior to be analyzed, cells were washed in Cell wash twice and finally 
resuspended in SYTOX blue dead cell stain (final dilution 1:2000 in FACS buffer). 
10,000 viable cells were acquired with BD FACS Canto and .fcs files analyzed with 
FlowJo 10 software. 
 
3.2.2.2 Production of fluorescent cells 
To monitor tube formation in the angiogenesis coculture assays, HUVEC and 
HRMVEC were stably transfected with a lentiviral vector expressing GFP. In addition, 
HUVEC and HRMVEC were also transfected to express dTomato fluorescent protein. 
These cells were used in angiogenesis cocultures established for Aim 3 to determine 
pericyte-like markers on ASC. 
 
3.2.2.2.1 Plasmid amplification 
To perform plasmid amplification, LB medium as broth culture medium and LB-medium 
with agar were prepared. Both solutions were autoclaved at 121°C for 15 minutes and 
after cooling, ampicillin was added (final concentration 100μg/ml). LB-medium with 
agar was poured in petri dishes to create selective bacterial growth plates. 
Competent E. coli, were gently thawed on ice and 50μl were moved into four pre-chilled 
Eppendorf tubes. 400 ng of each plasmid (dTomato or GFP, pMD.G and 
pCMVDR8.91; Appendix 8.1.1) were added to the 50μl of bacterial suspension and 
thoroughly mixed. These mixtures were incubated 15 minutes in ice. Afterwards, a heat 
shock at 42°C for 42 seconds was provided, followed by 5 minutes of incubation in ice. 
300μl of SOC medium were added to each tube, which was incubated on a 
thermomixer for 1 hour at 37°C with 300 rpm shaking. After incubation, 50μl of 
transfected bacterial suspension were plated on LB-agar plates with ampicillin and left 
overnight upside down at 37°C. 
The following day, one bacterial colony was picked up from each of four selective 
plates and transferred into Erlenmeyer flasks with 200 ml of LB-medium supplemented 
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with ampicillin (final concentration 100μg/ml) to expand the bacterial culture. Flasks 
were incubated overnight at 37°C under 200 rpm shaking. 
The day after, plasmid DNA was isolated with the EndoFree Plasmid Maxi Kit (Qiagen), 
following the manufacturer’s instructions. Briefly, 100ml of bacterial cultures from each 
plasmid were centrifuged in 50ml tubes at 6,000g for 15 minutes at 4°C. Pellets from 
the same bacterial culture were combined and thoroughly resuspended in 10 ml of P1 
buffer. Next, 10 ml of P2 buffer were added, the tube inverted for 5 times and incubated 
at room temperature (RT) for 5 minutes. To enhance genomic DNA precipitation, 10 
ml of P3 buffer were added to the lysate solution and mixed vigorously. The lysate was 
then transferred to the QIAfilter Cartridge and incubated 10 minutes at RT. After 
inserting the plunger, the lysates were filtered into a 50 ml tube. 2.5 ml of ER Buffer 
were added to the filtrate lysates, mixed and incubated on ice for 30 minutes. Filtered 
lysates were applied to the QIAGEN-tip and the flow through discarded. After washing 
step with QC Buffer, plasmid DNA was eluted with the application of 15 ml of QN Buffer 
and collected into 50 ml tubes. DNA was precipitated with 0.7 volumes of isopropanol 
and the solution mixed and centrifuged at 15,000g for 30 minutes at 30°C. 
Subsequently, pellets were washed with 70% ethanol and centrifuged at 15,000g for 
10 minutes. Pellets were air dried and dissolved in 100μl of distilled water and stored 
at -30°C. 
To determine the yield of plasmid DNA extraction, DNA concentration was determined 
by spectrophotometry with 260/280 nm readings.                                                                                    
 
3.2.2.2.2 Plasmid validation 
To validate plasmid amplification and extraction, all four plasmids (dTomato, GFP, 
pMD.G and pCMVDR8.91) were crosschecked with enzymatic restriction on agarose 
gel to check if the number of fragments after restriction was as expected, according to 
the plasmid maps. Restriction enzymes and related buffer are reported in the following 
table. 
 
 dTomato GFP pMD.G pCMVDR8.91 
   Mix 1 Mix 2 Mix 1 Mix 2 
Plasmid 
DNA 1 μg 1 μg 1 μg 1 μg 1 μg 1 μg 
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Buffer Tango 2X Tango 1X 
EcoRI 
buffer Tango 2X Tango 2X 
EcoRI 
buffer 
Enzyme 
1 EcoRI - EcoRI EcoRI EcoRI EcoRI 
Enzyme 
2 XBal XBal - XBal XBal - 
H2O 
Up to 
20μl total 
volume 
Up to 
20μl total 
volume 
Up to 20μl 
total volume 
Up to 20μl 
total volume 
Up to 20μl 
total volume 
Up to 20μl 
total volume 
 
These mixtures were incubated for 1 hour at 37°C. After incubation, 10μl of each 
mixture sample were mixed with 2 μl of Loading Dye. 10 μl of this mixture were loaded 
on 1% agarose gel and run for 45 minutes at 150 V. 
Once checked that the enzymatic restriction gave the number of expected fragments, 
plasmids were used to produce viral particles (Appendix 8.1.2., Figure 41).   
3.2.2.2.3 Lentivirus production 
293FT cells were kindly provided by Prof. Patrick Maier (Department of Radiation 
Oncology, University Medical Centre Mannheim, Germany) and used as packaging 
cell line to produce viral particles. Cells were maintained in DMEM 10% FBS without 
antibiotics at 37°C, 5% CO2. Upon confluence, cells were washed with DPBS and 
treated with trypsin/EDTA. Trypsin was blocked after 5 minutes with stopping media 
and detached cells collected in a 15 ml tube. Cells were counted, and seeded 2x104 
cells/cm2 for normal maintenance or according to the experimental condition. All cells 
were cryopreserved in FBS with 10% DMSO, thawed and cultivated for at least three 
passages before use. 
Prior to use, Petri dishes were coated with poly-D-Lysine (final concentration 0.1 mg/ml 
in DPBS) and washed. 5x106 293FT/petri dish were seeded in 14 ml of DMEM 10% 
FBS and left overnight at 37°C. The next day, cells were transfected with the following 
procedure. 4.4 μg of lentiviral plasmid (GFP or dTomato), 3.4 μg of pCMVDR8.91 and 
2.2 μg of pMD.G (overall 10 μg of plasmid/petri dish) were mixed in pure DMEM without 
additives. Separately, a solution of pure DMEM without additives and metafectene 
(3.2% final concentration) was prepared. The two solutions were mixed 1:1 and added 
dropwise on top of the cell monolayer. Treated cells were incubated overnight at 37°C. 
The next day, cell medium was changed twice: in the morning, with DMEM 10% FBS 
supplemented with Na-butyrate (10 mM final concentration) and in the evening with 
DMEM without additives. The day after, supernatants were collected form each petri 
dish and filtered through a 0.44 μm filter. Viral supernatants were concentrated using 
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Vivaspin-tubes under 3000 rpm centrifugation at 4°C, until a volume of 1 ml was 
obtained. Viruses were stored in 50 μl aliquots at -80°C. 
 
3.2.2.2.4 HUVEC/HRMVEC transfection and selection 
Lentiviruses containing dTomato or GFP inserts were used to transfect HUVEC and 
HRMVEC with the following procedure. 1x104 HUVEC or HRMVEC/well were seeded 
in a 24 well plate in six replicates in ECGM-2 media and left overnight at 37°C. The 
day after, transfection medium was prepared as follow. Solutions of pure GFP or 
dTomato lentivirus were diluted 1:100 in ECGM-2 media supplemented with polybrene 
(8 μg/ml final concentration). This transfection medium was added to the cells and left 
for an overnight incubation. The next day, transfection medium was replaced with fresh 
ECGM-2 in which cells were left for two days. Cells were later harvested with 
trypsin/EDTA and prepared for sorting. They were first stained with Sytox Red and 
Blue for viability discrimination and GFP/dTomato positive cells were sorted with FACS 
Aria IIu. A representative sorting scheme for GFP HUVEC is reported in Appendix 
8.1.3, Figure 42. After sorting, GFP/dTomato HUVEC or HRMVEC were cultured 
following normal culture conditions. 
 
3.2.2.3 Coculture angiogenesis assay 
30,000 ASCNG-HG/well were seeded in a 96 well plate in ECGM ¼ Medium NG or HG 
for 1 hour. Then, 5,000 HUVECGFP or HRMVECGFP were seeded on top of the ASC 
monolayer. Cocultures were incubated for 72 hours. Phase contrast and fluorescent 
pictures were taken every 4 hours with IncuCyte Zoom live imaging device. Tube 
formation was measured with the IncuCyte S3 software, through quantitative kinetic 
processing metrics derived from time-lapse image acquisition and presented as total 
tube length per square centimeter (mm/mm²) over time (Figure 5). After 72 hours of 
coculture, CM of ASCNG-HG coculture was collected and frozen at -80°C. 
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Figure 5 Representative image of IncuCyte S3 software quantification of total tube length in a coculture 
angiogenesis assay. A) Fluorescent images are taken from each well at the desired time point. B) Analysis of 
angiogenesis: the software provides a metric for network length analysis. Parameters are defined by a customable 
processing definition, which is visualized as a blue mask. C) All pictures are analyzed over time and kinetic 
representation of the assay is provided as a graph and related raw data.       
 
To specifically test CM from these cocultures under similar conditions as used for 
assessing ROS (paragraph 3.2.1.3) 4x105 ASCNG-HG /well were seeded in a 24 well 
plate in RPMI 1640 with 2.5% FBS in HG for 1 hour. Afterwards, 2.4x104 HRMVECGFP 
were added on top of the ASC monolayer. After 72 hours of coculture, supernatants 
were collected, centrifuged at 420g for 10 min and freshly used in a BMA assay 
(paragraph 3.2.2.5). Phase contrast pictures were taken every 30 minutes with the 
IncuCyte Zoom system. Tube length was measured after 4 hours, analyzing pictures 
with the Angiogenesis tool plug-in on ImageJ software. 
 
3.2.2.4 Detection of proangiogenic growth factor in angiogenesis coculture 
supernatants 
Supernatants from angiogenesis cocultures were analyzed with two flow-cytometry 
based kits for detection and quantification of proteins involved in angiogenesis: the 
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Human Angiogenesis Array C1000 and the LEGENDplex Human Angiogenesis Panel 
1.    
3.2.2.4.1 Human Angiogenesis Array C1000 
CM collected from ASC:HUVEC coculture angiogenesis assays were analyzed with 
the human angiogenesis antibody array kit (RayBiotech, AAH-ANG-1000-4), following 
the manufacturer´s instructions. Briefly, each membrane was incubated with blocking 
buffer for 30 minutes at RT. After blocking, 1 ml of undiluted conditioned media pooled 
from four different experiments was added and incubated overnight at 4°C. 
Membranes were washed 5 times with wash buffer and subsequently incubated for 2 
hours with the biotinylated antibody cocktail. As the last step before 
chemiluminescence detection, two hours incubation with HRP-Streptavidin was 
performed. Chemiluminescence was measured with a chemiluminiscent detector (UVP 
Epi Chemi II Darkroom). Signal intensities on membranes were analyzed with the 
Protein Array Analyzer plug-in on ImageJ software. A representative picture of 
membranes analysis with ImageJ is reported below (Figure 6). 
 
 
Figure 6 Analysis of membranes of the Human Angiogenesis antibody array kit (RayBiotech, AAH-ANG-1000-4). 
Images of membranes were taken with a chemiluminiscent detector and each single membrane was analyzed as 
follow. Positions of spots are first defined in the matrix as well as blank, positive and negative controls. Next with 
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the function “Masterize” matrixes are normalized and analyzed. Numerical values of spots´ intensities are given as 
results. 
 
3.2.2.4.2 LEGENDplex Human Angiogenesis Panel 1 
CM collected from angiogenesis assays were analyzed with the LEGENDplex Human 
Angiogenesis Panel 1 (10-plex; Cat. No. 740698). 
Briefly, standards were reconstituted in Assay buffer and 1:4 serial dilutions were 
prepared to obtain an 8-points standard curve. A V-bottom plate was loaded first with 
15 μl/well of samples and standards in a 1:1 dilution with Assay Buffer and then 15 μl 
of Premixed Beads were added to each well. The plate was sealed and incubated for 
2 hours at RT under 800 rpm agitation. After incubation, each well was washed with 
150 μl of Wash Buffer, followed by 5 minutes centrifugation at 250g. The plate was 
again decanted, washed and centrifuged prior to the addiction of Detection Antibody 
(15 μl/well). 1 hour of RT incubation under 800 rpm shaking followed. Afterwards, SA-
PE was added in each well and incubated 30 minutes at RT with 800 rpm agitation. 
Finally, the plate was washed twice and the content of each well resuspended in 150 
μl of Wash Buffer. Each probe was transferred in FACS tube prior to BD FACS Canto 
II analysis. Data were acquired limiting the acquisition rate on 300 beads/analyte. 
Data analysis was performed with the LEGENDplex™ Data Analysis Software 
according to the manufacturer’s instructions. 
 
3.2.2.5 Assessing the proangiogenic potential of coculture conditioned medium 
17,000 HRMVEC/well were seeded in a 96 well plate on top of 50 μl/well layer of 
Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane Matrix. To 
maintain the same culture condition of ROS measurement (paragraph 3.2.1.3), BMA 
assay was set also in reduced RPMI medium (supplemented with 2.5% FBS). The 
following conditions were tested: (1) NG, (2) HG, (3) NG+NAC (final concentration 
1mM), (4) HG+NAC (5) CM from coculture angiogenesis assay, (6) CM from ASC 
monoculture. CM were always used freshly after harvesting. Phase contrast pictures 
were taken every 30 minutes with the IncuCyte Zoom live imaging device. Tube length 
was measured after 4 hours, analyzing pictures with the Angiogenesis tool plug-in on 
ImageJ software. 
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 Methods Aim 3: Evaluation of pericyte-like function of ASC 
Immunofluorescent staining was used to 
evaluate the expression of pericyte markers 
in ASC cocultured with HUVEC and 
HRMVEC. To compare pericytes to ASC in 
regard of their proangiogenic potential, 
coculture angiogenesis assays with 
HUVEC/HRMVEC and pericytes were 
established in NG/HG culture medium. 
3.2.3.1 Coculture immunofluorence 
To perform immunofluorescence, coculture angiogenesis assays were set on 8-well μ-
slides as follow. 1x105 ASC/well were seeded in ECGM ¼ Medium NG or HG for 1 
hour. Then, 5.5x104 HRMVECGFP were added on top of the ASC monolayer in a total 
volume of 300 μl of medium/well. Tube formation was monitored over 72h. On day 3, 
μ-slides were prepared for immunofluorescence staining (see below). 
 
After culture medium aspiration, each well was washed with 300 μl of DPBS and 
subsequently fixed in 2% PFA for 30 minutes at RT. After fixation, wells were washed 
and permeabilized with 0.5% TritonX100 solution for 3 minutes at RT. Then blocking 
with 2% BSA for 15 minutes was performed after washing. Before the addition of the 
primary antibody, each well was thoroughly washed with DPBS. Then, 50μl/well of anti-
human α-SMA were added and incubated for 1 hour in the dark at RT. After washing 
with 0.1% BSA solution, the secondary antibody Anti mouse-Alexa Fluor 488 F(ab´)2 
(1:1000 final dilution) was added and incubated for 1 hour in the dark at RT. The 
washing step with 0.1% BSA was followed by DAPI staining (1:1000 final dilution of 
1mg/ml stock) for 3 minutes. Finally, wells were washed and embedded in Ibidi 
mounting medium. 
Slides were analyzed at confocal microscope (Leica SP5 MP, Lima Core Facility, 
Center for Biomedicine and Medical Technology Mannheim (CBTM)) with 40x/1.3 NA 
oil objective.               
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3.2.3.2 Pericytes: endothelial cells coculture 
Human retinal microvascular pericytes (HRMVPC) were purchased from PeloBiotech 
and cultured following the manufacturer’s instructions. A frozen vial of HRMVPC was 
thawed in a 37°C water bath for 1 minute. Cell suspension was transferred in a 15 ml 
tube containing 10 ml of Pericytes Growth Medium (PGM) and centrifuged at 200g for 
5 minutes. Supernatant was discarded, cell were resuspended in 10 ml of PGM and 
placed into one T25 previously coated with Speed Coating Solution. Cells were 
maintained at 37°C, 5% CO2. Cell morphology was constantly monitored by 
microscope observation.  
Upon confluence, HRMVPC were first washed with DPBS and then treated with 
trypsin/EDTA. Cell detachment was monitored under microscope observation for 1 
minute. Detached cells were resuspended in PGM. Cell were counted with 
NucleoCounter cell counter and seeded in two T25 cell culture flask (1:2 passaging 
ratio) for normal maintenance or seeded according to the experimental conditions. 
All cells were cryopreserved in FBS with 10% DMSO in liquid nitrogen, thawed and 
cultivated for at least one passage before use. 
 
HRMVPC were used in angiogenesis coculture assays as followed. 30,000 
pericytes/well were seeded in a 96 well plate in ECGM ¼ Medium NG or HG for 1 hour. 
Then, 5,000 HUVECGFP or HRMVECGFP were seeded on top of the HRMVPC 
monolayer. Cocultures were incubated for 72 hours. Phase contrast and fluorescent 
pictures were taken every 4 hours with IncuCyte Zoom system. Tube formation was 
measured with the IncuCyte S3 software, through quantitative kinetic processing 
metrics derived from time-lapse image acquisition and presented as total tube length 
per square centimeter (mm/mm²) over time. As performed with ASC, HRMVPC were 
also used in cocultures for immunofluorescent staining (paragraph 3.2.3.1). 
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 Methods Aim 4: Evaluation of ASC immunomodulatory potential under 
hyperglycemia 
Cocultures between ASCNG-HG and 
stimulated/resting PBMC were set to 
investigate the immunomodulatory potential 
of ASC dissecting the interaction with CD4 T 
cells. Coculture supernatants were analyzed 
with ELISA and FACS-based protein 
detection assay.  
  
3.2.4.1 Peripheral blood mononuclear cell (PBMC) isolation 
Human PBMC were isolated from buffy coat from healthy donors, provided by the 
German Red Cross Blood Donor Service Institute Mannheim. Buffy Coats were 
collected into 50 ml tubes and diluted 1:1 with DPBS/EDTA. 25 ml of diluted Buffy coat 
were gently poured on top of 10 ml of Ficoll-Paque in a 50 ml tube and centrifuged 30 
minutes at 420g (with lowest deceleration factor). After centrifugation, supernatants 
containing plasma were aspirated and the interphase collected with a glass Pasteur 
pipette. Interphases from same donors were collected together in 50 ml tubes and 
washed with DPBS/EDTA. Tubes were centrifuged for 10 minutes at 420g. To 
eliminate contaminating red blood cells, pellets were washed with erythrocyte lysis 
buffer and left 10 minutes in incubation at RT. After a centrifugation step, pellets were 
resuspended in DPBS/EDTA and counted with the CASY cell counter.  
 
3.2.4.2 ASC: PBMC coculture 
For assessment of T cell proliferation, 3x107 PBMC were resuspended in DPBS and 
stained with violet proliferation dye (VPD450 final concentration 1μM in DPBS). After 
15 minutes incubation at 37°C, cells were washed, centrifuged and resuspended in 
RPMI 1640 10% FBS. Depending on the experimental conditions, PBMC were treated 
with/without CD3+CD28+ loaded Anti-Biotin MACSiBead particles (T cell 
Activation/Expansion kit human) using one loaded Anti-Biotin MACSiBead particle per 
two PBMC (bead to cell ratio 1:2) following the manufacturer´s instructions. In short, 
Anti-Biotin MACSiBead particles were thoroughly mixed with CD3-Biotin, CD28-Biotin 
and MACS buffer. This mixture was then incubated for 2 hours at 4°C under gentle 
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rotation. Prior to addiction to PBMC, loaded Anti-Biotin MACSiBead particles were 
washed with RPMI 1640 10% FBS. The treatment defined stimulated (with beads) and 
not stimulated (without beads) PBMC, which were then directly used to set cocultures 
with ASC. 
 
2x105 ASCNG-HG were seeded in full RPMI 1640 on the bottom of a 6-well plate. Directly 
after isolation, 1x106 VPD450 stained stimulated/not stimulated PBMC were added 
either (a) directly on top of the ASC monolayer (direct coculture) or (b) in a transwell 
insert placed in suspension in the same well of ASC (transwell coculture). As control, 
VPD450 stained stimulated/not stimulated PBMC were seeded in full RPMI 1640 either 
in a 6-well plate alone (direct coculture setting) or in a transwell insert placed in 
suspension in a well containing only media (transwell coculture setting). Direct and 
transwell cocultures each with stimulated/ not stimulated PBMC and their respective 
controls (PBMC alone) were set in parallel for each experiment. Controls and 
cocultures were treated with IL-2 (1:500 final dilution, 500 μg/ml stock). After 7 days 
cocultures were harvested and CM collected and stored at -80°C for further analysis. 
Harvested PBMC and ASC were processed following procedures reported in 
paragraphs 3.2.4.2.1 and 3.2.4.3.   
To investigate the long-term effect of ASC on PBMC, not stimulated PBMC from 
transwell cocultures were further cultured without ASC for the following 7 days (total 
days of culture 14). In details, PBMC were harvested after 7 days of coculture and 
counted. The same number of PBMC was then seeded in 6-well plate in fresh full RPMI 
1640 with IL-2 (1:500 final dilution, 500 μg/ml stock). The following conditions were 
defined: (a) PBMC (control condition of PBMC pre-cultured without ASC in the previous 
7 days) and (b) ex-Coculture (PBMC cultured with ASC in the previous 7 days). After 
7 days (total 14 days), PBMC were processed following procedures reported in 
paragraphs 3.2.4.2.1.1. The CM of these cultures was harvested, collected and stored 
at -80°C for further analysis. A representative picture of the whole work flow is reported 
below (Figure 7). 
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Figure 7 General work flow for ASC:PBMC cocultures. For each experiment fresh PBMC were isolated from buffy 
coat with Ficoll gradient and stained with violet proliferation dye. Stimulated and not stimulated cocultures were 
established with CD3/CD28 treated/not treated PBMC in direct and transwell settings with their respective controls. 
After 7 days PBMC and ASC were harvested and processed as reported in paragraph 3.2.4.2.1. CM was also 
harvested and frozen for further analysis. PBMC from transwells were also re-seeded and further cultured for 14 
days.  
 
3.2.4.2.1 Treg staining and detection 
After 7 days of culture, VPD450 stained stimulated/not stimulated PBMC were 
harvested from cocultures and controls. Mouse anti-human antibodies were used to 
specifically stain activated CD4 cells and Treg. 
3.2.4.2.1.1 Treg panel 
After harvesting, PBMC were collected in FACS tubes, washed with PBS and 
resuspended in FACS Buffer. After 5 minutes incubation with 10 μl of FcR blocking 
reagent, antibodies for surface cell staining were added: Anti-CD4, Anti-CD25 and 
Anti-CD127 and incubated 20 minutes in dark at 4°C. After washing, PBMC were 
resuspended in PBS, stained with Fixable Viability dye eF780 (1:2000 final dilution) 
and incubated for 30 minutes at 4°C. To perform the intracellular staining, the BD 
Pharmingen Transcription Factor Buffer was used, following the manufacturer’s 
instructions. Briefly, cells were resuspended by vortexing in 1 ml of 1X Fix/Perm Buffer 
and incubated for 50 minutes at 4°C. After incubation, two times washing step with 1X 
Perm/Wash Buffer were performed. Cells were then resuspended in 100 μl of 1X 
Perm/Wash buffer and stained with Anti-FoxP3. After 50 minutes of incubation at 4°C 
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cells were washed twice with 1X Perm/Wash buffer and finally resuspended in FACS 
buffer. 100 μl of cell suspension together with 25 μl of Precision count beads were 
analyzed immediately at BD FACS Canto II. Precision count beads were used during 
data analysis to calculate percentages of cell subpopulations. The .fcs files were 
analyzed with FlowJo 10 software. The gating strategy applied to calculate 
percentages of CD4+CD25+ and Treg cells in Live population is reported in Figure 8.
 
Figure 8 Representative gating strategy on Live population for CD4+CD25+ cells and Treg. Lymphocytes are gated 
on SSC and FSC, followed by a dead/live gating with FVD780, to define the Live population. The Live population is 
then inspected for CD4 and CD25 expression. Subsequently, CD127 and FoxP3 are assessed in the CD4+CD25+ 
population. CD4+CD25+CD127-FoxP3+ cells are defined as Treg. 
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3.2.4.2.1.2 Analysis of Proliferating/non proliferating subpopulations 
To evaluate the extent of proliferation of CD4+ cells in cultures, living VPD450 stained 
stimulated/not stimulated PBMC were gated and analyzed as follow. As VPD450 dye 
is distributed uniformly between daughter cells, it is possible to monitor cell division 
over time. VPD+ cells, which retain the dye, are not proliferating cells, while VPD- are 
actively proliferating cells, progressively losing the dye. Therefore, starting from 
unstimulated and stimulated PBMC controls, it was possible to set gating for 
proliferating (VPD-) and non-proliferating (VPD+) cells. A representative picture of this 
gating strategy is reported in Figure 9. 
 
 
 
 
Figure 9 Proliferating (VPD-) and non proliferating (VPD+) gating are defined on stimulated/not-stimulated PBMC 
in direct and transwell. A representative gating strategy is reported. Lymphocytes are gated on SSC and FSC, 
followed by a dead/live gating with FVD780, to define the Live population. The Live population is inspected for the 
Violet Proliferation Dye (VPD). Stimulated PBMC (dark gray) and not stimulated PBMC (light gray) are compared 
and the gating for Proliferating cells (VPD-) and non proliferating cells (VPD+) set. The slight auto-stimulation in 
not-stimulated PBMC is useful in defining the gate. 
Moreover, VPD-/+ fractions were further discriminated/gated for CD4+CD25+ cells and 
Treg. A representative picture of this gating strategy for CD4+CD25+ and Treg is 
reported in Figure 10. 
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Figure 10 Representative gating strategy on VPD-/+ population to define VPD+ and VPD– fractions of CD4+CD25+ 
cells and Treg. Lymphocytes are gated on SSC and FSC, followed by a dead/live gating with FVD780, to define the 
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Live population. The Live population is inspected for the Violet Proliferation Dye (VPD). The gating defined in Figure 
9, identify the VPD- and VPD+ fractions. The VPD- and VDP+ populations are then analyzed as reported in Figure 
8. 
CD4 cells proliferation was also analyzed with the Proliferation Tool of FlowJo 7 
software. The Proliferation Tool in fact, applies mathematical models to the 
proliferation data and develops statistics to describe it. Particularly, we focused on the 
“division index”, which is described as followed: “The Division Index is the average 
number of divisions for all of the cells in the original starting population” (FlowJo 7 
manual tutorial). A representative picture of how the Proliferation tool works is reported 
in Figure 11. 
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Figure 11 Representative picture of proliferation tool in FlowJo v.7 software. Lymphocytes are gated on SSC and 
FSC, followed by a dead/live gating with FVD780 to define the Live population. The Live population is then 
characterized for CD4 expression. CD4+ cells are subsequently evaluated for Violet Proliferation Dye (VPD) 
staining. The proliferation tool allows the custom to set a Peak zero, to define the original population. Peak zero 
(dashed line, orange peak) is here defined taking into account the VPD distribution in PBMC stimulated and not 
stimulated. After peak zero definition, the proliferation tool adjusts its algorithm on the curve and calculates the 
following proliferating generation (pink peaks) as well as the division index. 
 
3.2.4.3 Cytokines and protein detection  
To investigate the cytokine profile of CM collected from ASC:PBMC cocultures, two 
types of flow-cytometer based kits were used: the BD Cytometric Bead Array 
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(3.2.4.3.1) and the  LegendPlex Human Th Cytokine Panel (3.2.4.3.2). In addition: (1) 
kynurenine in coculture supernatants was measured; (2) TGF-beta, TNF-alpha and 
CCL-18 were assessed with ELISA and (3) intracellular IDO was detected in ASC from 
cocultures.  
3.2.4.3.1 BD Cytometric Bead Array (CBA) 
The BD Cytometric Bead Array (CBA) Human Th1/Th2/Th17 Cytokine Kit (Cat. 
Number 560484) was used to analyze CM from 7 day stimulated/not stimulated 
transwell cocultures and PBMC as well as CM from PBMC after 14 total days of culture, 
following the manufacturer’s instructions. Briefly, standards and samples were placed 
into FACS tubes followed by addiction of mixture of Capture beads. After the addiction 
of the Human Th1/Th2/Th17 PE Detection Reagent, CM was left 3 hours in incubation 
at RT. Then, a washing step with wash Buffer was performed and after aspiration of 
supernatants, tubes were ready for acquisition at the BD FACS Canto II. Data analysis 
on .fcs files was performed with the FCAP Array Software. 
3.2.4.3.2 LegendPlex Human Th Cytokine Panel 
CM collected from ASC:PBMC cocultures were analyzed with the LEGENDplex 
Human Th Cytokine Panel (13-plex; Cat No. 740722). 
Briefly, standards were reconstituted in Assay Buffer and 1:4 serial dilutions were 
prepared to obtain an 8-points standard curve. A V-bottom plate was loaded first with 
15 μl/well of samples and standards in a 1:1 dilution with Assay Buffer and then 15 μl 
of Premixed Beads were added to each well. The plate was sealed and incubated for 
2 hours at RT under 800 rpm agitation. After incubation, each well was washed with 
150 μl of Wash Buffer, followed by 5 minutes centrifugation at 250g. The plate was 
again decanted, washed and centrifuged prior to the addiction of Detection Antibody 
(15 μl/well). 1 hour at RT incubation under 800 rpm shaking followed. Afterwards, SA-
PE was added in each well and incubated 30 minutes at RT with 800 rpm agitation. 
Finally, the plate was washed twice and the content of each well resuspended in 150 
μl of Wash Buffer. Each probe was transferred in FACS tube prior to BD FACS Canto 
II analysis. Data were acquired limiting the acquisition rate on 300 beads/analyte. 
Data analysis was performed with the LEGENDplex™ Data Analysis Software 
according to the manufacturer’s instructions. 
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3.2.4.3.3 Kynurenine assay 
Kynurenine was measured in CM of 7 days stimulated and not stimulated ASC:PBMC 
cocultures and controls as follow. 100 μl of probes and standards were distributed on 
a 96-well plate (LightCycler® 480 Multiwell Plates 96) and mixed with 50μl of 30% 
Trichloroacetic acid (TCA). The plate was incubated 30 minutes at 50°C. After the 
incubation, the plate was centrifuged at 4004g for 10 minutes at RT. Without touching 
the pellets, 75 μl of supernatants were collected from each condition and transferred 
in a 96-well plate. 75 μl of 2% para-Dimethylaminobenzaldehyde were added to each 
well and incubated for 15 minutes at RT. The OD of each well was determined using a 
microplate reader set to 492 nm. Standard, best fitting (0.90≤R≤1) curves were 
elaborated with GraphPad Prism 7 software. No kynurenine was found in ASC cultured 
alone used as control. 
3.2.4.3.4 ELISAs 
TGF-beta, TNF-alpha and CCL-18 (Duo Set, R&D systems) were analyzed in CM of 7 
days and 14 days stimulated and not stimulated ASC:PBMC cocultures and controls 
following the manufacturer’s instructions. Capture antibody diluted in DPBS was used 
to coat a 96-well plate, which was incubated overnight at RT. The following day, after 
three aspiration/wash steps with Wash Buffer, the plate was blocked with Reagent 
Diluent and incubated for 1 hour at RT. At the end of incubation, three aspiration/wash 
steps were performed and standards and samples added. The plate was left 2 hours 
in incubation at RT. Three aspiration/wash steps were repeated and afterwards the 
detection antibody was added, followed by 2 hours incubation at RT. As last steps after 
washing, Streptavidin-HRP was added for 20 minutes, followed by other 20 minutes of 
incubation with substrate solution (1:1 solution of Color reagent A and B). The plate 
was finally treated with stop solution (2N H2SO4). The OD of each well was determined 
using a microplate reader set to 450 nm with wavelength correction at 570 nm. Best 
fitting standard curves (0.90≤R≤1) were elaborated with GraphPad Prism 7. 
3.2.4.3.5 Detection of  indoleamine 2,3-dioxygenase (IDO) 
Indoleamine 2,3-dioxygenase (IDO) detection in ASCNG-HG cocultured with 
stimulated/non stimulated PBMC, was measured as follow. After harvesting ASC from 
coculture, cells were collected in FACS tubes and washed with DPBS. IC Fixation 
Buffer was added to the cell suspension and left in incubation for 30 minutes at RT. 
After two washing/centrifuge steps with 1X Permeabilization Buffer, cells were stained 
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in 1X Permeabilization Buffer with IDO-PE and incubated for 30 minutes. After 
incubations, cells were washed and analyzed immediately at BD FACS Canto II. ASC 
in monoculture were used as control. The .fcs files were analyzed with FlowJo 10 
software. Data are presented as Median Fluorescence Intensity (MFI) of IDO-PE in 
living cells corrected for the MFI´s of the control tube (ASC in monoculture). 
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4 RESULTS 
The main focus of our study was to evaluate whether hyperglycemia might affect ASC 
in their phenotype and functions. Therefore, four aims were defined: (1) to evaluate 
glucose-mediated effects on ASC basic characteristic; (2) to assess whether 
hyperglycemia might affect the proangiogenic potential of ASC; (3) to investigate 
whether ASC might retain a pericytes-like phenotype and (4) to verify if HG might affect 
the immunomodulatory potential of ASC. Results of our research are presented below, 
following the distinctions between the four aims.  
 
4.1 Effects of hyperglycemia on cellular phenotypes 
The first aim of our study was to address 
glucose-mediated effects on basic 
characteristics of ASC such as cell growth, 
differentiation and cell surface phenotype. 
Intracellular redox balance and glucose 
uptake were also monitored. Similarly, 
HRMVEC were also characterized in regard 
of their glucose sensitivity. 
 ASC basic characteristics are unaffected by HG 
To test effects of HG, ASC were cultured in NG (ASCNG) and HG (ASCHG) medium 
directly after isolation from lipoaspirates. At passage 1 to passage 2 after isolation, HG 
caused a weak but significant reduction in cell doublings (ASCNG vs ASCHG , p<0.01; 
Figure 12 A, upper left panel) and correspondingly, an increased doubling time (ASCNG 
vs ASCHG, p<0.05; Figure 12 A, lower left panel). However, these differences were not 
detectable at following passages (Figure 12 A, right). 
Adipogenic and osteogenic differentiation profile of ASCHG was not different from 
ASCNG (Figure 12 B). 
Likewise, ASCNG and ASCHG had a similar immunophenotype (Figure 12 C).  
Despite some early transient reduction in proliferation rate, HG exerted no long-term 
effects on ASC. 
 
Results 
64 
 
 
Figure 12 ASC characteristics are largely unaltered by HG. (A) HG reduces ASC growth rate only at early passage 
(cell number calculated at split p1 to p2). Cell doublings (upper left panel) are significantly reduced in ASCHG (ASCNG 
6.67 ± 0.6 vs ASCHG 6.39 ± 0.65, p<0.01, n=10, paired T-test). Doubling time (lower left panel) is significantly 
increased (ASCNG 31.24 ± 5.9 hours vs ASCHG 32 ± 7.4 hours, p<0.05, n= 10, paired T-test). From passage 2 to 3 
on, cell doublings and doubling time (right panels) do not differ (n=10). (B) ASCNG and ASCHG do not differ in 
adipogenic and osteogenic differentiation potential (ADA and ODA respectively, AdipoRed and OsteoImage signal 
normalized to Hoechst signal, n=7; not significant, Paired t-test). (C) The immunophenotype of ASCNG and ASCHG 
addressed by flow cytometry is similar (n=8, not significant, 2-way ANOVA). 
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 Oxidative stress in ASC is increased upon HG exposure and it is not 
concomitant to glucose uptake 
Oxidative stress levels (total ROS measurement) were similar in ASCNG and ASCHG 
(Figure 13 A). The ROS inhibitor NAC had only a negligible effect on both, indicating a 
low basal oxidative stress level in ASC. However, a temporary switch of ASC to HG 
(ASCNG in HG) increased oxidative stress up to 1.5-fold (ASCNG in HG vs ASCNG and 
ASCNG: p<0.01 and p<0.05, respectively). This was significantly lowered by NAC 
treatment (ASCNG in HG: +NAC vs –NAC: p<0.01). This suggested that ASC might 
adapt to prolonged HG conditions to maintain a low oxidative stress.  
We next investigated the glucose uptake (Figure 13 B). In ASCNG, glucose uptake was 
significantly inhibited by the GLUT-1 inhibitor WZB (ASCNG –WZB vs +WZB: 
p<0.0001). Interestingly, glucose uptake of ASCNG in HG and ASCHG compared to 
ASCNG was very low at levels comparable to ASCNG cells treated with WZB (ASCNG vs 
ASCHG and ASCNG in HG: p<0.0001). Even, the switch to HG revealed low glucose 
uptake with values comparable to levels obtained using the GLUT1 inhibitor WZB-117. 
This suggested that ASC might adapt rapidly to HG in the medium by reducing glucose 
influx. 
 
 
Figure 13 HG-dependent oxidative stress induction is not related to increased glucose uptake. ROS were measured 
in ASC via Carboxy-H2DFFDA staining. The antioxidant NAC was tested as inhibitor of ROS. In addition, glucose 
uptake was monitored trough 2-NBDG detection after a period of glucose starvation. WZB-117 a GLUT-1 inhibitor, 
was added to block glucose uptake.  (A) Oxidative stress levels are comparable in ASCNG- HG and only inhibited to 
a low extent by the antioxidant NAC (mean fluorescence intensity (MFI) values of ASCNG set to 1). Switch of ASCNG 
to HG (ASCNG in HG) significantly increased ROS levels compared to ASCNG and ASCHG (p<0.01 and p<0.05). The 
same are inhibited by NAC treatment (p<0.01); n=3, 2-way ANOVA multiple comparison. (B) After glucose 
starvation, ASCNG take up glucose (levels set to 1). This is significantly inhibited by the GLUT-1 inhibitor WZB-117 
(ASCNG –WZB vs +WZB: p<0.0001; n=3, 2-way ANOVA multiple comparison). Glucose uptake is significantly 
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reduced in ASCHG and ASCNG in HG to levels obtained with the WZB-117 inhibitor (ASCNG vs ASCHG and ASCNG in 
HG: p<0.0001; 2-way ANOVA multiple comparison). 
 HG affects HRMVEC cell growth and angiogenic potential  
In complete medium (ECGM-2), no effect of HG on HRMVEC proliferation was 
apparent (Figure 14 grey and black ■ lines). Hypothesizing that growth factors and 
especially VEGF, as suggested by different authors [156, 157], in ECGM-2 medium 
might protect ECs from hyperglycemia, cells were grown in growth factor-reduced 
medium (¼ ECGM-2). The growth rate significantly decreased comparing ECGM-2 
with ¼ ECGM-2 (in NG media p<0.01 and HG media p<0.001, Figure 14, grey and 
black lines). Nevertheless, in both media HG did not reduce HRMVEC proliferation to 
a significant extent. 
 
 
 
Figure 14 HG slightly impairs HRMVEC cell growth. Growth curves of HRMVEC reveal diminished proliferation in 
growth factor reduced medium, ¼ ECGM-2 () compared to ECGM-2 () (NG-treated black lines: ¼ vs ECGM-2 
p<0.01; HG-treated grey line:s ¼ vs ECGM-2; p<0.001, n=3; 2-way ANOVA multiple comparisons). HG had no 
significant effect. 
The angiogenic potential of HG HRMVEC, tested in the BMA assay, however, revealed 
a significant reduction in total tube length (p<0.001, Figure 15 left panel) and in number 
of junctions (p<0.001, Figure 15 right panel). These differences were not seen in 
ECGM-2, supporting our notion that growth factors in the medium might overrule 
detrimental HG effects in endothelial cells (not shown). 
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Figure 15 HG impairs the angiogenic potential of HRMVEC. HG let to reduced tube formation in BMA assay in ¼ 
ECGM-2. Left: total tube length HRMVEC NG-treated 7.52 ± 0.97 mm/mm2 vs HG-treated 6.69 ± 1.02 mm/mm2 
p<0.0001 (n=4, Paired T-test). Right: number of junctions: NG-treated 217.3±35.57 vs HG-treated 165.8±38.7 
p<0.0001 (n=4, Paired T-test). 
 
 Oxidative stress increases in HRMVEC upon HG treatment in absence of 
simultaneous rise in glucose uptake 
As performed for ASC, we measured total ROS and glucose uptake in HRMVEC. 
HRMVEC similarly to ASC displayed a low oxidative stress basal level (NG HRMVEC: 
–NAC vs +NAC, not significant; Figure 16 A). This was significantly increased in HG 
conditions (NG HRMVEC vs HG p<0.01) and efficiently inhibited by NAC (HG 
HRMVEC –NAC vs + NAC, p<0.01).  
Glucose uptake (Figure 16 B) was reduced in HG condition compared to NG (NG 
HRMVEC vs HG: p<0.001). In contrast to ASC, where the GLUT-1 inhibitor greatly 
reduced glucose uptake almost to zero in all conditions, in HRMVEC glucose uptake 
levels were halved in NG HRMVEC (–WZB vs +WZB: p<0.001 ) and similarly reduced 
in HG conditions (HG –WZB vs +WZB: p<0.05). These findings suggested that while 
HG HRMVEC reduced glucose uptake compared to NG HRMVEC, the WZB-117 
GLUT-1 inhibitor only halved this uptake, proposing that other GLUT channels might 
be involved. The oxidative stress appeared to be not directly linked to increased 
glucose influx. 
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Figure 16 Total ROS were measured in HRMVEC via Carboxy-H2DFFDA staining. The antioxidant NAC was tested 
as inhibitor of ROS. In addition, glucose uptake was monitored trough 2-NBDG detection after a period of glucose 
starvation. WZB-117, a GLUT-1 inhibitor, was added to block glucose uptake. (A) In HRMEC, oxidative stress is 
significantly increased upon HG treatment (p<0.01; n=3, 2-way ANOVA multiple comparison) and significantly 
reduced by NAC treatment (p<0.01; n=3, 2-way ANOVA multiple comparison). (B) HG HRMVEC show reduced 
glucose uptake compared to NG (p<0.001; n=4, 2-way ANOVA multiple comparison). WZB-117 half-reduced 
glucose uptake in both conditions (NG: –WZB vs +WZB: p<0.001 and in HG: –WZB vs +WZB: p<0.02 and NG 
HRMVEC +WZB-117 vs HG HRMVEC +WZB-117 p<0.01; n=4, 2-way ANOVA multiple comparison). 
 
4.2 Evaluation of ASC proangiogenic potential under hyperglycemia 
Having established that HG did not affect ASC 
and had only negligible effects on cell growth 
of HRMVEC while reducing their 
proangiogenic potential, we investigated ASC 
interaction with endothelial cells. As our 
second aim was to prove the proangiogenic 
potential of ASC and to verify whether this was 
affected by hyperglycemia, cocultures between ASC and both HUVEC and HRMVEC 
where established. Coculture supernatant was collected and assessed for 
proangiogenic factors. 
 ASC support HUVEC angiogenic potential independently of glucose and 
secrete proangiogenic factors 
To investigate whether HG affected the proangiogenic potential of ASC, coculture 
angiogenesis assays in NG and HG culture media were run comparing ASCNG-HG and 
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NG/HG medium. ASC supported tube formation of HUVECGFP in any condition (Figure 
17 A and B). 
 
 
Figure 17 ASCNG and ASCHG similarly support HUVEC tube formation in an angiogenesis coculture assay. (A) 
Representative pictures of tube formation of HUVECGFP in the coculture angiogenesis assay (a, b) ASCNG + 
HUVECGFP and ASCHG + HUVECGFP respectively, in NG media; (c,d) ASCNG + HUVECGFP and ASCHG + HUVECGFP 
respectively, in HG media. (B) Quantitative evaluation of tube network length (mm/mm2) reveals no differences 
between ASCNG (●) and ASCHG (▲) in NG/HG medium (n=6, not significant, 2-way ANOVA). 
To screen whether HG modified growth factor secretion within the supernatants, 
pooled CM from ASCNG/HUVEC cocultures in NG and HG medium was analyzed using 
an angiogenesis protein array (Figure 18). Over all 43 cytokines analyzed, no 
significant difference was detectable. Despite the lack of significant changes (NG vs 
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HG, not significant), some factors in HG cocultures were found to be 
increased/decreased to a certain extent compared to NG cocultures. Among the 
increased factors, CCL-7 and PECAM-1 displayed a 2.8-fold and 1.9-fold respectively, 
while CCL-13 and MMP-1 had a 1.4-fold increase. On the other side, GM-CSF together 
with TNF-alpha was highly decreased in HG coculture (0.04-fold and 0.1-fold 
respectively). Similarly, CCL-1 (0.4-fold), PDGFB-BB (0.4-fold) and IL-4 (0.5-fold) were 
reduced in HG. All the other factors had a fold between 0.8 and 1.2. 
These data indicated that HG did not affect the angiogenic supportive capacity of ASC 
on HUVEC whilst exerting some minor changes on the cytokine profile of the coculture.  
 
 
Figure 18 HG affects only few angiogenic factors in CM of ASCNG + HUVECGFP coculture angiogenesis assay. CM 
was collected and pooled from four different coculture experiments and analyzed using an angiogenesis protein 
array (43 factors). Fold change of HG compared to NG (set as 1), is calculated. Over all 43 factors, no significant 
difference was found comparing NG and HG medium (not significant, paired T-test). Proteins with 0.5≤ fold ≥1.4 
are labeled. Proteins with fold change between 0.8 and 1.2 are bFGF, GRO, IFN gamma, IGF, IL-6, IL-8, MCP-1, 
PLGF, CCL5, TIMP-1, TIMP-2, VEGF-A, ANGPT1, ANGPT2, Angiostatin, Endostatin, CCL1, IL-1 alpha, IL-1 beta, 
IL-2, CXCL11, MMP-9, Tie2, uPAR, VEGFR2, VEGFR3. 
 
 HG HRMVEC angiogenic potential is rescued in coculture via secretion 
of proangiogenic factors by ASC 
It was apparent that HRMVEC showed markedly lower angiogenic potential when 
compared to HUVEC, network length in ASCNG:HRMVECGFP vs ASCNG:HUVECGFP 
p<0.0001 (not shown). Although tube formation capacity of HG HRMVEC was found 
to be significantly reduced in the BMA assay (Figure 15, paragraph 4.1.3), in the 
coculture assay no differences were seen when using ASCNG-HG under NG/HG culture 
medium (Figure 19 A, B). These findings not only confirmed the supportive role of ASC 
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to the tube forming potential of endothelial cells, but also suggested that ASC may 
protect HRMVEC from detrimental effects of HG. 
 
 
Figure 19 A) Representative pictures of coculture angiogenesis assay with HRMVECGFP; (a, b) ASCNG + 
HRMVECGFP and ASCHG + HRMVECGFP respectively, in NG media; (c,d) ASCNG + HRMVECGFP and ASCHG + 
HRMVECGFP respectively, in HG media. (B) ASCNG (●) and ASCHG (▲) equally support HRMVECGFP tube formation 
independently of culture conditions (n=8). 
 
We speculated that factors secreted from ASC might support endothelial angiogenic 
potential rescuing HRMVEC from HG detrimental effects. To test this, we analyzed the 
CM from ASCNG-HG:HRMVEC coculture angiogenesis assays using a multiplex 
cytokine assay (Figure 20 A). Again, glucose in the media caused no differences in the 
growth factor content of ASCNG-HG (not shown). In the CM of cocultures, the majority of 
analyzed factors were higher than in the monocultures of ASC. Some factors were 
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significantly changed under HG, such as FGF significantly higher in ASCNG cocultures 
than in ASCHG cocultures (p<0.05) and higher in ASCNG cocultures than in ASCNG 
monocultures (p<0.05). VEGF, highly concentrated in ASCNG-HG monocultures, was 
significantly decreased in CM of cocultures (p<0.05, VEGF panel in Figure 18 A). 
Despite the lack of significant differences, we also found that ASCNG-HG monoculture 
produced considerably high amounts of Ang-2 (mean value ASCNG monoculture 
665±405 pg/ml), which were even increased in ASCNG-HG cocultures (mean value 
ASCNG coculture 2247±1130 pg/ml). Similarly, Ang-1 levels were reduced in ASCNG-HG 
monoculture (ASCNG mean value 110±134 pg/ml) and increased in coculture (ASCNG 
mean value 319±360 pg/ml).  
Importantly, we observed a correlation between the concentration of secreted factors 
and the proangiogenic supportive capacity of ASC by comparing individual ASC 
isolates (Figure 20 B). These data indicated that ASC secreted a variety of 
proangiogenic factors, largely unaffected by HG. 
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Figure 20 A) Angiogenic growth factor content in CM of NG ASCNG-HG:HRMVEC cocultures and ASCNG-HG 
monocultures. FGF is significantly reduced in ASCHG coculture compared to ASCNG coculture (p<0.05). Moreover, 
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FGF is more concentrated in ASCNG coculture than in ASCHG monocultures (p<0.05).  VEGF is higher in ASCNG-HG 
monocultures than cocultures (both p<0.05). All n=4, One-way ANOVA. B) In angiogenic coculture assays, high 
angiogenic growth factor concentrations are linked to a better angiogenic support, dependent on ASC sample 
specificity (ASCNG, ASCHG; ♦, ●, ■, ▲ different ASC samples). Symbols to identify ASC samples are reported also 
in A. 
 
 Indirect proangiogenic supportive potential of ASC 
So far we observed that hyperglycemia impaired the angiogenic potential of HRMVEC 
and that this was rescued in direct cocultures with ASC, independently of glucose in 
the culture media. Therefore, we tested whether the proangiogenic factors produced 
by ASC and detected in their CM, were sufficient to rescue HG HRMVEC impaired 
angiogenic potential. Having previously found that hyperglycemia exposure caused an 
increase in oxidative stress level of HG HRMVEC, to verify a possible link with the 
reduced angiogenesis, we further tested the effect of the antioxidant NAC on their tube 
forming potential. Hypothesizing that ASC secreted factors and an antioxidant stimulus 
might protect HRMVEC from HG-mediated insults, we checked HRMVEC in a BMA 
assay. The following conditions were tested: (1) NG, (2) HG, (3) NG+NAC 
(antioxidant), (4) HG+NAC (5) CM from coculture angiogenesis assay, (6) CM from 
ASC monoculture. To further check HG-mediated effects, these CM media were 
obtained from angiogenesis coculture assays performed with ASCHG in HG medium. 
 
Indeed, NAC restored the angiogenic potential of HG HRMVEC to some extent 
(HRMVEC HG vs HG+NAC p<0.0001, Figure 21), but not to levels obtained in NG 
conditions (HRMVEC NG vs HG+NAC p<0.05, Figure 21).  
CM of both ASCHG mono- and coculture restored the impaired angiogenic potential of 
HG HRMVEC (HG HRMVEC vs CMHG-ASCHG coculture and ASCHG monoculture 
p<0.0001, Figure 21). CM media-treated HG HRMVEC had a network length 
comparable to NG HRMVEC (NG HRMVEC vs CMHG HRMVEC, not significant) and 
HG HRMVEC +NAC.  
These data indicated that ASC could restore the HG-impaired angiogenic function of 
HRMVEC by the production of proangiogenic factors. The fact that NAC-treated and 
CM-treated HG HRMVEC displayed a similar network length, let us speculate about a 
not yet defined ROS scavenging/antioxidant potential of CM or an overruling effect of 
angiogenic factors within the CM. 
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Figure 21 HG impairs the angiogenic potential of HRMVEC, which is restored by NAC, CM from ASC co- and 
monoculture assays. Tube forming potential of HRMVEC was tested in a BMA with NAC or pure CM, either from 
ASCHG monoculture and ASCHG:HRMVEC coculture in HG medium (CMHG). To resemble culture condition of ROS 
measurement, the assay was run in RPMI1640 (supplemented with 2.5% FBS, 1% Penicillin/streptomycin and 2% 
Glutamine). Tube formation is reduced in HG HRMVEC compared to NG HRMVEC (p<0.0001 one-way ANOVA, 
multiple comparison). NAC treatment increases network length in HG (p<0.0001), but not to levels seen in NG 
HRMVEC (p<0.05, n=5, one-way ANOVA, multiple comparison). CM from co- and monoculture restored tube 
forming capacity of HG HRMVEC (p<0.0001) to levels seen in NG (CMHG vs NG HRMVEC, not significant, one-way 
ANOVA, multiple comparison). 
 
4.3 Evaluation of pericyte-like function of ASC in coculture 
Pericytes are an important component in the 
microvasculature of the retina and many 
evidences sustain pericyte loss as one of the 
first sign of vessel degeneration. Their drop 
out would induce high microvascular instability 
[121]. As demonstrated by some studies in 
animals, MSC expressed pericyte-like 
markers once in the retinal microenvironment [125, 126]. In our third aim, we verified 
whether ASC might express pericyte-like markers when cocultured with HRMVEC. To 
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characterize the difference between ASC and HRMVPC, these were tested in 
coculture angiogenesis assays. 
 α-SMA positive ASC wrap around tube structures 
To assess whether ASC could take over pericytes supporting function of vascular 
structures, we performed immunofluorescence staining on coculture angiogenesis 
assays and investigated the expression of two pericyte markers: α-SMA and NG-2. 
In ASC:HUVEC cocultures, we observed that α-SMA positive ASCNG-HG, were more 
concentrated around tube structures and in some cases, they even surrounded tubes 
reminiscent of pericytes wrapping around vessels (Figure 22). Notably, α-SMA had 
only a bare expression in ASC monoculture (not shown), suggesting that the contact 
with endothelial cells might induce a kind of pericyte-like differentiation in ASC. 
 
 
 
Figure 22 Representative confocal fluorescent images of α-SMA staining in coculture angiogenesis assays with 
ASCNG (first line)/ASCHG (second line) and dTomato HUVEC. α-SMA positive ASC (green) wrap around the tubular 
structures (red), resembling pericytes in normal physiology. Red: dTomato HUVEC; Green: anti-mouse Alexa Fluor 
488 conjugated to anti-human α-SMA; Blue: DAPI. 50 μm scale bare; 40x oil immersion objective, images are a 
combination of 20 to 30 Z-stacks.  
 
The same approach was applied to ASC:dTomato HRMVEC coculture angiogenesis 
assays. As previously observed in coculture with HUVEC, α-SMA positive ASC 
wrapped around HRMVEC (Figure 23). In line with previous results, ASC monoculture 
had only a weak expression of α-SMA (Figure 23, last line). These observations 
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confirmed that, independently of endothelial cell types, the proximity between ASC and 
endothelial cells induced in ASC a stronger α-SMA expression.       
 
 
 
 
Figure 23 Representative confocal fluorescent images of α-SMA staining in coculture angiogenesis assays with 
ASCNG and dTomato HRMVEC. α-SMA positive ASC (green) are concentrated around tube structures (red) and 
wrap around them (line 1, 2 and 3 are individual examples) . In ASC monoculture (last line), α-SMA is barely 
expressed.  Red: dTomato HUVEC; Green: anti-mouse Alexa Fluor 488 conjugated to anti-human α-SMA; Blue: 
DAPI. 50 μm scale bare; 40x oil immersion objective; images in line 1,2 and 3 are a combination of 23 Z-stacks; 
last line, single plane image.  
 
α-SMA is a very general pericyte marker; therefore, we performed a staining for NG-2 
which is usually strongly expressed by capillary-associated pericytes [158]. In ASC: 
dTomato HRMVEC cocultures, we observed the whole ASC monolayer being positive 
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for NG-2 (Figure 24; line 1 and 2). In particular, no specific pattern of expression was 
found indicating that NG-2 expression was not aligned to tube-like structures. In ASC 
monolayer, NG-2 was similarly expressed as in coculture (Figure 24 last line). These 
observations suggested that, in contrast to α-SMA, NG-2 expression was constitutive 
in ACS and not related to endothelial cells and their tube formation.       
 
 
 
Figure 24 Representative confocal fluorescent images of NG-2 staining in coculture angiogenesis assays with ASC 
and dTomato HRMVEC. NG-2 (green) was uniformly expressed in the ASC monolayer of coculture (Line 1 and 2, 
two individual examples). A similar pattern was found in ASC monoculture (last line) Red: dTomato HUVEC; Green: 
anti-mouse Alexa Fluor 488 conjugated to anti-human NG-2; Blue: DAPI. 50 μm scale bare; 40x oil immersion 
objective; images in line 1 and 2 are a combination of 23 Z-stacks; last line, single plane image. 
 
 Pericytes have no angiogenic potential 
So far, we demonstrated that ASC not only retained a strong angiogenic supportive 
potential, but also that they expressed pericyte marker such as α-SMA and NG-2. To 
further compare ASC to pericytes, we decided to test HRMVPC in a coculture 
angiogenic assay. We observed that HRMVPC cocultures with either HUVEC or 
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HRMVEC, did not support any tube formation in NG or HG culture media (Figure 25). 
Indeed, endothelial cells clustered together. This observation suggested thatHRMVPC, 
compared to ASC, do not retain a pro-angiogenic potential. This may be in line with 
their physiological role as modulator of vessels maturation, which stabilize and protect 
the vasculature.  
 
 
 
Figure 25 Representative pictures of coculture angiogenesis assay (n=3) with HRMVPC and HUVECGFP/ 
HRMVECGFP. Overall, no tube formation is observed. (a, b) Pericytes + HUVECGFP, in NG and HG media 
respectively; (c,d) pericytes + HRMVECGFP in NG and HG media respectively. 
 
As expected, HRMVPC expressed NG-2 both in coculture and monoculture. In 
cocultures, NG-2 expression pattern did not have any relation to HRMVEC, which were 
clustering together (Figure 26). 
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Figure 26 Representative confocal fluorescent images of NG-2 staining in coculture angiogenesis assays with 
HRMVPC and dTomato HRMVEC. dTomato HRMVEC (red) clustered together in cocultures with HRMVPC (Line 
1). NG-2 (green) was expressed in the HRMVPC monolayer of coculture (Line 1). A similar NG-2 pattern was found 
in HRMVPC monoculture (Line 2). Red: dTomato HUVEC; Green: anti-mouse Alexa Fluor 488 conjugated to anti-
human NG-2; Blue: DAPI. 50 μm scale bare; 40x oil immersion objective; single plane images. 
Oppositely to NG-2, α-SMA expression in HRMVPC was very weak in coculture and 
almost absent in monoculture (Figure 27, Line 1 and 2), confirming the variability of α-
SMA expression depending on pericyte location and origin [159, 160]. 
 
 
 
Figure 27 Representative confocal fluorescent images of α-SMA staining in coculture angiogenesis assays with 
HRMVPC and dTomato HRMVEC. dTomato HRMVEC (red) clustered together in cocultures with HRMVPC (Line 
1). α-SMA (green) was weakly expressed in the HRMVPC monolayer of coculture (Line 1). In monoculture, 
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HRMVPC almost did not express α-SMA (Line 2). Red: dTomato HUVEC; Green: anti-mouse Alexa Fluor 488 
conjugated to anti-human α-SMA; Blue: DAPI. 50 μm scale bare; 40x oil immersion objective; single plane images. 
 
4.4 Evaluation of ASC immunomodulatory potential under hyperglycemia 
The fourth part of our project concerned the 
investigation of the immunomodulatory 
potential of ASC. As in the previous 
experiments, the distinction between ASCNG 
and ASCHG was kept, to evaluate potential 
hyperglycemia-mediated effects on ASC 
immunomodulation. Establishing ASC:PBMC 
direct and indirect (transwell) cocultures, we focused on the interaction between ASC 
and CD4 T cell subsets evaluating (1) the inhibitory effect of ASC on CD4 T cells, (2) 
the generation of Treg and (3) the soluble mediators involved. Two distinct conditions 
were evaluated: (a) stimulated cocultures, where PBMC were stimulated with 
CD3/CD28 beads and (b) not-stimulated cocultures, where resting PBMC were used.  
 
 ASC:PBMC stimulated coculture 
4.4.1.1 ASCNG-HG inhibit CD4 proliferation in coculture with stimulated PBMC 
To verify ASCNG-HG immunomodulatory capacity, direct and transwell cocultures with 
stimulated PBMC were established. As controls, stimulated PBMC monocultures 
placed in 6-well plate or in transwell inserts were used. After 7 days, CD4 cells highly 
proliferated in PBMC monocultures, as denoted by the high division index (Figure 28). 
In contrast, in both direct and transwell cocultures the division index significantly 
dropped (Figure 28), indicating that the presence of ASC, independently of cell-cell 
contact, was effective in inhibiting CD4 cell proliferation. Moreover, the extent of 
inhibition of CD4 proliferation was almost identical for ASCNG and ASCHG, suggesting 
that glucose did not interfere with ASC immunomodulatory potential. 
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Figure 28 Direct and transwell coculture inhibit the proliferation of CD4 cells in stimulated PBMC. The inhibitory 
potential of ASCNG-HG on stimulated PBMC was investigated in direct and transwell cocultures. After 7 days, 
cocultures and respective controls were harvested and analyzed. Division index of CD4 cells in stimulated PBMC 
monocultures and cocultures are reported. CD4 cells have similar division index in direct and transwell PBMC STIM 
monoculture (5.33±2.49 vs 4.76±2.08, respectively). ASCNG-HG, either in direct or transwell cocultures, significantly 
inhibit CD4 cells proliferation, causing a reduction of the division index (direct: ASCNG 1.45±0.4 and ASCHG 
1.45±0.5; transwell: ASCNG 1.6±0.5 and ASCHG 1.52±0.4; vs respective PBMC STIM controls: p<0.01). Data are 
normalized on division index of CD4 in not stimulated PBMC monoculture (division index =1). 2-way ANOVA 
multiple comparison, n=4. 
 
4.4.1.2 The inhibition of T cell proliferation is based on IDO-mediated tryptophan 
depletion 
Suppression of T cell proliferation is a well-established feature of the 
immunomodulatory potential of MSC and it has been related to IDO expression by 
MSC and the subsequent kynurenine production [161, 162]. 
To verify this mechanism to be relevant in our coculture, IDO levels were measured in 
cocultured ASC as well as kynurenine concentrations in coculture supernatants. 
While IDO in ASCNG-HG monocultures was not detectable, its level in ASCNG-HG isolated 
from direct and transwell cocultures were considerably high and not affected by 
glucose (Figure 29 A). Notably, IDO was higher expressed in direct than in transwell 
cocultures (p<0.05) for both ASCNG and ASCHG. Despite this difference in IDO 
expression, kynurenine concentration in coculture supernatants was similar in all 
conditions (Figure 29 B). No kynurenine was detected in monocultures of stimulated 
PBMC, confirming that its production is to be allocated uniquely to ASC. 
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Figure 29 ASC-mediated inhibition of CD4 proliferation is regulated by induction of IDO and kynurenine production. 
A) IDO is highly induced in ASCNG-HG of both cocultures when compared to ASC monoculture (not detectable, not 
shown); however, IDO induction is higher in ASCNG-HG direct cocultures than transwell cocultures (MFI: direct ASCNG 
160.3±1.4 vs transwell ASCNG 121.8±3.5, p<0.05 and transwell ASCHG 197.8±42.4 vs transwell ASCHG 141.8±50.2, 
p<0.05). No significant difference were found between ASCNG and ASCHG. 2-way ANOVA, n=3. B). Kynurenine 
production is similar in all conditions tested. No kynurenine was detected in ASCNG-HG monoculture (not shown). 2-
way ANOVA, n=3. 
 
4.4.1.3 CD4 cells become activated in ASC cocultures 
Having observed the significant suppression of CD4 cell proliferation in cocultures, we 
hypothesized that ASC might also inhibit their activation. Therefore, we dissected the 
CD4+ population looking for CD25 expression. CD25, known also as IL2RA 
(Interleukin-2 receptor alpha chain), is a type I transmembrane protein expressed on 
activated T cells and is considered one of the most prominent marker for cell activation 
[163]. 
The analysis of CD4+ viable cells revealed a similar degree of activation in PBMC 
monocultures in both direct and transwell conditions where CD4+CD25+ cells 
represented respectively 17.6±2.1% and 13.9±1.3% of the entire Live population 
(Figure 30 A). The fraction of CD4+CD25+ cells was increased in coculture with 
ASCNG-HG in direct and transwell cultures. Although the increase was significant only 
in transwell cocultures (PBMC STIM vs ASCNG and ASCHG, p<0.05), a similar trend 
appeared also in direct cocultures (Figure 30 A). To understand whether the increase 
of CD4+CD25+ fractions in cocultures was related to their effective proliferation, we 
investigated the distribution of CD4+CD25+ cells in the proliferating (VPD-) and non-
proliferating (VPD+) fractions (Figure 26 B). Despite the inhibition of CD4 proliferation 
previously documented in cocultures, we found a significant proliferation of 
CD4+CD25+ cells. Indeed, in the VPD- population, we observed a substantial increase 
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of CD4+CD25+ fractions in ASCNG-HG cocultures compared to the PBMC STIM controls 
(p<0.05 in direct and p<0.001 in transwell). As already observed, no differences 
between ASCNG and ASCHG were found, again confirming that HG exerted no effects 
on ASC. In VPD+ fractions no major changes were detected in the CD4+CD25+ 
population, despite a small but significant increase in transwell ASCHG coculture 
(p<0.05, Figure 30 B). 
In conclusion, we found that despite the inhibition of CD4 cell proliferation, ASC 
induced their activation and proliferation in transwell and direct cocultures, exceeding 
the mere activation of CD3/CD28 beads. 
 
 
 
Figure 30 ASC promoted activation (CD25+) of CD4+ cells in coculture with stimulated PBMC. CD4+CD25+ 
population was analyzed in stimulated PBMC monocultures and cocultures after 7 days. A) Distribution of the 
CD4+CD25+ population in the Live population. In coculture, the CD4+CD25+ population is expanded compared to 
the PBMC monoculture (Direct: PBMC STIM 17.67±2.1% vs coculture ASCNG: 22.3±4.7% and coculture ASCHG 
21.26±5.8, not significant; Transwell: PBMC 13.9±1.3% vs coculture ASCNG: 23.2±4.3% and coculture ASCHG 
23.1±4.3%, p<0.05). 2-way ANOVA multiple comparison, n=3. B) Despite ASC inhibition on CD4+ cells proliferation, 
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CD4+CD25+ expansion is evident in both cocultures (VPD- direct: PBMC STIM 20.38±3.1%  vs coculture ASCNG 
35.4±9.8% and coculture ASCHG 33.55±9.4%, p<0.05; VDP- transwell: PBMC STIM 15.33±1.2% vs coculture 
ASCNG 40.23±2.6% and coculture ASCHG 39.84±2.8%, p<0.001). The VPD+ fraction remains constant in direct 
culture but it is slightly increased in transwell ASCHG coculture compared to its control (PBMC STIM 14.3±2.4% vs 
coculture ASCHG 20.47±1.5%, p<0.05). 2-way ANOVA multiple comparison, n=3. 
 
4.4.1.4 The Treg fraction is unaffected by ASC coculture 
Beyond being an activation marker, the expression of CD25 together with FoxP3 in 
CD4 cells is known to be a trademark for Treg (defined as CD4+CD25+FoxP3+). To 
investigate the distribution of Treg subpopulation in our cell cultures we compared 
direct and transwell cocultures as well as ASCNG-HG to verify whether ASC could induce 
Treg. 
Surprisingly, the Treg fractions in both direct and transwell, either ASCNG or ASCHG did 
not differ from the one observed in their control PBMC monocultures (Figure 31 A). We 
further checked the distributions of Treg in the VPD- and VPD+ populations (Figure 31 
B). No difference was found between ASCNG-HG direct coculture and its PBMC STIM 
control in the VPD- fractions. However, in transwell ASCNG and ASCHG cocultures, the 
Treg fraction was reduced compared to the transwell PBMC STIM control (PBMC STIM 
vs coculture ASCNG p<0.01, PBMC STIM vs coculture ASCHG p<0.001). Importantly, 
the reduction of Treg in VDP- fractions of ASCNG-HG transwell cocultures was significant 
compared to the direct cocultures (direct coculture ASCNG vs transwell coculture 
ASCNG p<0.01 and direct coculture ASCHG vs transwell coculture ASCHG, p<0.01). The 
Treg distribution in VPD+ fractions was similar in all conditions (Figure 31 B).  
In contrast to data in the literature, which mainly reported ASC-mediated induction of 
Treg, these data showed that direct or transwell cocultures did not modify the Treg 
balance in stimulated PBMC. Indeed, ASC seemed even to reduce Treg proliferation 
especially in transwell cocultures. 
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Figure 31 Distribution of the Treg population in the Live population (A) and in the VPD-/VDP+ group (B).  A) The 
Treg fraction is equivalent in PBMC monocultures and ASCNG-HG cocultures, in direct and transwell conditions. B) 
In direct cultures VDP-, Treg population is similar in all conditions. In transwell VPD-, T reg in ASCNG-HG coculture 
are reduced compared to PBMC monoculture (transwell PBMC STIM 16.7±2.9% vs transwell coculture ASCNG 
8.5±1.2%, p<0.01 and vs transwell coculture ASCHG 6.2±0.5% p<0.001). Moreover, in transwell ASCNG-HG 
cocultures, Treg fraction was reduced compared to direct cocultures (direct coculture ASCNG 14.5±2.8% vs transwell 
ASCNG coculture 8.5±1.2%, p<0.01 and direct coculture ASCHG 13.6±1.8% vs transwell ASCHG coculture 6.2±0.5%, 
p<0.01). Overall, no differences were detected in the VPD+ fraction. 2-way ANOVA multiple comparison, n=3 
 
4.4.1.5 ASC cocultures restrict cytokines secretion  
We previously documented the inhibitory effect of ASCNG-HG in coculture with T cells, 
independently of direct or indirect contact and independently of glucose. As the 
immunosuppressive potential of MSC has been reported to occur in parallel to 
polarization of Th subsets (which secrete specific set of cytokines) [73, 74], we 
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examined the CM of stimulated PBMC monocultures and ASCNG cocultures for 
Th1/Th2 cytokines.  
Overall, we found a reduction of analyzed cytokines in coculture in comparison to 
PBMC monoculture (Figure 32). Notably, IL-13 (p<0.001), IL-5 (p<0.01), IL-10 (p<0.01) 
and TNF-alpha (p<0.01) were significantly reduced in coculture. Similarly, although not 
significantly lowered, IL-9, IL-17a and IL-17f were also reduced, while IL-22 resulted 
unchanged. 
These findings were in line with previous observations on the inhibitory effect of ASC 
on T cell proliferation. Indeed, it caused a reduction in number of cytokines producing 
cells and thus an overall reduction of cytokine levels. Moreover, we were not able to 
detect any specific Th1/Th2 polarization induced by ASC. 
 
 
 
 
Figure 32 Th1/Th2 cytokines are decreased in stimulated coculture CM. Th1/Th2 cytokines (LEGENDplex™ 
Human Th1/Th2 Panel, Cat. n. 740730) were analyzed in CM of stimulated PBMC monoculture and coculture. 
Overall, coculture restricts cytokine secretion, notably: IL-5 (p<0.01), IL-10 (p<0.01), IL-13 (p<0.001) and TNF-alpha 
(p<0.01). Ratio paired T-test, n=4. 
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 ASC:PBMC not stimulated coculture 
4.4.2.1 ASC do not affect CD4 proliferation in resting PBMC  
Having observed (1) the inhibiting effect of ASC on CD4 proliferation under CD3/CD28 
stimulation, (2) induction of T cell activation marked by CD25 expression and (3) slight 
inhibition of Treg numbers, we established similar experiments in an not stimulated 
setting. Cocultures and their controls were set up using ASCNH-HG and not stimulated 
PBMC.  
Because of their low immunogenicity, ASCNG-HG did not induce significant allogeneic 
proliferation of CD4 in both direct and transwell cultures (Figure 33). Intriguingly, CD4 
in transwell PBMC control showed a slight but significant increase in the division index 
compared to PBMC in direct culture (PBMC direct vs PBMC transwell, p<0.05), 
suggesting a sort of auto-stimulation. The presence of ASCNG-HG did not affect this low 
level of proliferation within the transwell.  
 
 
 
Figure 33 The inhibitory potential of ASCNG-HG in not-stimulated/resting PBMC coculture was investigated. ASCNG-
HG do not affect not-stimulated PBMC (PBMC NOT STIM) in cocultures. However, some auto-stimulation of PBMC 
monoculture is observed in transwell culture when compared to direct (p<0.05). 2-way ANOVA multiple comparison, 
n=4.  
 
4.4.2.2 IDO and kynurenine levels are low in coculture under not-stimulated 
conditions 
We showed previously that IDO-mediated kynurenine production was observed in 
CD3/CD28-stimulated cocultures and was related to the immune suppressive action of 
ASC. In ASCNG-HG:resting PBMC cocultures, both IDO and kynurenine were detectable 
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at low levels (Figure 34 A and B) while again no IDO was detected in ASC 
monocultures. Indeed, IDO levels in not stimulated ASCNG-HG cocultures were more 
than halved compared to the one in stimulated cocultures (direct: stimulated ASCNG-HG 
vs not stimulated ASCNG-HG, p<0.05, not shown). In ASCNG coculture with not 
stimulated PBMC, IDO was more expressed in ASC from transwell than in ASC from 
direct cocultures (p<0.05, Figure 34 A). Kynurenine concentrations were comparable 
in transwell and direct (Figure 34 B) but reduced when compared to stimulated 
cocultures (direct and transwell: stimulated coculture ASCNG-HG vs not stimulated 
coculture ASCNG-HG, p<0.05 not shown). 
All together, these findings supported our previous observations, confirming that the 
ASC mediated IDO-kynurenine axis was actively involved in the inhibition of CD4 cell 
proliferation in a stimulated setting. However, in absence of CD3/CD8-mediated 
stimulation on PBMC, the IDO-kynurenine pathway was downregulated without any 
consequence on CD4 proliferation. CD4 proliferation did not occur in absence of 
CD3/CD28-stimulation.  
  
 
 
Figure 34 IDO, in cocultured ASCNG.HG, and kynurenine, in cocultures CM, were measured. A) Low IDO levels are 
detected in both transwell and direct cocultured ASCNG-HG. IDO is significantly higher in ASCNG transwell coculture 
than direct coculture (p<0.05). Notably, IDO was not detectable in ASC monoculture. B) Kynurenine concentrations 
were low and comparable in both ASCNG-HG transwell and direct cocultures. No kynurenine was detected in ASC 
monoculture or PBMC (not shown). 2-way ANOVA, n=3.     
 
4.4.2.3 Unstimulated coculture do not activate CD4 cells 
As stimulated coculture promoted CD4 activation, we evaluated CD25 expression on 
CD4 cells also in not stimulated cultures. The absence of CD3/CD28-mediated 
stimulation on PBMC strongly reduced the overall CD4+CD25+ population in ASCNG-
HG cocultures and controls (stimulated vs not stimulated in direct and transwell cultures 
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for PBMC and ASCNG-HG coculture, from p<0.05 to p<0.001; not shown). In this case, 
no coculture-mediated activation of CD4 was detected (Figure 35 A). Zooming into the 
VPD- fractions (Figure 35 B), we found a similar trend in direct and transwell cultures, 
indicating a decrease of proliferating CD4+CD25+ cells in ASCNG-HG cocultures when 
compared to PBMC monocultures (direct: PBMC vs ASCNG-HG coculture, p<0.05; 
transwell: PBMC vs coculture, not significant, Figure 35 B). This indicated that despite 
the presence of ASC, in absence of CD3/CD28 stimulation, CD4 cells were not 
activated. No differences were detected in the distributions of CD4+CD25+ cells in 
VPD+ fraction. 
 
 
Figure 35 ASC do not induce activation (CD25+) of CD4+ cells under not-stimulated conditions. CD4+CD25+ 
population were analyzed in not-stimulated PBMC monoculture and coculture after 7 days. A) Distribution of the 
CD4+CD25+ population in the Live fraction. The CD4+CD25+ population is comparable in PBMC monoculture and 
ASCNG-HG coculture in either direct and transwell. B) Distribution of CD4+CD25+ cells in the proliferating (VPD-)/non 
proliferating (VDP+) group. VPD- CD4+CD25+ population is reduced in direct ASCNG-HG cocultures compared to 
PBMC (PBMC NOT STIM 15.37±5.7% vs coculture ASCNG 2.83±2.5% and coculture ASCHG 3.08±2.9%, p<0.05). 
A similar but not significant trend is observed in transwell (VPD- transwell: PBMC NOT STIM 21.5±8.9% vs coculture 
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ASCNG 10.4±4.7% and coculture ASCHG 11.52±5.7%, not significant). The proportion of the VPD+ CD4+CD25+ do 
not differ. 2-way ANOVA multiple comparison, n=3. 
4.4.2.4 ASCNG-HG cocultures promote Treg in not-stimulated setting 
Subsequently, we evaluated the Treg distribution in the Live and in the VPD-/VPD+ 
population. The analysis of the Live population revealed that ASCNG cocultures 
expanded the Treg fraction in both direct and transwell cocultures compared to PBMC 
monocultures (p<0.05). A similar but not significant trend was observed for ASCHG 
cocultures (Figure 36 A). Overall, Treg fractions were higher in unstimulated conditions 
than stimulated (stimulated vs not stimulated in direct and transwell cultures for PBMC 
and ASCNG-HG cocultures, from p<0.05 to p<0.001; not shown), suggesting that resting 
conditions might help in preserving Treg, which are further increased in presence of 
ASC.  
These observations were further confirmed by dissecting the VPD-/VPD+ populations. 
Indeed, the proliferating fraction of Treg was increased in coculture, especially in direct 
cocultures (Figure 36 B). The VPD+ fraction did not vary upon culture conditions.  
In summary, we observed that coculture between ASC and unstimulated PBMC did 
not promote CD4 cell activation. Instead, they promoted active proliferation of Treg. 
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Figure 36 Distribution of Treg population in the Live fraction and in the VPD-/VDP+ fraction. A) The Treg fraction is 
increased in both cocultures compared to PBMC NOT STIM controls (direct: PBMC NOT STIM 27.35±1,7% vs 
ASCNG coculture 37.9±5.6%, p<0.05; PBMC NOT STIM vs ASCHG coculture 34.9±4.7%, not significant. Transwell: 
PBMC NOT STIM 17.7±5% vs ASCNG coculture 29.3±5.2%, p<0.05; PBMC NOT STIM vs ASCHG coculture 
25.7±5.9%, not significant). 2-way ANOVA multiple comparison. B) Within the proliferated cell, the Treg fraction is 
increased in direct coculture (VPD- direct: PBMC NOT STIM 9.12±4% vs ASCNG coculture 32.7±5.6% and ASCHG 
coculture 34.7±21.5%, not significant). A similar trend is reported in transwell (VPD- transwell: PBMC NOT STIM 
12.4±5.5% vs coculture 23.6.7±2.1% and ASCHG coculture 18.9±5.6%, not significant). The distribution of Treg in 
the VPD+ population is similar in all condition. 2-way ANOVA multiple comparison, n=3. 
 
4.4.2.5 ASC coculture reduces Th1/Th2 cytokine concentrations, while CCL-18 
is highly concentrated in coculture 
So far our data showed that cocultures between ASCNG-HG and not-stimulated PBMC 
induced Treg proliferation independently of glucose, in contrast to cocultures with 
CD3/CD28-stimulated PBMC. As next step, we screened the CM of unstimulated 
cocultures for Th1/Th2 cytokines.  
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The analysis of Th1/Th2 showed a similar trend to the one observed in stimulated 
cultures. Indeed, all analyzed factors were reduced in coculture compared to PBMC 
monoculture (Figure 37). A significant reduction in coculture was found in the following 
factors: IL-5 (p<0.05), IL-9 (p<0.05), IL-10 (p<0.05) and IL-13 (p<0.01). On the 
contrary, IL-17f and IL-22 were similarly produced in PBMC monoculture and coculture 
while IL-17a and TNF-alpha were not detectable in coculture. To investigate whether 
CD3/CD28 mediated stimulation of PBMC influenced Th1/Th2 cytokine secretion, we 
compared unstimulated PBMC monoculture and coculture with their stimulated 
counterparts (not shown). We found that stimulated PBMC monocultures had generally 
higher level of cytokines compared to not stimulated PBMC. For instance, IL-10 
(p<0.001), IL-13 (p<0.01), TNF-alpha (p<0.01), IL-17a (p<0.05) and IL-17f (p<0.05) 
were lower in not stimulated PBMC monoculture, in line with a quiescent not-activated 
state. Regarding cocultures comparison, a similar trend was detected within IL-10 
(p<0.01), IL-9 (p<0.05), and IL-17f (p<0.05), which were lower in not stimulated 
coculture. These findings confirmed the immunosuppressive potential of coculture, 
which was detected in either unstimulated or stimulated coculture and proved that in 
absence of stimulation PBMC retained a different cytokine profile compared to 
stimulated PBMC. 
In addition to the Th1/Th2 cytokine panels, we evaluated also IFN-gamma, IL-4 and 
CCL-18 (Figure 37). While IFN-gamma and IL-4 were substantially identical in PBMC 
and coculture, CCL-18 was highly concentrated in coculture (p<0.05).  
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Figure 37 Th1/Th2 cytokines are inhibited in not stimulated coculture; IFN-gamma and IL-4 are unchanged. On the 
contrary, CCL-18 is highly produced in coculture. Th1/Th2 cytokines (LEGENDplex™ Human Th1/Th2 Panel, Cat. 
n. 740730) were analyzed in CM of stimulated PBMC monoculture and coculture. In addition, IFN-gamma, IL-4 and 
CCL-18 were also investigated. A) Overall, Th1/Th2 cytokines drop off in coculture, notably: IL-5, IL-9, IL-10 
(p<0.05) and IL-13 (p<0.01). IFN-gamma and IL-4 have similar level in PBMC and coculture; CCL-18 is highly 
produced in coculture compared to not-stimulated PBMC monoculture (p<0.05). Ratio paired T-test n=3 to 4. 
 
 
4.4.2.6 Coculture induces prolonged changes in the PBMC cytokine profile 
Our early findings demonstrated that ASC mediated induction of Treg was evident only 
in coculture with resting PBMC. To explore whether the presence of ASC was sufficient 
Results 
95 
to activate a long lasting Treg expansion in resting PBMC, we further cultured pre-
cocultured not stimulated PBMC in absence of ASC for further 7 days (a total of 14 
days in culture). Afterwards, CD4+CD25+ and Treg populations were characterized as 
well as some selected cytokines analyzed in their CM. 
The analysis of CD4+CD25+ cells in the Live population, revealed a similar distribution 
in control PBMC and PBMC from cocultures (ex-coculture; Figure 38 A). We found a 
higher percentage of Treg in control than in ex-coculture PBMC (p<0.001).  
To assess whether the cytokine profile of PBMC was long-lastingly changed upon pre-
treatment in coculture, we isolated CM from these PBMC cultures and analyzed 
selected cytokines (Figure 38 B). In contrast to previous observations, where cytokine 
concentrations were overall reduced in cocultures, ex coculture PBMC produced 
higher amounts of cytokines than their counterparts from monocultures (Figure 38 B). 
Specifically IL-10 (p<0.01), IFN-gamma (p<0.01), TNF-alpha (p<0.05) and CCL-18 
(p<0.01) were increased in ex-coculture PBMC than control, only IL-4 was unchanged. 
In conclusion, we observed that PBMC, which were cocultured with ASC, did not retain 
a long-lasting proliferation of Treg. Their cytokines profile indicated a high production 
of IL-10 and CCL-18, which was not observed during the coculture.  
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Figure 38 PBMC from coculture (ex-coculture) and control (PBMC) were cultured alone for further 7 days, 
CD4+CD25+ and Treg were measured in the Live population as well as cytokines in their CM. A) The CD4+CD25+ 
population is similarly detected in PBMC and ex-coculture PBMC (13±4.6% vs 14.3±4.9%, not significant). The Treg 
fraction in the Live population is higher in PBMC than ex-coculture PBMC (35.4±2.2% vs 18.1±3.1, p<0.01). Ratio 
paired T-test, n=4 to 5. B) IL-10, IFN-gamma and TNK-alpha are highly present in CM from ex-coculture PBMC 
than PBMC cultured alone (IL-10 and IFN-gamma p<0.01 and TNF-alpha p<0.05). IL-4 is equally present in both 
conditions. CCL-18 remains high in ex-coculture PBMC (p<0.01). Ratio paired T-test, n=4 to 5. 
 
 TGF-β is a mediator for Treg induction 
Our findings generally denoted that glucose had no effect on the immunomodulatory 
potential of ASC. Moreover, we documented that cocultures induced Treg formation 
and proliferation only in resting conditions and that the same PBMC in culture for 
further 7 days were changed in their cytokine profile. 
To confirm our observations on Treg induction in coculture, we investigated TGF-β 
production in direct and transwell cocultures as well as in stimulated and not stimulated 
settings. Indeed, TGF-β is considered a very important mediator in Treg generation 
being involved in their regulation [164]. 
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Thus, we measured TGF-β in CM of direct and transwell cocultures of unstimulated 
PBMC and ASC, using ASC monoculture as control (Figure 39). All conditions 
produced more TGF-β than ASC alone (dotted line) and TGF-β was not found in CM 
from stimulated/not stimulated PBMC. These first findings suggested that TGF-β 
production was to be allocated uniquely to ASC. In not stimulated cocultures, we found 
that TGF-β was highly produced in direct coculture compared to transwell (p<0.001). 
In addition, comparing direct cocultures, not stimulated cocultures produced more 
TGF-β than stimulated one (p<0.01). 
These data were in line with the observed increment of Treg in cocultures of 
unstimulated PBMC, especially in direct coculture, supporting the notion that TGF-β 
production was strongly related to Treg generation in our coculture and being 
dependent on both direct cell contact and resting condition of PBMC.   
 
 
 
Figure 39 TGF-β was measured in CM of direct and transwell cocultures. TGF-β is more concentrated in direct and 
transwell cocultures than in the control (ASC monoculture, dotted line). In stimulated conditions, production of TGF-
β is higher in direct than transwell cocultures (103.5±12.5 pg/ml and 66.5±10.6 pg/ml, respectively) but not 
significant. Whereas in not stimulated conditions, TGF-β is considerably more concentrated in CM of direct than 
transwell cocultures (196.2±46.7 pg/ml vs 95.2±12.8 pg/ml, p<0.0001). Moreover, comparing direct coculture, TGF-
β is higher in not stimulated settings than stimulated ones (p<0.001). TGF-β was not detected in monoculture of 
stimulated/not-stimulated PBMC. 2-way ANOVA, n=4.   
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5 DISCUSSION 
The rationale of this study was to evaluate whether ASC were affected by 
hyperglycemia in their basic characteristics and functional potentials. As mentioned in 
the introduction, hyperglycemia is considered one of the main factors driving cell 
damage in pathologies related to poor glycemic control such as diabetes and metabolic 
disorders. Glucose-mediated cell damage has been strongly related to microvascular 
complications and particularly to endothelial cell dysfunctions in secondary diabetic 
complication as DR [133]. MSC and especially ASC, have been recently proposed as 
potential cell-based treatment for DR and many studies on several animal models 
demonstrated the safety and efficacy of this approach. Indeed, ASC have been shown 
to interact within the retinal microenvironment through the following mechanisms: (1) 
secretion of proangiogenic factors and stimulation of neovascularization, (2) secretion 
of anti-inflammatory factors and reduction of inflammation/lymphocyte infiltration and 
(3) acquisition of a pericyte-like function giving support and stabilizing the retinal 
vasculature. All these studies proposed only allogenic application of MSC as many 
reports suggested that MSC isolated from diabetic donors, might be impaired in their 
potency and functions. In this context, (a) the evaluation of autologous MSC 
applications in hyperglycemia-related pathologies as well as (b) the investigation of 
diabetic/hyperglycemia-mediated effects that may occur once healthy MSC are in a 
diabetic/hyperglycemic environment, can give important insights on how MSC-
mediated cell therapy can be improved in the particular pathological setting of DR. 
In this study, we investigated hyperglycemia-mediated effects on ASC through a series 
of in vitro experiments 
 
5.1 Does hyperglycemia affect ASC basic characteristics? 
 
The first step in our study was to address “basic” effects 
of hyperglycemia on ASC, hypothesizing that potential 
HG-mediated effects would have been detected on 
cellular phenotype, differentiation and cell growth. As the 
vascular compartment represents the main target of 
MSC-based therapy in DR, we conduced similar analysis on HRMVEC.   
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 Hyperglycemia on ASC causes a transient increase of oxidative stress 
Many studies already demonstrated the impairment of ASC isolated from diabetic 
patients/animals. Reduced therapeutic capacity in wound healing [145, 165] and even 
impaired ability to protect retinal vasculature in Akimba mice [148] were documented. 
However, none of them was uniquely focused on investigating potential cell damages 
mediated by hyperglycemia. In our study, we observed that hyperglycemic culture 
conditions had no major effect on (1) ASC basic characteristics (immunophenotype 
and differentiation potential), (2) nor their angiogenic supportive capacities, (3) nor their 
immunomodulatory properties. We speculate that this might be related to the capacity 
of ASC to regulate glucose uptake and thus, to control adverse intracellular events 
such as ROS formation and oxidative stress. Supporting our findings, Hajmousa et al. 
described that HG cultured ASC were largely refractory to hyperglycemia, despite an 
increased production of ROS and mitochondrial reorganization. Moreover, in presence 
of HG, ASC changed their metabolic profile decreasing oxygen consumption and 
glycolysis [151]. Taken together these findings suggested that ASC might have intrinsic 
regulatory mechanisms, to guarantee an efficient and rapid adaptation to metabolic 
changes in the surrounding microenvironment. 
Since we cultured ASC in HG directly after isolation from lipoaspirate and kept this 
condition within experiments, we provided an even stronger evidence of ASC tolerance 
to HG, indicating that prolonged/long term HG cultures did not affect ASC. Only at the 
first passage after isolation, ASCHG displayed a slower cell growth compared to ASCNG, 
confirmed by an increase in doubling time and a reduction of cell doublings. The first 
phase of cell growth after isolation is the most delicate as cells face for the first time 
the in vitro culture. Therefore, being in contact with HG might have represented an 
additional obstacle for cells, which was then translated in a reduction of cell growth 
rate. Importantly, these effects were transient and restricted to the first passage, 
indicating and confirming that ASC could rapidly adapt to this culture condition. The 
measurement of intracellular oxidative stress (total ROS measurement) further 
supported this notion. Indeed, while ASCNG and ASCHG displayed similar and low levels 
of oxidative stress, in ASCNG switched to HG (ASCNG in HG) ROS levels increased and 
were sensitive and reduced upon antioxidant treatment. Again, in line with Hajmousa 
et al., only a transient effect of glucose was demonstrated. 
Increased glucose influx in cells is defined by the unifying hypothesis as the main 
driving force of cellular destabilization as well as the principal cause of increased ROS 
Discussion 
100 
production [133]. Therefore, in parallel to measurement of intracellular oxidative stress, 
we evaluated glucose uptake in ASCNG and ASCHG. We found that both ASCHG and 
ASCNG in HG had a reduced glucose uptake compared to the one of ASCNG. This was 
supported by similar observations provided by Hajmousa and colleagues. In ASCHG, 
glucose uptake levels were as low as those when applying a GLUT-1 inhibitor (WZB-
117) on ASCNG. These results are of crucial importance as, in contrast to the unifying 
hypothesis, they appear to disconnect ROS production from glucose uptake.  
In our experimental setting, ROS production was not relatable to increased glucose 
influx. However, we cannot exclude that, at earlier time points of HG switching, a 
transient increase of glucose influx might have occurred together with an increase in 
oxidative stress, which could have been detectable even after several hours. 
Furthermore, our measurement of ROS may have been slightly imprecise, reflecting 
several cytoplasmic oxidative stressors rather than solely ROS. Indeed, as carboxy-
H2DFFDA penetrates in cells, it is subject to oxidation by several cytoplasmic ROS 
species such as hydrogen peroxide, organic hydroperoxides, nitric oxide and 
peroxynitrite, which turn it into being fluorescent. Moreover, its oxidation has been 
found to be influenced by glutathione (GSH) [154]. In light of this, we have to argue 
that our data: (1) could not be related to specific mitochondrial ROS production, which 
are the one effectively addressed in the unifying hypothesis, and (2) should be 
interpreted as a transient increase of oxidative stress index upon glucose switch.  
In conclusion, our findings on ASCNG-HG, were in line with the previous proposed by 
Hajmousa and colleagues, indicating a solely transient effect of glucose in increasing 
the oxidative state of cells, while other characterizing parameters were not affected. 
The absence of glucose-related damages on ASC appeared to be related to the 
restricted uptake of glucose, in virtue of their rapid metabolic adaptation to the 
hyperglycemic surrounding microenvironment. 
 
 Hyperglycemia induces an angiogenic dysfunction in HRMVEC 
Considering ASC as potential therapy for DR, this study focused next to HRMVEC to 
investigate potential glucose toxicity. Hyperglycemia-mediated cell damage, especially 
for microvascular cells, is a well-established concept with multiple evidences confirmed 
in vivo and in vitro  [135]. Loss of vascular permeability and induction of pro-
inflammatory pathways are only some of the described indicators of HG toxicity [133, 
166]. The common denominator triggering hyperglycemia-mediated injuries is ROS 
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overproduction. For metabolic reasons, mitochondrial ROS overproduction is the 
principal consequence of increased glucose influx inside endothelial cells. Indeed, 
ROS overproduction gives rise to a destabilizing cascade of detrimental events 
(increased polyol and hexosamine pathway, AGE production and PKC activation), 
which destabilize and damage endothelial cells [134]. Therefore, we first examined HG 
impact on HRMVEC growth rate and then, we focused on ROS production/oxidative 
state and glucose uptake. In last instance, we assessed whether hyperglycemia might 
affect their angiogenic potential 
 
HRMVEC growth rate was not affected by HG. Thus, this first outcome was rather 
unexpected, as our rationale based on previous reports on pronounced glucose-
toxicity in endothelial cells. We argued that optimal culture conditions, provided by the 
cell culture media, might potentially overrule detrimental effect of glucose. Indeed, the 
presence of growth factors in the culture media, such as VEGF, has been 
demonstrated to be protective for HG-mediated injuries [156, 157]. Therefore, cell 
growth monitoring was repeated in ¼ ECGM-2 medium (cell medium containing only 
¼ of supplemented growth factors). Because of the lowered serum/growth factors 
provision, HRMVEC general growth rate diminished compared to ECGM-2. Only a 
slight reduction was caused by HG. Further readings revealed that, in fact, 
hyperglycemia-mediated effects on endothelial cell proliferation may vary. While some 
studies demonstrated hyperglycemia being effective in reducing endothelial cell growth 
[167, 168] and even promoting apoptosis [169], others found HG inducing their 
proliferation [170, 171]. We restricted our analysis on monitoring proliferation, thus, we 
cannot speculate on whether both findings might have occurred in parallel. Indeed, a 
feed forward mechanism in which dead cells were replaced by new proliferating ones, 
can be an explanation to an unchanged growth rate. To undercover this, a deeper 
analysis on cell cycle of HG exposed cells as well as apoptosis quantification could be 
performed.  
Another aspect to be considered is the timing of hyperglycemic injury. Duration of HG 
exposure, especially a temporary switch from NG to HG (intermitted glucose) has been 
reported to cause a more pronounced proliferation than exposing cells to prolonged 
HG [170]. 
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Similarly to ASC, where we observed that a transient switch to HG induced oxidative 
stress whilst glucose uptake became efficiently restricted, we performed similar 
experiments in HRMVEC. Here, HG caused an increase in intracellular oxidative 
stress. However, in contrast to many findings in the literature, this was not related to 
glucose uptake. Indeed HG HRMVEC showed a reduced glucose uptake compared to 
NG and the addition of the GLUT-1 inhibitor even lowered that uptake. We concluded 
that HG-mediated induction of oxidative stress (increased in detection of total ROS) 
was not related to glucose uptake. On one hand, our results are in line with findings in 
the literature (glucose-mediated oxidative stress induction), on the other, the 
fundamental milestone of intracellular hyperglycemia, as consequence of extracellular 
HG, is not corroborate. As ASC, HRMVEC restricted glucose uptake, however, in 
contrast to ASC they appeared to rely on at least some level of glucose uptake even 
in HG conditions. Thus, the fundamental link between extracellular hyperglycemia 
translating to intracellular hyperglycemia does not appear to be true in our study. 
Admittedly, similar shortcomings as discussed in the ASC section also apply to the 
HRMVEC, with respect to timing and kinetics of hyperglycemia exposure. Indeed, we 
can postulate an increased glucose uptake in the very first moments after HG 
application, which is later restricted. In support of our hypothesis, it was observed that 
chronical and acute glucose exposure resulted in different outcomes both in vitro and 
in vivo [170, 172].    
 
In last instance, we assessed the proangiogenic potential of HRMVEC in regard of HG. 
In DR the first signs of the disease appear as microaneurysms and non-perfused 
capillaries. This degeneration is related not only to pericytes loss, but also to 
dysfunctions of the endothelium, which bring to an aberrant remodeling of the 
vasculature [121].To investigate whether hyperglycemia is directly involved in affecting 
angiogenic potential of HRMVEC, we set basement membrane angiogenesis (BMA) 
assays to monitor their tube formation potential upon glucose. The total tube network 
length as well as the number of junctions of HG HRMVEC was notably reduced 
compared to the one of NG HRMVEC. We concluded that HG induced angiogenic 
dysfunction of HRMVEC. Hyperglycemia is reported in many papers to reduce 
angiogenic potential of endothelial cells and VEGF transcription/production was found 
to be often involved in the process [135]. For instance, VEGF production by endothelial 
cells was diminished upon HG treatment resulting in reduced migration and tube 
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formation [173]. RasGRP1 was found to mediate these processes, since its 
overexpression rescued HG-mediated impairments [174]. The critical role of VEGF in 
protecting from apoptosis and ROS as well as regulating the angiogenic potential was 
also demonstrated [156]. Even miRNA were documented to be involved in the post-
transcriptional regulation of VEGF. miR117 was found to be induced by hyperglycemia, 
reducing VEGF in vivo and in vitro and affecting endothelial cells’ tube formation [175]. 
However, opposite findings observed also an HG-mediated induction of angiogenesis 
[176], which was usually related to an extended period of HG exposure [177, 178].  
 
In conclusion, HG did not affect basic characteristics of ASC but it induced angiogenic 
dysfunction in HRMVEC. In both cell types, a transient increase of oxidative stress was 
reported upon HG exposure without being directly related to glucose uptake in our 
experimental settings. As suggested by literature, we found that hyperglycemia-
mediated effects on ASC and HRMVEC relied on oxidative stress induction causing in 
the latter, a possible ROS-related functional impairment in the angiogenic potential.   
 
5.2 Does glucose exposure influence ASC angiogenic supportive potential? 
To fulfill our second aim we investigated hyperglycemia-
mediated effects on ASC functions, asking whether (1) 
HG could affect ASC pro-angiogenic potential and if not, 
whether (2) ASC could rescue the HG-induced 
angiogenic dysfunction in HRMVEC. 
 
The supportive angiogenic potential of ASC was untouched by glucose. Not only 
ASCNG and ASCHG induced tube formation in coculture angiogenic assays with HUVEC 
and HRMVEC to a similar extent, but also the presence of glucose in the culture media 
did not affect the outcome. In contrast, in a similar assay, Hajmousa and colleagues 
observed reduced tube formation of HUVEC when cocultured with ASC in HG condition 
[151].  
Similarly, HG in the medium as well as ASCNG-HG, did not alter significantly cytokine 
production in ASC monoculture and ASC cocultures. HG in culture medium was barely 
relevant in influencing cytokine production, with a few exceptions. CCL-7 surprisingly 
had a 2.8-fold increase in HG medium culture compared to NG. CCL-7, known also as 
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monocyte chemotactic protein 3 (MCP-3), is a chemokine mainly involved in the 
recruitment of monocytes [179]. It can be produced by several types of cells, including 
endothelial cells and MSC, especially upon inflammatory stimuli. On one side, CCL-7 
acts as fundamental regulator in the management of the immune response, but on the 
other, its overexpression has been demonstrated being highly tumorigenic, 
contributing to the induction of a suitable tumor microenvironment as well as to tumor 
metastasis [180]. CCL-7 does not appear to be directly related to angiogenic 
processes; therefore, its high concentration in HG coculture was unexpected. In our 
assay, we cannot specify whether CCL-7 is produced by HUVEC, ASC or both. 
HUVEC-mediated CCL-7 secretion might be related to injury, maybe caused by 
hyperglycemia, possibly explaining the 2.8-fold increase in HG coculture. This would 
be in line with the 1.9-fold increase in soluble PECAM-1 (known also as CD31), a 
typical surface marker of endothelial cells, which might indicate increased endothelial 
cell damage and eventually death. Despite CCL-7 and PECAM-1 levels were 
increased in HG coculture, the outcome of vascular tube formation was not affected. 
This represented our first evidence that ASC angiogenic support could overcome any 
detrimental effect of glucose on endothelial cells. 
When we compared ASCNG-HG in coculture and monoculture, all analyzed factors, 
except for VEGF, were increased in coculture and identical in ASCNG and ASCHG, 
confirming the proangiogenic milieu of cocultures and no effects of glucose on cytokine 
secretion. 
VEGF concentrations were higher in ASC monoculture than coculture indicating that 
coculture might consume VEGF to support tube formation. In DR, especially in the 
proliferative stage, the combination of VEGF with Ang-1/Ang-2/Tie-2 signaling 
represents the driving force of hyperproliferation of retinal vessels [181]. Therefore, the 
detection of VEGF, Ang-1 and Ang-2 in coculture supernatants was carefully 
evaluated. Production of VEGF by ASC, together with other proangiogenic factors, is 
well known and largely documented [182]. However, little information is available 
regarding Ang-1/Ang-2. We found that ASCNG-HG produced considerable amounts of 
Ang-2 in monoculture, which were even increased in cocultures. Similarly, Ang-1 was 
found in monoculture and coculture but its level were generally lower in comparison to 
Ang-2. These findings let us speculate that the angiogenic process in the assay was 
sustained (1) by VEGF, produced mainly by ASC and (2) by Ang-2, which is produced 
by ASC in combination to VEGF activating the autocrine Ang-2/Tie2 signaling [183]. 
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As Ang-1 is reported to be mainly involved in maintaining vessels quiescence and 
homeostasis [184], we argue that low level of Ang-1 did not contrast tube formation, 
but were fundamental in supporting the tube structure, which could last up to two weeks 
in coculture (not shown). 
FGF is another well-known angiogenesis-related factor. It can combine with VEGF to 
promote endothelial cell proliferation and migration [185]. In our ASCNG coculture, FGF 
was more concentrated than in ASCNG monoculture as well as in ASCHG coculture, 
confirming again the establishment of a proangiogenic microenvironment. 
Interestingly, cytokine secretion was related to the extent of tube formation. Indeed, as 
the number of endothelial cells was always identical within experiments, these 
differences were attributed to ASC samples, indicating a donor-dependent angiogenic 
supportive capacity related to cytokine secretion.  
 
To explain the rescuing capacity of ASC: HRMVEC cocultures, we considered also the 
possibility that MSC could rescue injured cells via mitochondrial transfer, as shown 
previously [186]. In an in vitro ischemia-reperfusion model, Liu et al. showed that 
mitochondrial transfer via tunneling nanotube like structures (TNT-like structures) was 
able to prevent endothelial cells apoptosis and promote aerobic respiration [187]. In 
addition, foreign-derived mitochondria from injured cells have been shown to sensitize 
MSC, inducing heme oxygenase-1 (HO-1), mitochondrial biogenesis and final 
mitochondrial transfer to injured cells. Interestingly, these results were even 
recapitulated in an in vivo model of myocardial infarction [188] and of middle cerebral 
artery occlusion [189]. Here, upon MSC engraftment on ischemia-reperfusion-
damaged cerebral microvasculature, mitochondrial transfer from MSC was observed 
and promoted angiogenesis as well as amelioration of mitochondrial respiration in the 
microvasculature [189]. These studies clearly demonstrate the ROS-scavenging 
potential of MSC, especially in the interaction with endothelial cell. Therefore, we 
consider mitochondrial transfer via either TNT-like structure or microvescicles [186] as 
an option of interaction between hyperglycemia injured endothelial cells and ASC in 
our coculture system. Our data, however, showing that transfer of CM was sufficient to 
promote HG HRMVEC angiogenesis, favor secreted factors. However, future studies 
aim to investigate this putative mechanism by which ASC could rescue hyperglycemia 
injured endothelial cells, restoring their redox balance and reestablishing their 
angiogenic potential.   
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Overall, our analysis on supernatants of coculture angiogenesis assays corroborated 
our previous findings on glucose, which is not functionally affecting ASC in cytokine 
secretion. Moreover, ASC in combination with endothelial cells, created a 
proangiogenic microenvironment that sustained endothelial cell tube formation. In 
addition, the mechanism of mitochondrial transfer might be considered as an option for 
protection/restoration of endothelial cell angiogenic potential. 
 
While HG induced a reduction of HRMVEC angiogenic potential, the treatment with the 
antioxidant NAC restored it to some degree. CM from angiogenesis assay cocultures 
and ASC monoculture restored HRMVEC tube formation similarly to NAC treatment. 
These findings fully confirmed our previous data on ASC/coculture growth factor profile 
analysis. The indirect presence of ASC (i.e. CM) overcame detrimental effects of 
hyperglycemia on the angiogenic potential of HRMVEC. Moreover, as NAC and CM 
treatments similarly restored HG HRMVEC angiogenic potential, the hypothesis of an 
additional oxidative stress/ROS scavenging potential (e.g. via mitochondrial transfer) 
of ASC CM becomes more concrete. 
Although, we did not provide evidence to fulfill this last hypothesis, our preliminary 
findings raised the question about the importance of redox balance in angiogenesis. 
Indeed, the study of redox signaling in angiogenesis has been shown to be of 
importance. ROS, as a byproduct of the activity of several enzymes (such as 
mitochondrial enzymes, cyclooxygenase, myeloperoxidase), can be specifically 
produced by the family of NADPH oxidases (Nox). Nox are multiprotein complexes 
associated with membranes in cytoplasmic or intracellular locations, involved in the 
maintenance of redox balance in cells as well as in the mediation of intracellular 
signaling [190]. It has been demonstrated that ROS-derived Nox play a role in 
VEGF/VEGFR2 signaling by promoting cell mobilization (via tyrosine phosphorylation 
of VE-cadherin and beta catenin) as well as VEFGR2 activation itself (via tyrosine 
phosphorylation of the intracellular domain) [191]. Nox involvement in pathological 
angiogenesis has been demonstrated in several OIR animal models. While in the 
hyperoxia phase Nox2 was not changed, in the neovascularization phase 
(normoxia/hypoxia) of OIR increased expression of Nox2 as well as increased VEGF 
and ROS were documented. On the contrary, Nox2 knock-out animals and treatment 
wiht apocyanin (Nox inhibitor) reduced neovascularization [192, 193]. Similarly, the 
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Nox4 isoform led to pathological neovascularization in the OIR model and its knock-
out reduced VEGFR2 phosphorylation (activation) as well as STAT3 activation [194]. 
Overall, these studies demonstrated that the ROS producer Nox proteins are involved 
in the regulation of angiogenesis in the retina suggesting that redox signaling is actually 
strongly related to angiogenesis. These observations, together with our findings 
propose a deep investigation on redox balance and angiogenesis in respect to ASC 
and HRMVEC interaction. 
Our data in line with the published ones, suggest the following: 
 Increased ROS production related to hyperglycemia exposure may interfere 
with the redox balance necessary for the angiogenic processing, resulting in 
reduction of the total tube length in the BMA assays. 
 NAC as antioxidant may recover the angiogenic potential decreasing the total 
ROS content in the cell. 
 CM from either ASC monoculture or coculture may restore angiogenic 
dysfunction providing the proangiogenic factors VEGF, Ang-1/Ang-2 and/or 
FGF (especially the VEGF/VEGFR2 pathway activation may be involved).  
 CM may restore HRMVEC angiogenic dysfunction inducing a favorable redox 
balance potentially via mitochondrial transfer as the presence of mitochondrial 
containing vesicles in CM from ASC cannot be excluded.  
In summary, we showed that while ASC are not affected by hyperglycemia in 
phenotype and proangiogenic function, it induced vascular dysfunction in HRMVEC, 
accompanied by an increase in oxidative stress. The direct (angiogenesis coculture) 
and indirect (CM from monocultures or cocultures) presence of ASC as well as 
antioxidant treatment restored the HG-mediated angiogenic dysfunction. A number of 
different pathways related to both redox balance and growth factor-mediated induction 
of angiogenesis may be involved and should be investigated in following studies. 
 
All these evidences have to be carefully evaluated in the context of DR. Indeed, 
although ASC-mediated proangiogenic stimuli might be beneficial in early phases of 
DR to counteract early vasoregression, it might be highly detrimental if not accurately 
regulated/controlled. An overexpression of angiogenesis-related factors might open 
doors to diabetic vasoregression and even accelerate the progression to the 
proliferative stage. Indeed, recent data suggest that intravitreal ASC injection in a 
genetic animal model of DR worsened the pathological events [195]. These evidences 
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highlight the importance of deeper investigations on the role of ASC in the retinal 
microenvironment, with a focus on the long-term characterization of 
beneficial/dangerous trophic factors.  
  
5.3 Do ASC retain a pericyte-like phenotype in vitro under hyperglycemic 
culture? 
As an extension of the proangiogenic potential we 
investigated whether ASC could retain a pericyte-like 
phenotype in vitro under hyperglycemic culture. 
 
 
We finally investigated whether ASC could gain pericyte features in EC cocultures. 
Indeed, a variety of published studies showed that ASC acquired a pericyte-like 
location enwrapping EC and exerting vascular support, suggesting that ASC may 
undergo pericyte-like differentiation [196]. We detected α-SMA positive ASC wrapping 
around tubular structures of EC in cocultures. ASC in monolayer barely expressed a-
SMA. α-SMA positive ASC were found in coculture with HUVEC [151] and ASC 
localization on retinal vessel was demonstrated after their intravitreal injection in mice 
model of ROP [126], in STZ rats [124] and in a murine model of OIR [125]. Activin-A 
signaling has been shown to be involved in α-SMA expression in ASC:EC cocultures 
suggesting that EC may initiate a smooth muscle cell differentiation in adjacent ASC 
[197]. In HRMVPC: HRMVEC cocultures, however, HRMVPC did not express α-SMA 
as well as their monoculture. Although α-SMA is often reported as pericytes marker, 
its expression has been demonstrated being variable depending on developmental 
stage and location [159, 160]. Therefore, in contrast to ASC, the lack of α-SMA 
expression in HRMVPC could be related to the differentiation stage of pericytes and it 
is not induced by EC.      
We also evaluated NG-2 expression. As expected, NG-2 was highly expressed in 
HRMVPC mono- and cocultures. Surprisingly, ASC were constitutively positive for NG-
2 without any specific pattern related to endothelial cell vessels. NG-2 was mainly 
expressed at the cytoplasmic membrane delineating cell´s shape. We did not expected 
this pattern of expression since, during flow cytometry characterization, ASC were 
always negative for this marker (not shown). It is important to underline that NG-2 
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expression on pericytes is not always homogeneous and it seems to be related to the 
nature of microvascular vessels (arterioles and venules) [198]. 
Separate investigations in our laboratory (not shown here), further evaluated pericyte 
marker expression in cocultures, focusing on RGS-5 and PDGFRβ [120]. RGS-5 
(regulator of G-protein signaling) was defined as another pericyte marker, which 
expression varies upon pro/anti angiogenic stimuli [199]. Despite trying several 
different antibody clones, ASC resulted always negative in both monoculture and 
coculture. Similarly, PDGFRβ was also not detectable, even if ASC were found to be 
highly positive for this marker at flow cytometry (here not shown). We concluded that, 
despite the lack of complete overlap in terms of marker expression, as demonstrated 
by our and other results both in vitro and in vivo, ASC can acquire a pericyte-like 
phenotype when in contact with endothelial cells, supporting the formation and stability 
of vascular structures.  
 
The fact that ASC did express NG-2 and α-SMA pericyte markers in coculture was 
highly indicative in confirming their “pericyte potential”. However, the distinction 
between ASC and pericytes is still a matter of debate [200]. Retinal pericytes have 
been demonstrated to be fundamental in the stabilization and regulation of adult retina 
as well as responsive to angiogenic signals during developmental angiogenesis [119]. 
Their drop-out in DR is considered one of the first signs of the retinal vasoregression 
and degeneration, suggesting that their loss might represent a starting signal for the 
pathological proliferation [121]. Overall, these findings provided evidences on their 
important role as “stabilizer” of the endothelium rather than “promoter” of angiogenesis. 
We also observed this phenotype in our angiogenesis assays, where HRMVPC, being 
positive for NG-2 lacked any supportive proangiogenic activity. In contrast, ASC 
showed profound angiogenic support. In regard of this, we hypothesize that 
proangiogenic potential might represent a distinctive criterion to characterize these two 
cell type. We, at least, argue that the coculture angiogenic assay could be used as 
potency test to discriminate ASC/MSC and pericytes.  
 
With respect to the therapeutic concept, these finding are of utmost importance raising 
concerns about the potential risks of ASC therapy. Due to their angiogenic supportive 
activities, ASC application might represent a good preventive strategy in early DR to 
prevent vascular regression and obliteration. However, the proangiogenic potential 
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represents a concrete risk in later stages of DR and it might even promote and sustain 
the neovascularization.  
In summary, being in line with in vivo experiments, we demonstrated that ASC acquired 
pericyte-like phenotype in EC cocultures expressing α-SMA. Besides that, having 
demonstrated that HRMVPC did not support EC angiogenesis, we propose the 
coculture angiogenesis assay as a potency test to better discriminate ASC/MSC and 
pericytes.  
We auspicate in depth in vitro and in vivo analyses, to further characterize the 
differentiating potential of ASC towards the pericyte-like phenotype and to define 
functional efficacy of ASC-derived pericytes.   
 
5.4 Are ASC affected in their immunomodulatory potential upon HG exposure? 
As our fourth aim, we assessed hyperglycemia-
mediated effect on ASC immunomodulatory potential on 
T cell subtypes. Establishing ASCNG-HG:PBMC 
cocultures, we investigated ASC-mediated effects on (1) 
CD4 activation and proliferation, (2) Treg generation 
and (3) PBMC Th1/Th2 cytokine profile. To mimic a local (direct contact) and systemic 
(indirect contact) environment, experiments were set in direct and transwell cocultures 
respectively. In addition, resting and CD3/CD28-stimulated PBMC were used to mimic 
homeostatic and inflammatory conditions. 
 
As introduced earlier, ASC have been applied with differing success in models of DR. 
One aspect, which has not been addressed yet in these studies, is the effect on the 
immune system. In our opinion, the role of the immune response and its changes in 
presence of MSC, represents an intriguing topic even in DR. Because of retinal 
microvascular involvement as well as alteration/disruption of the BRB, we hypothesize 
that circulating immune cells might reach the vascular retina and modulate the local 
(para-) inflammation. Considering that after systemic MSC infusion, changes in the 
general skewing of immune response toward an anti-inflammatory milieu were 
observed, we can hypothesize that MSC-mediated anti-inflammatory immune cells 
might participate in the regulation of retinal vascular remodeling, even after local 
administration of MSC in the vascular retina. These aspects together, with recent 
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evidences on Treg involvement in DR [128] prompted us to investigate ASC:T cell 
interaction.  
 
 ASC and CD3/CD28-stimulated cocultures 
Suppression of T-lymphocyte proliferation induced by cellular/non-specific stimuli was 
one of the first mechanism of MSC-mediated immunomodulation to be provided [201]. 
To verify whether hyperglycemia might affect ASC in this capacity, we established 
coculture between ASCNG-HG and CD3/CD28-stimulated PBMC. We saw that ASCNG 
and ASCHG equally inhibited CD4 proliferation in either direct or transwell culture 
systems. In line with previous results on ASC refractory behavior towards 
hyperglycemia, we observed that HG did not affect ASC suppression capacity on 
stimulated T cells. To our knowledge, this is the first report having assessed glucose 
effects on ASC immunomodulatory potential.  
MSC-mediated effects on T cells have been shown to be dependent on several 
mechanisms, which involve secretion of cytokines and growth factors as well as nitric 
oxide (NO) production or increased activity of indoleamine-2,3-dioxygenase (IDO) 
[202]. IDO is a catabolic enzyme which converts tryptophan to kynurenine [161]. 
Increased IDO activity in MSC has been related to suppression of T cell proliferation 
in vitro, indicating that tryptophan deprivation is a key mechanism in inhibiting T cell 
proliferation [162]. Our findings documented this mechanism to be key for the anti-
proliferative effect as well. Kynurenine concentrations were similar in all cocultures and 
not detected in PBMC monoculture as well as in ASC monoculture. IDO levels were 
higher in direct than in transwell coculture for ASCNG-HG. As kynurenine levels were 
similar in all conditions we did not expect higher IDO levels in ASC from direct coculture 
than transwell. IDO induction was found to be dependent on IFN-γ stimulation [203], 
which is produced by stimulated PBMC. IFN-γ is a well-known and strong mediator of 
the immune response involved in both innate and adaptive immune responses [204]. 
The participation of IFN-γ in mediating the interaction between MSC and PBMC has 
been widely studied. Indeed, IFN-γ stimulated MSC displayed an enhanced 
immunosuppressive potential on T cells, often related to increased IDO expression 
[205]. To explain our observation, we speculate that the direct contact between ASC 
and PBMC might represent an additional or stronger activation stimulus, resulting in 
increased PBMC activation and IFN-γ production. IFN-γ levels have not been 
measured in this series of experiments, as previous findings documented rapid 
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induction of IFN-γ mRNA already after 3h of stimulation and IFN-γ protein expression 
to level up at 12-24 hours of stimulation (medical doctoral thesis P. Mattar). The ASC-
IDO-mediated mechanism of inhibition of PBMC proliferation was further confirmed in 
separate experiments in our laboratory through tryptophan addition and IDO inhibition 
via Epacadostat (Torres Crigna, manuscript in preparation). These experiments 
corroborated our results showing that addition of tryptophan to ASC:PBMC cocultures 
resulted in abrogation of ASC inhibitory functions. Similarly, Epacadostat, a known 
inhibitor of IDO, blocked its activity (but not its expression in ASC), promoting PBMC 
proliferation. 
 
Having confirmed the inhibitory potential of ASC on CD4 cells in stimulated PBMC, we 
zoomed into the CD4 T cell population investigating phenotypical changes related to 
activation (CD25+) and Treg induction (FoxP3+, CD127-). CD25 is defined as 
activation marker and its expression is highly induced in T cell upon CD3/CD28 
stimulation, moreover, as part of the IL-2R, it is a mediator of the IL-2/IL-2R signaling 
[163]. Surprisingly, we found that, despite T cell inhibition of proliferation, in presence 
of ASCNG-HG, CD25 expression on CD4 T cells was significantly increased in both 
transwell and direct coculture compared to PBMC monoculture. This result was 
apparently in contrast with findings in literature, where ASC were previously 
documented to reduce CD25 expression when cocultured with stimulated PBMC [206, 
207]. Moreover, addition of IL-2 to cocultures was able to abrogate MSC-mediated 
inhibitory effect on T cells [208]. Two main reasons could explain our different results. 
First, timing of the coculture; our cocultures lasted 7 days, while in all previously 
reported studies T cells analysis were performed after 48 or 72 hours. Second, IL-2 
addition; to guarantee T cell survival over 7 days we added exogenous IL-2 to 
cocultures. Indeed, previous experiments in our laboratory revealed that after 7 days 
of coculture without IL-2, PBMC survival was highly compromised and cells numbers 
were not enough to perform cell surface analysis with flow-cytometry. We are aware 
that IL-2 addition might influence our results, however we previously assured the ASC 
inhibitory effect to occur in presence and absence of IL-2 upon CD3/CD28 stimulation. 
The increasing CD25 expression might be also explained by an additional PBMC-
mediated IL-2 secretion due to CD3/CD28 stimulation.  
We observed an even stronger increase in CD4+CD25+ cells in the proliferating 
fraction of cocultures. Thus, despite the general suppression of CD4 cell proliferation, 
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a significant proliferation of CD4+CD25+ cells was taking place, in contrast to what 
was observed in the not stimulated cocultures. This may suggest that some activation 
and proliferation of CD4+CD25+ cells may occur in presence of ASC and may not be 
inhibited, but even potentially induced by ASC themselves. Possibly, it can be an 
allogeneic stimulation or potential innate responses triggered by e.g. dying cells and 
occurrence of danger-associated molecular patterns (DAMPs).  
  
MSC were reported to induce Treg generation in several studies. These Treg cells 
were functional in inhibiting T cell proliferation in a mixed lymphocyte reaction (MLR) 
[35, 83, 209]. We quantified Treg cells in mono- and coculture, defining them as 
CD4+CD25+FoxP3+CD127- cells [210]. Unexpectedly, we noticed that in the Live 
population, percentages of Treg fractions were similar in PBMC monoculture controls 
and ASCNG-HG cocultures. 
There are different possible explanations for this difference to previously published 
data:  
(1) Definition of Treg: previous reports, indicating an increase in Treg, used only 
CD4/CD25 as marker. We have previously discussed that we considered this 
as a sign of activation rather than indicative of a regulatory phenotype. 
(2)  Mode of stimulation [211-213]. 
(3) Timing of coculture. We cannot exclude Treg generation at earlier time point in 
our coculture, speculating that they might undergo apoptosis or lose FoxP3 
expression after 7 days. A reduction of FoxP3 expression was indeed 
documented after 5 days in coculture with MSC [87].  
(4) Presence of IL-2. 
  
Finally, zooming in the VPD- fraction corroborated our previous observation of not 
changed Treg numbers observed in the general Live population. While in direct 
cultures, the amount of Treg was similar in ASCNG-HG coculture and PBMC 
monoculture, in transwell we found that Treg proportions were significantly reduced in 
ASCNG-HG coculture compared to PBMC. In addition, Treg were even reduced in 
comparison to direct coculture. Because of these findings, we hypothesized that the 
lack of direct cell-to-cell contact between ASC and PBMC might reduce the survival of 
naïve (naturally occurring) Treg. No differences were detected in the Treg VPD+ 
fraction. 
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To sum up this part, we observed that ASC exerted a strong anti-proliferative effect on 
CD4 cells; a fraction of these, however, became activated being marked by CD25 
expression and proliferating. Treg numbers remained unchanged in direct coculture, 
but were reduced in transwell cultures. IDO was identified as key inhibitor of CD4 T 
cell proliferation. 
 
The screening of Th1/Th2 cytokines revealed that all analyzed cytokines were reduced 
in coculture compared to PBMC monoculture. Significant reduction was found in IL-13, 
IL-5, IL-10 and TNF-α concentrations. Thus, not only pro-inflammatory cytokines (TNF-
alpha, IL-17a, IL-17f and IL-22) but also anti-inflammatory ones (IL-13, IL-5, IL-10, IL-
9) were reduced in coculture. These data partially fit to the overall suppression of CD4 
T cell proliferation. Indeed, the ASC-mediated inhibition of CD4 T cells proliferation 
observed in cocultures might correlate with the reduction of pro-inflammatory 
cytokines. On the other hand, the reduction of anti-inflammatory factors might be 
related to the absence of Treg induction, resulting in an overall decrease of pro/anti-
inflammatory factors. Once again, it has to be taken into account that we analyzed a 
single time point after 7 days and thus, we cannot speculate about expression kinetics. 
Indeed, ASC were often reported to induce increased IL-10 expression in T cells after 
few days of coculture [71, 83].  Further, the CD3/CD28-mediated stimulation and IL-2 
have to be taken into account in the evaluation of these outcomes and comparison to 
literature.  
The screening of Th1/Th2 cytokines in cocultures was not indicative of any T cell 
polarization suggesting that these events may occur at earlier time points [35, 73]. Our 
data underline the importance of a time-monitoring study on MSC:PBMC interaction, 
which might help in a better understanding of kinetics in T cell polarization and Treg 
induction. 
 
Globally our findings on ASC and stimulated PBMC cocultures demonstrated that: 
 ASC were not affected by hyperglycemia; 
 ASC-mediated suppression of CD4 T cell proliferation occurred in both 
transwell and direct coculture denoting the central role of IDO-kynurenine axis; 
 CD4+CD25+ cells were induced in coculture and actively proliferated despite 
the overall inhibition of CD4 T cell proliferation; 
 No Treg induction as well as proliferation was detected in cocultures; 
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 Screening of Th1/Th2 cytokines did not suggest any T cell polarization, 
resulting in an overall reduction of all cytokines/growth factors tested.  
 Direct and transwell coculture behaved almost identically in all tested 
parameters. 
 
 ASC and resting PBMC coculture 
In the previous chapter, we focused on the analysis of stimulated cocultures. As 
controls, non-stimulated cultures were always run in parallel. The analysis of these 
data provided highly interesting results. As expected, CD4 cells within resting PBMC 
did not proliferate and the division index did not change in ASCNG-HG cocultures. 
Surprisingly, we denoted a slight but significant increase in CD4 proliferation in PBMC 
monoculture transwell compared to the direct control. We hypothesized that this 
difference was mainly related to the culture condition per se. Indeed, the culture 
surface of a transwell insert (4.5 cm2) is reduced compared to a well of a 6-well plate 
(9.6 cm2) and this might affect PBMC in terms of media availability and cell 
concentration/ml and cm2 (even if the final volume of media in the well was the same 
in direct and transwell cultures). Moreover, transwell inserts and well plate differed in 
terms of material as they were made of polyethylene terephthalate (PET) and 
polystyrol, respectively. For these reasons we cannot exclude that PBMC in transwell 
might have been subject to slight auto-stimulation, causing an increased division index. 
Importantly, the auto-stimulation observed in transwell controls was slightly diminished 
in ASCNG-HG cocultures denoting somehow an inhibitory effect exerted by ASC. 
Similarly, Cuerquis and colleagues demonstrated that resting PBMC were not affected 
by MSC in terms of suppression of proliferation, but that MSC induced a slight 
activation of them (increased CD69 expression) in the first days of cocultures 
concluding that “..MSCs support a modest activation of initially resting PBMCs rather 
than a primary stimulatory full immune response followed with an inhibitory response.” 
[214]. However, our and other results are openly in contrast with the study from Crop 
and colleagues [215]. They observed that ASC, despite the lack of expression of HLA-
class I and co-stimulatory molecules, did actually promote expansion and proliferation 
of T cells in resting PBMC, suggesting that ASC induced an allogeneic response, like 
in a mixed lymphocyte reaction. These same cells underwent accelerated proliferation 
when cultured without ASC, but once cultured again in presence of ASC their 
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proliferation was almost abrogated [215]. Although this study confirmed the 
immunosuppressive capacity of ASC as well as their Treg induction, it indicated that 
under certain conditions ASC might promote and activate T cells. As coculture 
conditions were extremely similar to ours, we hypothesize that these contrasting 
results might be attributed to (1) the use of IL-2, which might provide in our case a 
stabilizing factor for PBMC survival when cocultured with ASC and (2) the source of 
ASC. In fact, while our ASC were isolated from lipoaspirate, the one used by Crop and 
colleagues were obtained from perirenal adipose tissue of living kidney donors. The 
well-known functional differences between diverse sources of MSC [216] as well as 
the peculiarity of perirenal fat pads [217] might be the reason of these opposing 
outcomes. 
 
IDO expression in ASCNG-HG from cocultures was very low, more than halved compared 
to ASCNG-HG in cocultures with activated PBMC. Again, no IDO was detected in ASC 
and PBMC monocultures. This indicated that, despite the low ASC inhibitory function 
suggested by low IDO levels, the slight degree of activation of PBMC, especially in the 
transwell, was inducing a minimal increase in the expression of IDO in ASC. As, IDO 
induction has been found to be associated to secretion of IL-6 [218] and considering 
that very high level of IL-6 were found in coculture supernatants (not shown, because 
out of scale), we could also postulate that IL-6 might have mediated IDO induction. 
Yet, evidences of high IL-6 levels concomitant to IDO expression in ASC was provided 
[215]. Notably, IDO expression in ASCNG from transwell cocultures was considerably 
higher than in ASCNG from direct cocultures, most probably reflecting the low levels of 
PBMC auto-stimulation that we found in transwell cocultures. In line with that, 
kynurenine levels were significantly lower compared to stimulated cocultures and again 
no differences were found between all conditions tested. 
 
As the previous data from ASC: stimulated-PBMC cocultures suggested that coculture 
induced CD25 expression in CD4 T cells, we expected to find here similar outcomes 
with a reduced extent. However, we saw that there was no difference between 
CD4+CD25+ fractions among all conditions and the percentage of activated CD4 was 
overall the same. The amount of CD4+CD25+ cells was reduced almost of one quarter 
in contrast to CD4+CD25+ cells in stimulated cocultures. This reduction was uniformly 
observed in coculture as well as in PBMC monoculture. Of note, the portion of 
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CD4+CD25+ in transwell PBMC monoculture was slightly higher than the one in direct 
monoculture, mirroring again a possible effect of auto-stimulation. Low degree of 
activation in PBMC monoculture as well as low IDO/kynurenine levels were related to 
the lack of inhibitory effects, being in line with the hypothesis about the requirement of 
pro-inflammatory stimuli (or priming factors) to induce MSC-mediated 
immunosuppression [219, 220]. Moreover, as mentioned in the previous chapter, the 
lack of CD3/CD28 stimulation might reduce IL-2 additional secretion from PBMC, 
resulting in an overall reduction of CD25 induction. In addition, we observed that in 
absence of stimulation, CD25 expression was not induced in PBMC monoculture 
neither in coculture with ASC, being in line with some results proposed by Le Blanc 
and colleagues [221]. However, in the same study, a significant reduction on CD25 
expression is reported in stimulated cocultures [221], which is in contrast to our 
previous finings. Conflicting evidences are reported in another paper where 
CD3/CD28-activated lymphocytes did not changed CD25 expression upon cocultures 
[222]. These evidences suggest that CD25 expression on CD4 T cells might correlate 
not only with the CD3/CD28-mediated PBMC stimulation but also with the presence of 
ASC. The dual interpretation of CD25 expression on T cell as activation marker and/or 
Treg marker [223] is still generating confusing outcomes, highlighting the need of more 
detailed studies on kinetic changes in CD25 expression with/without stimulation and 
MSC.    
CD4+CD25+ cells were then assessed for their FoxP3 expression to evaluate a 
potential induction of Treg in ASC:not-stimulated PBMC cocultures. Overall, the 
proportion of Treg were significantly increased in comparison to PBMC:stimulated 
PBMC cocultures. Resting PBMC monoculture had more Treg than stimulated PBMC 
and in not-stimulated setting cocultures promoted Treg proliferation. Similar outcomes 
were reported in resting cocultures of induced pluripotent stem cells MSC (iPSC-MSC) 
and PBMC where the percentage of FoxP3+CD4+ cells significantly increased in 
cocultures. Moreover, iPSC-MSC were found to cause an higher increase in FoxP3 
mRNA levels in CD4 cells than BM-MSC did [224].  
 
Overall, these results indicated that ASC were able to induce Treg expansion and 
proliferation in coculture with resting PBMC. As our investigation focused on the 
phenotypic characterization of CD4 T cells dissecting differences between proliferated 
and non-proliferated ones, we did not have enough Treg to functionally test whether 
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they exerted immunoregulatory functions. This was further hampered by the fact that 
we used FoxP3 for Treg characterization. FoxP3 is an intracellular marker, which 
detection is necessarily related to cell death. Despite several trials in using alternative 
markers (CD127, CD69, CD73, CD39) in order to select and sort Treg from our 
cocultures, we were not able to find a suitable candidate. However, as our outcomes 
reproduced findings provided also by others [82-84] not only in terms of cells (CD4 T 
cell inhibition and Treg induction) but also in terms of cytokine secretion (see below), 
we can reasonably infer that the Treg induced in our study would be functional in 
suppressing T cell proliferation. 
 
Also for the resting condition, we analyzed the supernatant screening Th1/Th2 
cytokines. The overall levels of Th1/Th2 cytokines (IL-5, IL-9, IL-10, IL-13, IL-17a, IL-
17f, IL-22, TNF-α) were low compared to the ones in stimulated cultures in both PBMC 
monoculture and cocultures. However, also this screening confirmed that ASC 
cocultures, even in a resting condition and with no obvious CD4 inhibition, exerted a 
general suppressive effect in cytokines secretion. As discussed in previous 
paragraphs, our investigation on immunomodulatory cytokines might have a timing 
limitation suggesting that ASC-mediated effect of PBMC might be extended only few 
days after the beginning of the coculture.  
Having observed that coculture induced the expansion and proliferation of the Treg 
fraction, being indicative of an anti-inflammatory microenvironment, we further checked 
the coculture supernatant for IL-4, IFN-γ and CCL-18 concentrations. 
In our assays, we did not find differences between IL-4 in PBMC monoculture and in 
coculture, confirming the lack of any Th polarization. Indeed, IL-4 is produced by the 
subset Th2 of T cells in response to T receptor stimulation [225] and deregulation of 
its pathway has been linked to allergic diseases such as asthma [226]. MSC have been 
reported to favor the skewing of T cell response towards anti-inflammatory Th2 in an 
animal model of allergic encephalomyelitis and even in NOD mice [227, 228]. However, 
contrasting evidences from Kavanagh and colleagues, reported a suppression of 
allergen specific Th2 in a mouse model of airway inflammation denoted by inhibition of 
IL-4 production and reduction of eosinophil infiltration [229].  
INF-γ was produced in both PBMC monoculture as well as in ASC cocultures but in a 
lower extent. The presence of IFN-γ in resting PBMC monoculture might be explained 
as the results of an auto-stimulation of PBMC for the long lasting culture. Importantly, 
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IFN-γ detected in coculture correlated with the low but increased level of IDO in 
cocultured ASC. Moreover, the reduction of IFN-γ in coculture in comparison to PBMC 
monoculture, could be an indication of immunosuppressive potential of ASC even in 
coculture with resting PBMC. 
Inspired by findings provided by Melief and colleagues we also checked the presence 
of CCL-18 in coculture supernatants. Indeed, they reported CCL-18 being produced 
by monocytes as sign of MSC-mediated skewing of monocytes towards the anti-
inflammatory type 2 [83, 230]. Moreover, as reported by other studies, the presence of 
CCL-18 as well as monocytes in PBMC:MSC coculture was fundamental for the 
generation of Treg [83, 231]. In line with these results, we found remarkably high levels 
of CCL-18 in cocultures, while it was almost absent in PBMC monocultures. This was 
indicative at least of an anti-inflammatory switch of monocytes, whose survival in the 
culture was probably sustained by ASC. In addition, the high concentration of CCL-18 
correlated with the observed increased of Treg in coculture.  
Also TGF-β is reported being one of the main soluble factors involved in Treg induction 
[164] and several paper documented this central role in ASC:PBMC cocultures [36, 82, 
83]. Therefore, we compared TGF-β concentrations in stimulated and not stimulated, 
direct and transwell cocultures. Despite a low basal TGF-β level in ASC, our data 
showed a remarkable high concentration of TGF-β in direct non-stimulated coculture 
compared to transwell and its direct stimulated counterpart. These findings supported 
the Treg proliferation observed in resting direct coculture. However, we did not expect 
to find low and similar TGF-β levels in resting transwell coculture and stimulated ones. 
We hypothesized this being related to the auto-stimulation we observed in the resting 
transwell coculture. Overall, TGF-β quantification in supernatants of coculture 
demonstrated to be in line with the previous results and its high concentration in resting 
coculture denoted its involvement in Treg generation.   
 
In conclusion, our data demonstrated that ASC were able to induce Treg proliferation 
and expansion when cocultured with resting PBMC. In parallel, ASC did not support 
activation of resting PBMC as demonstrated by the general low level of Th1/Th2 
cytokines in coculture supernatant. Even if IL-10 was not increased in coculture, the 
reduction of IFN-γ together with a substantial increase of CCL-18 (and the general low 
level of Th1/Th2 cytokines) and TGF-β were indicative of an anti-inflammatory/pro-
Treg microenvironment induced by ASC. Comparing our findings to the literature, we 
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identified the timing of the coculture as an important limiting factor for the evaluation of 
MSC-mediated effects on polarization of Th subsets.  
 
In the last part of our study on the immunosuppressive capacity of ASC, we evaluated 
potential “long-term” effect of ASC on PBMC, asking whether ASC might “prime” PBMC 
in term of Treg induction and changing in their cytokine profile. No differences were 
found in the CD4+CD25+ fractions of control PBMC and ex-coculture PBMC, indicating 
that both resting and ex-coculture PBMC did not undergo activation. Surprisingly, we 
found a prominent reduction in Treg from ex-coculture PBMC in comparison with 
controls. These results displayed that, despite a previous Treg induction at day 7 and 
the provision of IL-2 in the culture medium, Treg did not survive and expand further. 
These outcomes were partially in contrast with previous reports, which accounted Treg 
proliferation as well as an increased inhibitory potential of these population [83, 215]. 
As a very prominent indicator of Treg induction and functionality, we found markedly 
high concentrations of IL-10 and CCL-18 in ex-coculture PBMC, exceeding values 
measured after 7 days. A similar concomitant production of Treg and monocyte-
derived IL-10 and CCL-18 was also reported by Melief et al. [83]. There were no 
changes in IL-4 concentrations, suggesting that no skewing towards Th2 phenotype in 
both conditions occurred. IFN-γ and TNF-α were considerably increased ex-coculture 
PBMC. The presence of these cytokines, traditionally coming from CD8 T cells and NK 
cells, was unexpected at these high levels. However, as separate experiments in our 
lab denoted an increase in NK cells after 1 week of coculture, we might postulate an 
expansion of CD8 and NK cells in the second week of cultures producing high level of 
these cytokines. 
 
In summary, the analysis on ASC:resting PBMC cocultures showed that: 
 ASC did not affect resting PBMC in terms of inhibition of proliferation and 
activation; 
 Cocultures induced Treg expansion in both transwell and direct cultures; 
 Cocultures caused a general reduction in secretion of Th1/Th2 cytokines 
without any specific polarization of Th subsets; 
 CCL-18 and TGF-β were highly concentrated in cocultures denoting (a) the 
participation of monocytes in driving Treg induction as well as (b) ASC-
dependent TGF-β secretion as reported by Melief et al [83]; 
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 Cocultures induced prolonged changes in PBMC cytokine profile towards an 
anti-inflammatory phenotypes with high secretion of IL-10 and CCL-18. 
However, concomitant high concentrations of IFN-γ and TNF-α might indicate 
an expansion of CD8 and NK cells.  
 
In conclusion, our data demonstrated the immunomodulatory potential of ASC being 
strictly dependent on the activation state of PBMC. This is in line with the hypothesis 
about the requirement of priming factors to induce MSC-mediated immunosuppression 
[219, 220]. These assumptions have to be taken into consideration in the development 
of MSC-mediated therapies together with the specific diseased context. In the case of 
DR, our data support the concept that an early MSC treatment would be preferred to 
increase circulating Treg which might act in the retina. Importantly, this has been 
documented in an animal model of OIR [128]. These promising findings still need to be 
fully elucidate especially in vivo. Further investigations on Treg involvement in MSC-
mediated therapy for DR will take place.    
 
Summary 
122 
6 SUMMARY 
Hyperglycemia and poor glycemic controls are two marked features of metabolic 
disorders, such as diabetes or metabolic syndrome. Patients affect by these 
pathologies often develop secondary complications, which involve the vascular 
system. Besides macrovascular complications at the expense of the cardiovascular 
system, microvascular disorders can seriously affect quality and, in some cases, 
duration of life. This is the case of diabetic complications such as DR, diabetic 
nephropathy and diabetic neuropathy. Hyperglycemia represents a connection point 
between all these secondary complications since high glucose has been identified as 
one of the causes mediating cell damage. Through years, clear evidences on 
hyperglycemia-mediated cell damage have been produced, leading to the elaboration 
of the “unifying hypothesis”. Here, glucose-mediated cell damage is explained as the 
result of a deleterious increase of oxidative stress in cells, which induces cell 
dysfunction and death. This mechanism has been demonstrated in several cell types 
from endothelial to neuronal cells, however, some aspects of hyperglycemia-mediated 
cell damages still need to be elucidated. This is the case of the cell/stem cell-mediated 
therapeutic approach. 
The application of cell/stem cell-mediated therapies in diabetes and diabetic 
complications already gave some positive outcomes. In particular, MSC-mediated 
therapies demonstrated to be safe and efficient. Thanks to their trophic, differentiation 
and immunomodulatory potential MSC promoted reconstitution of β-cell islets in the 
pancreas, wound healing in diabetic foot and an overall reduction of inflammation. 
However, the majority of studies used an allogenic approach proposing the application 
of MSC from healthy donors. Indeed, MSC from diabetic donors often revealed to be 
impaired by the disease which caused reduction of their potency and even affecting 
their survival. In this context, specific investigations focused on possible effects of 
diabetes/hyperglycemia on MSC are lacking.  
Our study proposes an investigation of possible hyperglycemia-mediated effects on 
ASC through in vitro experiments. In particular, we assessed effects of hyperglycemia 
on (1) cellular phenotype, (2) ASC proangiogenic potential, (3) ASC pericyte-like 
function and (4) immunomodulatory potential. 
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Overall, we observed that hyperglycemia did not affect any of the evaluated aspects. 
Indeed, ASC demonstrated as strong refractory behavior towards HG exposure 
resulting only in a transient increase of intracellular oxidative stress. This was 
corroborated by observing that, when exposed to HG, ASC reduced glucose uptake. 
On the contrary, HRMVEC appeared sensitive to HG and glucose uptake resulted to 
be not only GLUT-1 dependent. In HRMVEC, hyperglycemia increased the level of 
oxidative stress and affected the angiogenic potential suggesting a possible 
connection between the two aspects.  
ASC proangiogenic potential was not affected by glucose and ASC sustained 
HRMVEC angiogenesis giving structural support and secreting proangiogenic growth 
factors. Moreover, conditioned media form ASC monoculture and ASC:HRMVEC 
cocultures reproduced the effect of antioxidant application on HG treated HRMVEC, 
rescuing their angiogenic potential. This observation not only confirmed the 
proangiogenic potential of ASC but also indicated a possible antioxidant effect exerted 
by ASC. 
ASC pericyte-like function was detected being unaffected by HG. α-SMA positive ASC 
clearly wrapped around tubular structures reminding pericytes in normal physiology. In 
contrast to ASC, pericytes did not support the angiogenesis of EC, confirming their role 
in supporting homeostasis in the vascular department. Importantly, because of the still 
ongoing discrepancies in distinguishing MSC from pericytes, this finding indicates that 
the coculture angiogenesis assay might be used as a potency assay to functionally 
discriminate the two cell types. 
Finally, we found that glucose did not affect the immunomodulatory potential of ASC, 
which was evaluated in terms of (1) inhibition of CD4 proliferation, (2) induction of 
CD25 expression and Treg and (3) production of immunomodulatory cytokines. 
Actually, the major discriminant in the outcomes of the experiments was represented 
by the presence of CD3/CD28-stimulated or not stimulated (resting) PBMC. In 
simulated cocultures, ASC strongly inhibited CD4 proliferation via IDO-kynurenine. 
Despite this, cocultures strongly enlarged the CD4+CD25+ positive fractions, 
promoting CD4 activation but not Treg expansion. Cytokines analysis showed and 
overall cytokines reduction in cocultures compared to PBMC monocultures but did not 
reveal specific polarization towards specific Th subsets.                              
In resting cocultures, IDO and kynurenine were also measured at low levels but ASC-
inhibiting effect of CD4 was not detectable. Here, CD4+CD25+ were even reduced 
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compared to the control. Although, Treg highly proliferated in cocultures. Cytokines 
analysis was similar to the stimulated coculture having overall general lower 
concentrations. Having observed Treg formation in this condition, we further analyzed 
CCL-18, IL-4, INF-γ and TGF-β to eventually confirm the anti-inflammatory skewing of 
CD4. No distinction between IL-4 and INF-γ were found and CCL-18 resulted to be 
highly produced in cocultures, suggesting the involvement of monocytes in Treg 
induction. Also TGF-β, which is produced by ASC and drive Treg induction, was 
detected in high concentration in resting direct coculture confirming Treg proliferation. 
Contrarily, low TGF-β levels were detected in stimulated cocultures. Further, 
cocultures induced a long-term priming of PBMC, which after 14 days in culture 
secreted high levels of IL-10, TNF-α, IFN-γ and CCL-18. The analysis of the 
immunomodulatory potential of ASC confirmed ASC-mediated immunosuppression on 
activated PBMC and ASC-mediated Treg induction, highlighting how much the 
activation/resting condition of PBMC might be determinant in affecting the direction of 
the ASC-mediated immune response. 
 
In relation to DR and the eventual application of MSC-based cell therapy our study 
provides the important evidence that hyperglycemia does not affect ASC in their basic 
characteristics, proangiogenic and immunomodulatory potential. However, some 
separate considerations have to be done for MSC from diabetic patients. It is worth to 
mention that several papers described impaired therapeutic capacity of diabetic-MSC, 
especially in terms of reduced angiogenic potential and secretion of angiogenic factors 
[145, 148, 232]. Dysfunction of diabetic-MSC were observed in proliferation, 
mitochondrial activity, signaling pathway and secretome profile [144, 233, 234]. We 
also had the chance to perform some experiments with diabetic ASC, but the restricted 
number of samples limited us in collecting significant amount of data. In our hand, 
these ASC were not different from healthy ASC in terms of growth rate and 
immunophenotype but their differentiation potential to adipogenic lineages was 
reduced. Notably, their proangiogenic potential in coculture angiogenesis assays 
resulted slightly reduced in comparison to healthy ASC, while the immunosuppressive 
function on CD4 proliferation as well as Treg induction was not changed. From these 
assumptions, we hypothesize that diabetic-MSC might indeed have alterations in some 
of their functions, which are not mediated exclusively by hyperglycemia, as it is 
reported by our experiments. 
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Our data on the proangiogenic function of ASC suggest a careful evaluation of ASC 
application in the context of DR. Indeed, proangiogenic stimuli might be beneficial in 
the early phases of the disease to prevent vasoregression and even to replace 
pericytes. However, a prolonged proangiogenic stimuli might cause highly detrimental 
effects if not accurately regulated/controlled, promoting hyperproliferation of retinal 
vessels and accelerating the progression to the proliferative stage. This highlights the 
importance of deeper investigations on the role of ASC in the retinal microenvironment, 
with a focus on the long-term characterization of beneficial/dangerous trophic factors. 
In addition to the proangiogenic potential, we hypothesize that ASC may retain a ROS 
scavenging potential, acting as a second potential mechanisms to rescue damaged 
endothelial cells. As the redox signaling has been demonstrated to be involved in the 
regulation of angiogenic processes, we propose ASC-ROS scavenging potential as a 
new aspect to be further investigated in the modulation of retinal dysfunction. 
Lastly, having demonstrated the strong immunomodulatory effect of ASC in vitro and 
because of the recent publication on Treg involvement in the retina, we auspicate that 
in vivo experimentations may clarify and characterize this mechanism, which may 
represent a real novelty in DR treatment.         
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8 APPENDIX 
8.1 Generation of fluorescent cells 
 Plasmids  
 
 
 
 
Figure 40 Plasmid maps. A) GFP plasmid; dTomato plasmid has the same backbone with dTomato gene replacing 
GFP ; B) pCMVDR8.91; C) pMD.G plasmid. 
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 Enzymatic restriction 
 
 
Figure 41 Representative agarose gel loaded with enzymatically restricted plasmids: a) pCMVDR8.91 Mix 1; b) 
pCMVDR8.91 Mix 2; c) pMD.G Mix 1; d) pMD.G Mix 2; e) dTomato; f) GFP. 
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 Sort gating strategy 
 
Figure 42 Representative gating strategy to sort fluorescent cells. HUVEC were first morphologically selected on 
the SSC and FSC. Viable cells were then gated and further selected after duplets discrimination. Then GFP positive 
HUVEC (green population) were gated and sorted.  
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